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11General introduction
HEPATITIS B INFECTION
Hepatitis B virus (HBV) is a virus that primarily affects the human liver. Infection 
occurs through vertical transmission (mother-to-child) or horizontal transmission 
(for example sexual transmission or blood contact) 1. Chronic HBV infection 
(deﬁned as an HBV infection that lasts longer than 6 months)  is one of the most 
prevalent infectious diseases worldwide, affecting 257 million patients 2. In the 
Netherlands, the incidence of acute HBV infection is 0.7 per 100.000 persons 
per year, and an estimated 30.000-60.000 persons (0.2-0.4% of people) have 
chronic HBV infection 3. Despite development and implementation of an effective 
and safe vaccine, chronic HBV leads worldwide to approximately 900,000 
deaths every year  because of complications of cirrhosis , hepatic failure or 
development of hepatocellular carcinoma (HCC, liver cancer) 2. Most of these 
complications occur predominantly through chronic inﬂammation of the liver 
caused by the host immune response 1. Because of the severity of the complica-
tions, patients who develop chronic infection need to be routinely monitored, and 
patients with a high risk of complications require treatment. For both monitoring 
and treating chronic HBV infection, insights in the complex interplay between the 
host immune system and the virus are essential.
LEVELS OF IMMUNE CONTROL 
In order to control infection with the hepatitis B virus (HBV), both innate and 
adaptive immune responses play an important role 4. At the time of infection, 
natural killer (NK) cells and dendritic cells (antigen-presenting) cells are acti-
vated, leading to the production of interferons and other cytokines stimulating 
the initiation of the adaptive immune response. HBV-speciﬁc T-cell responses 
eventually lead to control of infection in case of self-limiting HBV infection 5, 6. In 
chronic HBV, the immune responses are inadequate, resulting in viral persistence 
with either high or low replication activity depending on the disease phase. 
The reason that chronicity can occur is that HBV, after entering the hepatocyte, 
forms a mini-chromosome called covalently closed circular DNA (cccDNA) that 
is the main transcription template for the virus 7.  During the two initial phases 
of chronic HBV, formerly known as the immune-tolerant phase (IT) and immune 
clearance or immune active phase (IA), HBeAg is an important marker of HBV 
replication. These phases were recently renamed HBeAg-positive chronic HBV 
infection and HBeAg-positive chronic hepatitis, respectively 8. HBeAg-positive 
patients have a high level of viral replication illustrated by high serum levels of 
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HBV DNA. Classically in the ﬁrst phase, alanine transaminase (ALT) level is not 
elevated whereas in the second phase, ALT level is elevated reﬂecting signiﬁcant 
liver inﬂammation. Loss of HBeAg is often followed by an inactive carrier state 
of infection, which is characterized by normal ALT levels and suppression of viral 
replication. This stage, now called HBeAg-negative chronic infection, can be 
considered as a ﬁrst step in immune control of chronic HBV, as loss of HBeAg is 
generally associated with lower risk of liver-related complications and improved 
survival 9. However, in the years following spontaneous HBeAg-seroconversion, 
up to 33% of patients develop HBeAg-negative hepatitis with active inﬂamma-
tion and viral replication 10. This can be partially explained by mutations in the 
precore and core promotor region of the HBV genome, causing viral inability to 
produce HBeAg with maintenance of the capacity to produce virus and induce 
active inﬂammation. However, since HBeAg-negativity does not guarantee 
stable disease, a higher level of immune control should be pursued. At pres-
ent, seroclearance of the Hepatitis B surface Antigen (HBsAg) with appearance 
of antibodies (anti-HBs positivity is regarded as the highest degree of immune 
control and the clinical endpoint closest to cure. Although HBV DNA is often not 
detectable in the blood of HBsAg-negative individuals and reactivation does not 
occur in an immunocompetent state, a risk of reactivation does exist at the time 
of immunosuppression due to persistence of the cccDNA 11, 12. 
TREATMENT FOR CHRONIC HEPATITIS B INFECTION
According to current treatment guidelines, treatment of chronic HBV is required 
in case of severe or persistent liver inﬂammation, in case of a high risk of HBV-
related complications (such as in patients with liver cirrhosis), or in case of a 
high risk of transmission or reinfection (such as pregnancy or liver transplanta-
tion) 8, 13. The two available classes of treatment are nucleos(t)ide analogue (NA) 
therapy and interferon-alpha (IFN)-based therapy. 
NAs are potent inhibitors of viral replication that are to be taken orally once 
daily. They interfere with viral replication, and therefore NA treatment leads to a 
strong decline of infectious HBV particles in serum and durable suppression while 
remaining on treatment.  One year after treatment is started, HBV DNA levels 
are suppressed in approximately two third of HBeAg-positive patients and more 
than 90% of HBeAg-negative patients 8. Lower HBV DNA levels are associated 
with less inﬂammation activity, reversal of liver ﬁbrosis, and lower incidence of 
HBV-related complications 14, 15. However once started, lifelong antiviral therapy 
is required in most of chronic HBV patients. This is due to the high probability 
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of relapse after treatment discontinuation and low rates of functional cure, as 
HBsAg loss on the long-term is achieved in only 10-12% of HBeAg-positive 
patients and 1-2% of HBeAg-negative patients 16, 17. The long therapy duration 
leads to high healthcare costs and to potential antiviral resistance due to adher-
ence problems. In addition, long-term viral suppression decreases but does not 
eliminate the risk of HCC and may be inferior to viral suppression maintained 
by the host immune system 18. 
IFN treatment acts on different steps in the viral life cycle, but the exact mechanisms 
are not fully understood 19. It has mainly immunomodulatory effects, but has also 
effects on epigenetic regulation of the cccDNA 20, 21. The advantages of PEG-IFN 
treatment are that it has a ﬁnite course of 48 weeks, and that the serological 
response rates are higher and more durable than achieved by NA therapy. In 
patients who lost HBeAg during IFN-a or PEG-IFNa treatment, HBeAg loss is 
sustained in around 85% of patients when assessed 6 months after treatment 
discontinuation 22-25. In contrast, HBeAg-seroconversion induced by NA therapy 
is sustained in a minority of cases 26-28. HBsAg loss at one year of treatment 
is achieved in 3-7% in HBeAg-positive patients and in 4% in HBeAg-negative 
patients 8. However, PEG-IFN side-effects like ﬂu-like symptoms or myelosuppres-
sive effects are common, PEG-IFN administration requires subcutaneous injection, 
only a subset of patients responds to therapy, and PEG-IFN is contraindicated in 
patients with liver cirrhosis. This restricts the use of IFN and worldwide only a 
small minority of patients are currently treated with this compound.
As clearly both treatment modalities have advantages and disadvantages and 
functional cure of chronic HBV is hardly achieved, an need for progress in 
chronic HBV therapeutic options still exists. Current research not only focusses on 
achieving HBsAg loss, but also on silencing or eradicating the cccDNA (which 
would imply complete cure), or on disrupting the viral life cycle 29. While await-
ing new drugs that either increase the probability of functional cure or are even 
able to achieve a complete cure, optimization of current treatment options is 
warranted. This thesis will focus on 2 different optimization strategies, namely 
on combining currently available treatment modalities PEG-IFN and NA, and on 
response prediction.   
OPTIMIZING HBV TREATMENT BY COMBINING TREATMENT 
MODALITIES 
Since PEG-IFN and NAs are both potent in targeting HBV but with different 
modes of action, modiﬁed treatment strategies with both PEG-IFN and potent 
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NAs have unsatisfying success rates in the achievement of sustainable immune 
control. Although it does not seem beneﬁcial to simultaneously start PEG-IFN and 
NAs 30, 31, observations of the effects of HBV on the immune system have led to 
new hypotheses for other combination regimens. HBV is known to negatively 
impact NK-cell function, IFN-mediated cell signalling and T-cell function 32-34. 
Lowering HBV DNA is therefore thought to restore immune cell function. Indeed, 
in vitro and in vivo studies showed that NAs are able to improve HBV-speciﬁc 
T-cell responses 35, leading to the hypothesis that the immunomodulatory effect 
of PEG-IFN may be stronger when PEG-IFN is added at the time of NA-induced 
viral suppression. In a randomized controlled trial in HBeAg-positive patients, 
patients were randomized after 24 weeks of ETV treatment to either 24 weeks 
of PEG-IFN addition or continuation of ETV monotherapy 36. Rates of HBeAg loss 
were higher in patients who had PEG-IFN addition compared to patients who 
continued monotherapy. In addition, sustainability of off-treatment response was 
better in patients who received PEG-IFN addition, which was also illustrated by a 
signiﬁcantly stronger HBsAg decline in the PEG-IFN add-on group 36.  In patients 
who had received a longer duration of NA therapy before adding PEG-IFN, 
it was reported PEG-IFN did not lead to a signiﬁcant increase of HBeAg loss 
rates in the overall study population, but did signiﬁcantly improve response in 
IFN-naïve patients 37. 
Because the add-on strategy is relatively new, the long term effects have not 
been addressed and few analyses have yet been performed to identify factors 
associated with response. Balancing the add-on induced gain in response rates 
versus the well-known PEG-IFN side-effects, in our opinion the response rates to 
add-on that were found earlier were not high enough to treat every patient this 
way. Chapter 1 of this thesis therefore aimed to identify those patients who 
are likely to beneﬁt from this modiﬁed treatment strategy. We have learned from 
earlier studies in PEG-IFN monotherapy that factors such as HBV genotype and 
quantitative HBsAg and HBV DNA levels in serum are of major importance in 
the pre-treatment and on-treatment identiﬁcation of patients who are less likely to 
respond 38-40. We expected that these factors would also be relevant to PEG-IFN 
add-on therapy. Additionally we aimed to investigate the long-term effects of the 
PEG-IFN strategy in Chapter 2. If the add-on induced improvement in response 
rate is maintained or increases even more beyond week 96 of follow-up, this 
would underline the potency of a short-term add-on course.
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OPTIMIZING HBV TREATMENT BY BIOMARKER MONITORING
Ideally, HBV replication activity would be measured by a single, non-invasive 
test, which not only reﬂects the current replication activity but also the degree of 
immune control related to the future replication activity. As written before, detect-
ability of HBsAg in serum quite meets these needs, since it implies functional cure 
and HBV reactivation only occurs in an immune  incompetent state. Sustained HB-
sAg undetectabilty in serum therefore is a highly desired treatment outcome from 
a clinical point of view. However even more desired these days is a biomarker 
that reﬂects activity of the intrahepatic cccDNA, as HBV treatment that would be 
able to eliminate cccDNA would theoretically also prevent HBV reactivation 41. 
CccDNA itself can be measured in liver biopsies, but as quantiﬁcation is difﬁcult 
and no international reference standard is available, studies describing cccDNA 
quantities and cccDNA activity cannot be compared one on one. Also several 
assays lack speciﬁcity because of the risk of simultaneous detection of relaxed 
circular DNA (rcDNA), and cccDNA itself is probably not spread throughout 
the liver in a homogeneous way. These limitations complicate interpretation of 
cccDNA quantities 41, 42. To avoid the need for a biopsy for estimation of HBV 
replication activity, serum markers correlating with cccDNA replication activity 
could be the solution. Serum markers that have been extensively studied include 
quantitative HBV DNA, HBsAg, and HBeAg, of which especially the ﬁrst two are 
commonly used in clinical practice 8, 13. However since these biomarkers cannot 
be used in all patients and all treatment settings, novel serum markers are still 
under investigation, especially now new compounds are in development. 
The second part of this thesis will therefore focus on the question if measuring 
serum levels of two novel serum biomarkers hepatitis B core-related antigen 
(HBcrAg, Chapters 3 & 4) and HBV RNA (Chapters 5, 6, 7 & 8) can be 
used for treatment monitoring and help to identify the best treatment strategy for 
individual HBV patients. The general design of these studies is shown in Figure 1. 
HBcrAg is a biomarker that simultaneously measures hepatitis B core antigen 
(HBcAg), HBeAg and a 22-kDa precore protein called p22cr.   The luminescent 
antibodies used in this CLEIA-based test are directed against the amino acid 
sequence that these proteins have in common. HBV RNA on the other hand 
is detected by RACE-PCR. Both markers were reported to correlate to intrahe-
patic cccDNA and to treatment response in small study populations 43-48, but 
in order to determine their value for clinical and research purposes, we were 
interested in the dynamics of these biomarkers in larger and more heterogenic 
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patient groups. We therefore explored the relation between serum levels of these 
biomarkers and levels of biomarkers that are already used in daily practice. 
Because studies on HBV RNA levels in untreated patients were lacking because 
of the recent development of the test, we ﬁrst aimed to do so in untreated patients 
who require treatment according to current treatment guidelines (Chapter 5). 
Next, we studied the relation of both biomarkers to treatment response in PEG-
IFN based-therapy for HBeAg-positive hepatitis (Chapter 3 for HBcrAg and 
Chapters 6 & 8 for HBV RNA), and HBeAg-negative hepatitis (Chapter 4 for 
HBcrAg, Chapter 7 for HBV RNA). 
Treatment
Start (Stop)
Follow-up Response?
Biochemical
ALT normalization
Virological
HBV DNA suppression
cccDNA silencing
cccDNA eradication
Serological
HBeAg loss
HBsAg decline
HBsAg loss
Serum sample
Serum sample
Clinical
Liver cirrhosisÈ
Liver decompensation È
Liver cancerÈ
Liver transplantation È
Death È
New biomarker
Figure 1. General design for biomarker studies
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ABSTRACT
Background & aims. Various treatment combinations of peginterferon (PEG-
IFN) and nucleos(t)ide analogues have been evaluated for chronic hepatitis B 
(CHB), but the optimal regimen remains unclear. 
Methods. We studied whether PEG-IFN add-on increases response compared 
to entecavir (ETV) monotherapy, and whether the duration of ETV pre-treatment 
inﬂuences response. Response was evaluated in HBeAg positive patients previ-
ously treated in two randomized controlled trials. Patients received ETV pre-
treatment for at least 24 weeks and were then allocated to 24-48 weeks of ETV 
+ PEG-IFN add-on, or continued ETV monotherapy. Response was deﬁned as 
HBeAg loss combined with HBV DNA <200 IU/mL 48 weeks after discontinuing 
PEG-IFN. 
Results. Of 234 patients, 118 were assigned PEG-IFN add-on and 116 con-
tinued ETV monotherapy. Response was observed in 38/118 (33%) patients 
treated with add-on therapy and in 23/116 (20%) with monotherapy (p=0.03). 
The highest response to add-on therapy compared to monotherapy was observed 
in PEG-IFN naïve patients with HBsAg levels below 4,000 IU/mL and HBV DNA 
levels below 50 IU/mL at randomization (70% vs. 34%; p=0.01). Above the 
cut-off levels, response was low and not signiﬁcantly different between treatment 
groups. Duration of ETV pre-treatment was associated with HBsAg and HBV 
DNA levels (both p<0.005), but not with response (p=0.82). 
Conclusions. PEG-IFN add-on to ETV therapy was associated with higher 
response compared to ETV monotherapy in patients with HBeAg positive CHB. 
Response doubled in PEG-IFN naïve patients with HBsAg below 4,000 IU/
mL and HBV DNA below 50 IU/mL, and therefore identiﬁes these as the best 
candidates for PEG-IFN add-on.
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1INTRODUCTION
The achievement of functional cure for chronic hepatitis B infection (CHB) re-
mains difﬁcult due to a persistent infection of hepatocytes with covalently closed 
circular DNA (cccDNA).1,2 CccDNA is a minichromosome that serves as a 
transcription template for hepatitis B virus (HBV) antigen and virion production. 
Nucleos(t)ide analogue (NA) therapy only marginally reduces levels of cccDNA 
such that cccDNA depletion would require years of NA treatment.3,4
NA therapy effectively suppresses the hepatitis B virus (HBV) up to eight years 
with few side-effects, but serological response rates remain low. The discontinu-
ation of NA therapy leads to frequent virological relapse and patients therefore 
require long-term, if not indeﬁnite NA therapy.5–10 In contrast, a ﬁnite course of 
pegylated interferon (PEG-IFN) achieves more sustained immune response than 
NA therapy.9,11,12 PEG-IFN is also able to directly target cccDNA and induce 
cccDNA decline in combination with NA therapy.13,14 PEG-IFN monotherapy 
however induces sustained response in only 30-40% of patients and has limited 
tolerability.15,16
These limitations of CHB therapy have led to the evaluation of various treatment 
combinations of NAs and PEG-IFN to maximize response rates, among which is 
the strategy of adding PEG-IFN to NA treatment (PEG-IFN add-on). One of the 
rationales for the PEG-IFN add-on strategy is that long-term NA treatment enables 
partial restoration of the liver-speciﬁc immunology of both the adaptive (T-cells) 
and innate immune system (natural killer cells).17–20 Viral load suppression 
could thus increase the immunomodulatory effect of PEG-IFN therapy resulting in 
increased HBsAg loss and HBeAg loss or accelerated HBsAg decline rates.11
Several randomized controlled trials (RCT) employed a PEG-IFN add-on strategy 
in HBeAg positive and negative patients on long-term NA monotherapy.21–23 
PEG-IFN add-on increased HBeAg seroconversion and viral antigen decline, but 
primary efﬁcacy endpoints were not reached, possibly because of insufﬁcient 
power or because the effect was limited to a subgroup of patients only. Clinical 
practice could beneﬁt substantially if these responsive patients can be identiﬁed 
at the start of PEG-IFN therapy with readily available laboratory markers. Other 
remaining issues concern the optimal duration of PEG-IFN add-on and of NA 
pre-treatment. 
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We therefore evaluated whether PEG-IFN add-on to ETV treatment increases 
serological response compared to ETV monotherapy in CHB, and whether the 
duration of ETV pre-treatment or the length of PEG-IFN addition therapy inﬂu-
enced response. To this purpose, we performed an analysis in a large HBeAg 
positive CHB population that was previously treated in two global RCTs. 
PATIENTS AND METHODS
Combined study design
We conducted a post-hoc analysis of two international RCTs (ARES and PEGON; 
registered at ClinicalTrials.gov, Identiﬁer: NCT00877760, NCT01532843).21,23 
Detailed inclusion and exclusion criteria have been previously described. In short, 
patients with CHB were eligible if they were HBeAg positive at randomization 
(baseline) and had a serum alanine aminotransferase (ALT) between 1.3 and 5 
times the upper limit of normal (ULN). Patients had received pre-treatment with 
ETV for at least 6 months. The main exclusion criteria were history of decompen-
sated liver disease, co-infection with hepatitis C virus or HIV, other concomitant 
liver disease, and any contra-indication for interferon therapy.
After initial treatment with ETV (Baraclude, 0.5 mg once-daily), patients were 
randomized to either 6-12 months of PEG-IFN addition or of continued ETV mono-
therapy (Figure 1). Patients treated within the ARES trial received PEG-IFN a2a 
(Pegasys, 180 μg once-weekly) and patients in the PEGON study PEG-IFN a2b 
(PegIntron, 1.5 μg/kg once-weekly). If patients achieved HBeAg seroclearance 
in combination with an HBV DNA level below 200 IU/mL at the end of PEG-IFN 
treatment (EOT) or at the corresponding time point for patients allocated to ETV 
monotherapy, ETV was discontinued after a minimum of 24 weeks consolidation 
therapy. Otherwise, ETV was continued until the end of follow-up (EOF), which 
was 48 weeks after EOT for all patients regardless of treatment response.
Several patients within the ARES study did not reach the designated primary 
endpoint at the end of treatment. These patients were allowed to enroll in the 
subsequent PEGON trial and were then randomized again to PEG-IFN add-on or 
ETV monotherapy. This study was approved by local ethics boards of all centers 
and performed in concordance with Good Clinical Practice guidelines and the 
Declaration of Helsinki. All patients provided written consent.
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1Study endpointsResponse was deﬁned as combined HBeAg loss with HBV DNA <200 IU/mL at 
EOF. We analyzed the modiﬁed intention-to-treat population, which includes all 
patients who received at least one dose of the allocated treatment after baseline. 
Patients were considered non-responders in case of missing HBeAg status or 
HBV DNA at EOF. To assess the potential for functional cure, as studied with 
therapeutic compounds now in development, we also investigated speciﬁc other 
virological and serological outcomes (Table 2).
Study follow-up and measurements
During PEG-IFN treatment, routine examination and laboratory testing were 
performed every 4 weeks. After PEG-IFN treatment was stopped, patients visited 
the outpatient clinic every 12 weeks until EOF. Patients on ETV monotherapy 
had study visits every 12 weeks throughout the entire study period. Routine 
biochemical and hematological tests were assessed locally at every visit. Serum 
ALT levels were standardized according to the ULN per center and gender. 
Serum HBV DNA was measured with the Cobas TaqMan 48 polymerase chain 
reaction assay (lower limit of detection: 20 IU/mL; Roche Diagnostics, Basel, 
Switzerland). Serum HBeAg, anti-HBe and HBsAg were evaluated with Architect 
(Abbott Laboratories, North Chicago, IL, USA) or Cobas Elecsys 411 (lower 
limit of detection 0.30 IU/L and 0.05 IU/mL, respectively; Roche Diagnostics). 
HBV genotyping was performed with the INNO-LiPA HBV genotype assay (Fu-
jirebio Europe, Ghent, Belgium). If HBV genotype could not be assessed due to 
undetectable HBV DNA levels at baseline, we reviewed HBV genotype data in 
medical charts where possible. The presence of cirrhosis was deﬁned by Ishak 
stage 6 on liver biopsy, or an aspartate aminotransferase to platelet ratio index 
(APRI) score >1.0.24
Statistical analysis
Variables are summarized with mean ± SD or frequency (percentage). Non-
normally distributed variables were log-transformed. Differences in outcomes 
were evaluated by chi-squared test, Student’s t-test or Mann-Whitney test, where 
appropriate. To study the inﬂuence of PEG-IFN addition on response and adjust 
for confounders, we performed logistic regression analysis. Pre-deﬁned covari-
ates included age, gender, HBV genotype, cirrhosis, previous use of PEG-IFN, 
duration of ETV pre-treatment, ALT, HBV DNA and HBsAg. The duration of ETV 
pre-treatment and HBV DNA were categorized due to a skewed distribution. Pre-
dictors that were signiﬁcantly associated with response in univariable regression 
(p-value <0.10) were further evaluated in multivariable regression (backward 
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stepwise selection). Interactions between response and baseline variables in-
cluded in the ﬁnal model were explored.
Cut-off values for HBV DNA and HBsAg at baseline were evaluated to ﬁnd clini-
cally useful starting rules for PEG-IFN add-on. HBsAg levels were dichotomized 
at thresholds between 2.7 and 5.0 log IU/mL in steps of 0.1. HBV DNA was 
categorized at 50, 100, 500 and 1,000 IU/mL. The likelihood-ratio test and 
sum of log-likelihood ratios of the two treatment groups were calculated. We 
selected optimal cut-off values based on a minimum response difference of 15% 
between add-on and monotherapy; a signiﬁcant likelihood ratio test of add-
on vs. monotherapy below the cut-offs, but not above; and the lowest sum of 
likelihood ratios. For each threshold Receiver Operating Characteristic (ROC) 
curves were constructed and AUCs were calculated and compared to each 
other. Furthermore, a sensitivity analysis was performed among non-responding 
patients within the ARES study who subsequently received retreatment in the 
PEGON study by modeling the correlated data in a generalized estimating 
equation.25 Analyses were performed in SPSS (v. 22.0, Chicago, IL) and SAS v. 
11.2 (SAS Institute Inc., Cary, NC). Two-sided p-values <0.05 were considered 
signiﬁcant. 
RESULTS
Patient population
A total of 234 patients met the inclusion criteria. Excluded were 5 patients as-
signed PEG-IFN add-on and 10 assigned ETV monotherapy who had achieved 
HBeAg loss at baseline (during ETV pre-treatment). At baseline, 118 patients 
were allocated to PEG-IFN add-on and 116 patients continued ETV monotherapy. 
Baseline characteristics were comparable between the two groups (Table 1). The 
mean age was 33 (SD 9) years, the majority of patients were male and of Asian 
ethnicity. HBV genotypes A/B/C/D/other were present in 4%, 17%, 41%, 24% 
and 1% of patients, respectively. In total, 80/118 (68%) patients received PEG-
IFN add-on for 24 weeks and 38/118 (32%) patients received PEG-IFN add-on 
for 48 weeks. Among patients included in the ARES study, 36 non-responders 
were re-included in the subsequent PEGON trial. The baseline characteristics per 
trial are shown in Supplementary Table 1.
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1
Response 
Response was reached in 38/118 (33%) patients allocated to add-on therapy 
and in 23/116 (20%) patients with ETV monotherapy (p=0.03; Figure 1 and 
Table 2).Other serological, virological and biochemical outcomes are reported 
in Table 2. HBeAg seroconversion rates at EOF were also signiﬁcantly higher in 
PEG-IFN add-on patients. The response group comprised signiﬁcantly more males 
(84 vs 69%, p=0.03), and had a higher frequency of genotype B (26% vs 13%) 
and fewer genotype D (12% vs 28%) compared to non-responders. Furthermore, 
Table 1. Characteristics of the modiﬁed intention-to-treat population at randomization.
PEG-IFN add-on
(n=118)
ETV monotherapy
(n=116)
Age, years (SD) 33 (10) 33 (9)
Male gender 87 (74%) 83 (72%)
Ethnicity Asian 85 (72%) 84 (72%)
Caucasian 31 (26%) 31 (27%)
Other 2 (1.7%) 1 (0.9%)
HBV genotype† A 3 (2.5%) 6 (5.2%)
B 22 (19%) 17 (15%)
C 45 (38%) 51 (44%)
D 30 (25%) 26 (22%)
Other/unknown† 18 (14%) 16 (14%)
Cirrhosis‡ 3 (2.5%) 5 (4.3%)
Previous (PEG-)IFN therapy 16 (14%) 20 (17%)
ETV pre-treatment 6-12 months 80 (68%) 79 (68%)
1-2 years 12 (10.2%) 9 (7.9%)
2-3 years 16 (22%) 28 (24%)
Alanine aminotransferase, ULN (IQR) 0.5 (0.3-0.9) 0.5 (0.4-0.9)
HBV DNA, IU/mL Undetectable§ 38 (32%) 42 (36%)
20-100 16 (14%) 27 (23%)
100-1,000 27 (23%) 18 (16%)
>1,000 37 (31%) 29 (25%)
Quantitative HBsAg, log IU/mL (SD) 3.7 (0.7) 3.6 (0.7)
Quantitative HBeAg, log IU/mL (IQR) 1.1 (0.5-2.0) 1.0 (0.4-1.9)
PEG-IFN duration 24 weeks 80 (68%) -
48 weeks 38 (32%) -
† HBV genotyping was not possible for 32 patients (all Asian) due to undetectable HBV DNA at randomization. 
‡ Cirrhosis was deﬁned as Ishak stage 6 on liver biopsy; all 81 patients with unavailable biopsy data had an APRI 
score <1.0, which suggests absence of cirrhosis.
§ <20 IU/mL.
IQR: interquartile range; SD: standard deviation; ULN: upper limit of normal.
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responders had signiﬁcantly lower ALT (0.4 vs. 0.6 x ULN, p=0.01), HBsAg 
(3.3 vs. 3.8, p<0.005) and HBeAg (0.5 vs. 1.4, p<0.005) levels at baseline, 
and a higher frequency of undetectable HBV DNA at baseline (53% vs. 28 %, 
p<0.005) than non-responders. Other baseline characteristics were comparable 
between patients with and without a response. Response occurred in 12/16 
patients assigned to PEG-IFN add-on vs. 2/2 assigned to ETV monotherapy 
(p=0.42) in the subgroup that achieved HBeAg loss in combination with HBV 
DNA <200 IU/mL at EOT.
The two sensitivity analyses (cohort without 36 retreated non-responders and 
whole cohort with adjustment for correlated data) were consistent with our 
ﬁndings indicating that PEG-IFN add-on signiﬁcantly increased response to ETV 
monotherapy (Supplementary table 1). 
HBsAg decline and loss
HBsAg decline >0.5 log IU/mL occurred more often in the PEG-IFN add-on group 
compared to the ETV monotherapy group at EOF (25 [23%] vs. 11 [9.6%]; 
p=0.01). HBsAg <1,000 IU/mL was reached by 35/118 (30%) patients with 
PEG-IFN add-on and by 25/116 (22%) with ETV monotherapy (p=0.32) at 
EOT, which increased to 27% at EOF in both groups (p=0.97). The proportions 
of patients with HBsAg <100 IU/mL in PEG-IFN add-on vs. ETV monotherapy 
were 1 (1%) vs. 5 (4%) at baseline (p=0.09), and 6 (5%) vs. 5 (4%) at EOF 
(p=0.77). The proportion of patients in the add-on group with HBsAg <100 IU/
ETV Pretreatment wks
ETV 24-48 wks
ETV 24-48 wks
PEG-IFN add-on 24-48 wks
Randomization
ETV 48 wks
Yes
No
Yes
No ETV 48 wks
Response?*
Follow-up 24 
wks
Consolidation 
24 wks
EOF
ETV Pretreatment wks
EOT PEG-IFN End Of Consolidation**
n=118
n=16
n=102
n=2
n=114
Follow-up 24 
wks
Consolidation 
24 wks
n=116
25/118
93/118
7/116
109/116
HBeAg loss combined with HBV DNA <200 IU/mL?
Figure 1. Combined study design
* Response: HBeAg loss in combination with HBV DNA <200 IU/mL at end of follow-up. 
** Only for responders. Non-responders were treated with ETV until EOF.
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mL increased from baseline to EOF (p=0.06). HBsAg loss was observed in one 
patient assigned to PEG-IFN add-on.
Response prediction
By univariable analysis, response was associated with PEG-IFN add-on (odds 
ratio [OR]: 1.9; 95% conﬁ dence interval [CI]: 1.1-3.5; p=0.03), male sex 
(OR: 2.3; 95%CI: 1.1-4.9; p=0.03), HBV genotype (p=0.02), lower ALT (OR: 
0.3; 95%CI: 0.1-0.7; p=0.01), lower HBV DNA level (OR: 0.5; 95%CI: 0.3-
0.7; p<0.005) and lower HBsAg level at baseline (OR: 0.4; 95%CI: 0.2-0.6; 
p<0.005; Table 3). The duration of ETV pre-treatment was associated with 
HBsAg and HBV DNA at baseline (both p<0.005), but not with response (1-3 
years vs. 0-1 year, OR: 1.1; 95%CI: 0.6-2.2; p=0.76), nor was duration of the 
PEG-IFN add-on regimen (p=0.92). In multivariable analysis, PEG-IFN add-on 
remained independently associated with response (OR: 2.5; 95%CI: 1.3-4.8; 
p=0.01, when adjusted for HBV DNA and HBsAg level at baseline). Response 
rates to PEG-IFN add-on compared to ETV monotherapy increased especially 
in PEG-IFN naïve patients with lower serum HBV DNA and HBsAg at baseline 
(Supplementary ﬁ gure 1).
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Figure 2. Response
Out of 32 patients who reached combined HBeAg loss and HBV DNA <200 IU/mL at week 48, 18 discontinued 
treatment after ETV consolidation therapy.
* P <0.05. 
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1
Response-guided therapy using HBV DNA and HBsAg 
To establish clinical starting rules for PEG-IFN add-on, the relationship between 
different cut-off values of HBsAg and HBV DNA at baseline and likelihood of 
response was evaluated. As previous use of PEG-IFN was strongly associated 
with a lack of response, we evaluated all PEG-IFN naïve patients (n=198/234, 
85%). Based on this analysis, PEG-IFN naïve patients with an HBsAg level below 
4,000 IU/mL (3.6 log) and HBV DNA level below 50 IU/mL (1.7 log) at base-
Table 3. Logistic regression on response at end of follow-up.
Univariable regression Multivariable regression
Variable OR 95%CI p-value OR 95%CI p-value
Age, years 1.02 0.99-1.05 0.24
Gender, male vs. female 2.31 1.09-4.90 0.03* NS
HBV genotype‡ 0.02* NS
- C Reference
- A vs. C 1.50 0.35-6.47 0.59
- B vs. C 2.09 0.95-4.59 0.07
- D vs. C 0.43 0.17-1.07 0.07
- Other vs. C 1.44 0.61-3.37 0.41
Cirrhosis 1.76 0.41-7.59 0.45
Duration of ETV, months 0.79
- 0-1 yr Reference
- 1-3 yrs vs. 0-1 yr 1.12 0.56-2.23 0.76
- >3 yrs vs. 0-1 yr 1.28 0.46-3.54 0.64
PEG-IFN experienced vs. naïve 0.64 0.27-1.56 0.33
PEG-IFN duration, 12 vs. 6 mo 0.96 0.41-2.20 0.92
PEG-IFN add-on, compared to ETV 
monotherapy
1.92 1.06-3.49 0.03*
- within PEG-IFN naïve 3.72 1.76-7.87 <0.005*
- within PEG-IFN experienced 0.24 0.04-1.66 0.15
ALT, x ULN 0.32 0.14-0.74 0.01* NS
HBV DNA, IU/mL† <0.005* 0.02*
- Undetectable Reference 1.00
- 20-100 vs. undetectable 0.67 0.30-1.49 0.33 0.62 0.26-1.47
- 100-1,000 vs. undetectable 0.53 0.24-1.17 0.12 0.47 0.19-1.16
- >1,000 vs. undetectable 0.10 0.03-0.29 <0.005* 0.12 0.04-0.42
HBsAg, log IU/mL 0.38 0.24-0.60 <0.005* 0.51 0.29-0.89 0.02*
* P <0.05.
† HBV DNA groups: < lower limit of detection (<20 IU/mL); 20-100 IU/mL; 100-1,000 IU/mL; ≥1,000 IU/mL
NS: not signiﬁcant; ULN: upper limit of normal.
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line achieved the largest gain in probability of response with PEG-IFN add-on 
compared to ETV monotherapy (70% vs. 34%, p=0.01; Figure 3). Patients who 
met one of the above criteria achieved a moderate gain in response from PEG-
IFN add-on, compared to ETV monotherapy (44% vs. 17%; p=0.02). Above 
the proposed HBsAg and HBV DNA cut-off levels, response was very low and 
not signiﬁcantly different between treatment groups (PEG-IFN add-on vs. ETV 
monotherapy: 9.3% vs. 5.9%; p=0.58). The cut-off values combined had an 
AUC of 0.79 (95%CI: 0.72-0.86) for probability of response. 
DISCUSSION
In this combined analysis of two global RCTs, PEG-IFN add-on to ETV increased 
response compared to ETV monotherapy in HBeAg positive patients with CHB. 
Response was 33% for add-on patients versus 20% for ETV monotherapy. HBeAg 
seroconversion rates at EOF were also signiﬁcantly higher in add-on patients. 
The response to PEG-IFN add-on was especially high (up to 70%) among patients 
HBsAg  
<4,000 IU/mL 
 
 
Recommendation 
 
 
 
Response 
 
 
 
 
HBV DNA  
<50 IU/mL 
 
 
Yes No 
PEG-IFN add-on 
not recommended 
Yes 
PEG-IFN add-on 
recommended 
PEG-IFN : 70% 
ETV: 34% 
OR (95%CI): 2.2 (1.1-4.2) 
P=0.01 
ETV-treated HBeAg positive chronic hepatitis B 
PEG-IFN naïve 
N=198/234 
n=82  
(41%) 
n=55 
(28%) 
No 
n=116 
(59%) 
PEG-IFN : 9.3% 
ETV: 5.9% 
OR (95%CI): 1.0 (0.9-1.2) 
P=0.58 
Baseline 
PEG-IFN add-on 
should be considered 
PEG-IFN : 44% 
ETV: 17% 
OR (95%CI): 1.5 (1.1-2.1) 
P=0.02 
No Yes 
n=27 
(14%) 
n=39 
(20%) 
n=77 
(39%) 
Fig. 3
Figure 3. Algorithm for probability of response at end of follow-up based on HBV DNA and 
HBsAg at baseline.
The algorithm stratiﬁes patients on ETV treatment by using HBV level and HBsAg level at baseline.
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1who were naïve to PEG-IFN therapy and had low HBV DNA (< 50 IU/ml) and HBsAg levels (< 4000 IU/ml) at the start of PEG-IFN therapy.
This is the ﬁrst study demonstrating a higher response in patients allocated to 
PEG-IFN add-on compared to ETV monotherapy. The strengths of this study are 
inclusion of a large multi-ethnic cohort of patients comprising treatment naïve 
and experienced patients who after ETV treatment did not reach HBeAg sero-
conversion. These patients are representative of the majority of treatment eligible 
patients seen in clinical practice who would otherwise continue NA therapy 
for longer duration. A ﬁnite PEG-IFN add-on regimen offers disease remission 
and discontinuation of treatment, thereby preventing additional costs and the 
potential of non-adherence and resistance associated with long-term or indeﬁnite 
NA therapy. 
To avoid unnecessary side-effects and costs of PEG-IFN it is essential to identify 
the optimal candidates for add-on therapy as only a subset will respond. The 
current HBV clinical practice guidelines only broadly mention the usefulness 
of quantifying HBV DNA and HBsAg to decide when and in whom to start 
PEG-IFN. Evidence to support one cut-off value over another is limited.26,27 We 
established clinical starting rules for PEG-IFN add-on based on widely available 
biomarkers. Based on results from this study, we recommend starting PEG-IFN 
add-on in PEG-IFN naïve patients with an HBsAg level below 4,000 IU/mL (3.6 
logs) and HBV DNA below 50 IU/mL (1.7 log) at randomization. A sufﬁciently 
large subgroup (28% of PEG-IFN naïve patients) had laboratory levels below 
these thresholds. PEG-IFN add-on response rates were nearly twice as high as 
the average PEG-IFN response in previous studies.15,16 In patients with values 
below either of the cut-off values, PEG-IFN add-on should be considered, as 
these patients have a moderately high response to PEG-IFN. PEG-IFN add-on is 
not recommended in patients with both HBsAg and HBV DNA levels above the 
cut-off values, because of the low probability of response. Our HBsAg threshold 
is concordant with a threshold found in another study which showed that HBsAg 
<1500 IU/mL predicted response.28 Moreover, the higher and thus more lenient 
HBsAg cut-off value established in this study would allow practitioners to identify 
even more candidates for PEG-IFN add-on at an earlier stage in their disease 
course. None of the previous add-on studies provided a comprehensive grid 
search to establish response-guided therapy. Apart from response, the side ef-
fects and cost-effectiveness should to be taken into consideration when deciding 
on a treatment strategy.
In recent RCTs that compared PEG-IFN add-on to continuing NA monotherapy, 
HBsAg decline rates were signiﬁcantly higher in the add-on group, yet the pri-
mary endpoints (HBsAg loss at week 96; combined HBeAg loss with HBV DNA 
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<200 IU/mL at week 96) were not reached, potentially due to a type II error.21–23 
In the ARES study response was achieved in 19% of patients in the add-on arm 
vs. 10% in the monotherapy arm (p=0.095); declines in HBsAg, HBeAg and 
HBV DNA were also larger in the add-on group (all p<0.001).21 Uncontrolled 
studies in HBeAg positive and negative patients reported similar ﬁndings.29,30
The PEGAN study in HBeAg negative patients did not ﬁnd a signiﬁcant effect 
of PEG-IFN add-on on HBsAg loss at week 96, but was possibly underpowered 
and included older-generation NAs.22 This study showed that PEG-IFN add-on 
treatment resulted in signiﬁcantly greater HBsAg declines and, within patients 
who received a full 48 week course, larger proportions of HBsAg loss and 
seroconversion. Within patients with an HBsAg titre below 3 log IU/mL at base-
line, 6/26 (23%) achieved HBsAg loss (full dose analysis). The PEGAN study 
suggested using add-on only in patients with baseline HBsAg levels of less than 
3 log IU/mL. Other regimens of PEG-IFN and NA therapy, such as sequential 
or combination therapy have been evaluated in CHB, but the optimal strategy 
remains unclear.28,31
The optimal duration of ETV pre-treatment or PEG-IFN add-on therapy has not yet 
been established. Prolonged NA pre-treatment partially restores immune function 
(NK and T cells).17–20 In our study the duration of ETV pre-treatment correlated 
to baseline HBV DNA and HBsAg, but not to response. This suggests that levels 
of HBsAg and HBV DNA at the start of PEG-IFN therapy are more important in 
considering which patients to treat than the actual duration of ETV pre-treatment. 
The duration of PEG-IFN add-on treatment did not correlate with response. A 
post-hoc analysis in a previous study revealed larger HBsAg decline after 24 
weeks of PEG-IFN add-on to ETV therapy compared to 52 weeks of combined 
PEG-IFN and LAM therapy.32 This suggests that a PEG-IFN course of 24 weeks 
is at least as effective as 52 weeks, while the shorter regimen would reduce the 
risk of IFN-related adverse events and treatment costs. Our analysis lacked a 
comparison to PEG-IFN monotherapy. However, the focus of this study was to 
investigate PEG-IFN add-on in the large population of patients currently on NAs, 
and not treatment naïve patients.
The endpoint of HBeAg seroclearance is clinically relevant because it is associ-
ated with a lower risk of HCC and improved survival.9 Since only a subset of 
patients stopped ETV therapy after receiving consolidation therapy the durability 
of sustained response after treatment discontinuation could not be studied in 
further detail. Long-term follow-up studies could focus on the effect on HBsAg 
loss or development of important clinical outcomes (decompensation, HCC and 
death), although such studies will be difﬁcult to perform. Due to the fact that part 
of the patients had received long-term HBV suppressive therapy HBV genotype 
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1and cirrhosis status was not known for some patients. Nevertheless, the sensitivity analyses performed to adjust for these partially missing baseline characteristics 
also showed higher response and HBsAg decline achieved by PEG-IFN add-on 
compared to ETV monotherapy. It is important that our ﬁndings will be validated 
in new PEG-IFN add-on studies. 
In conclusion, PEG-IFN add-on to ETV therapy was associated with a higher prob-
ability of response and HBeAg seroconversion compared to ETV monotherapy 
in HBeAg-positive CHB. Response was highest in patients who were naïve to 
PEG-IFN therapy with levels of HBsAg below 4000 IU/ml and HBV DNA below 
50 IU/ml. In particular these patients should be offered PEG-IFN add-on therapy.
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SUPPLEMENTARY TABLES
Supplementary table 1: Patient characteristics of ARES and PEGON trial patients at randomiza-
tion.
ARES
(n=159)
PEGON
(n=75)
Age, years (SD) 32 (9) 35 (9)
Male gender 114 (72) 56 (75%)
Ethnicity Caucasian 59 (37%) 3 (4.0%)
Asian 97 (61%) 72 (96%)
Other 3 (1.9%) 0 (0.0%)
HBV genotype A 9 (5.7) 0 (0.0%)
B 30 (19%) 9 (12%)
C 67 (42%) 29 (39%)
D 53 (33%) 3 (4.0%)
Other 0 (0.0%) 34 (45%)
Cirrhosis 8 (5.2%) -
PEG-IFN naive 141 (89%) 57 (76%)
ETV pre-treatment 6-12 months 159 (100%) -
1-3 years - 55 (73%)
>3 years - 20 (27%)
Alanine aminotransferase, x ULN (IQR) 0.7 (0.4-1.0) 0.4 (0.3-0.5)
HBV DNA, IU/mL Undetectable§ 25 (16%) 55 (73%)
20-100 29 (18%) 13 (17%)
100-1,000 44 (28%) 2 (2.7%)
>1,000 61 (38%) 5 (6.7%)
Quantitative HBsAg, log IU/mL (SD) 3.9 (0.7) 3.3 (0.7)
Quantitative HBeAg, log IU/mL (SD) 1.2 (1.0) 1.1 (0.8)
Therapy arm PEG-IFN add-on 80 (50%) 38 (51%)
ETV monotherapy 79 (50%) 37 (49%)
PEG-IFN duration 24 weeks 80 (50%) -
48 weeks - 38 (51%)
§ <20 IU/mL
IQR: interquartile range; SD: standard deviation; ULN: upper limit of normal.
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SUPPLEMENTARY FIGURES
Supplementary ﬁgure 1. Predicted probability of response at end of follow-up according to treat-
ment, serum HBV DNA and HBsAg levels at baseline in PEG-IFN naïve patients.
On the y-axis, black lines represent the predicted probability of response for patients treated with PEG-IFN add-on 
for the baseline level of HBsAg level shown on the x-axis. Grey dotted lines represent the predicted probability for 
patients treated with ETV monotherapy. The 4 boxes represent patients categories stratisﬁed by  HBV DNA level at 
baseline.
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ABSTRACT
Background & aims. Addition of peginterferon alpha (PEG-IFN add-on) to 
entecavir (ETV) treatment after a short lead-in phase results in more response 
than ETV monotherapy in HBeAg positive chronic hepatitis B infection (CHB). 
This study is the ﬁrst to assess long-term efﬁcacy of this treatment strategy.
Methods. Patients who received ETV +/- 24 weeks of PEG-IFN add-on in a 
global trial (ARES study) and completed follow-up were eligible to participate in 
this observational LTFU study if they had at least one combined HBeAg and HBV 
DNA measurement beyond week 96 of the ARES study. The primary endpoint 
was combined response (HBeAg loss and HBV DNA <200 IU/mL) at LTFU. 
Results. In total, 48 patients treated with PEG-IFN add-on and 48 patients treated 
with ETV monotherapy were included. The median follow-up duration was 226 
(IQR 51) weeks, and 86/96 (90%) patients were initial non-responders. At LTFU 
combined response was present in 13 (27%) vs. 11 (23%) patients (p=0.81), 
and 1 log10 HBsAg decline in 59% vs. 28% (p=0.02) for PEG-IFN add-on and 
ETV monotherapy, respectively. In 41 initial non-responders who continued ETV 
therapy, combined response at LTFU was present in 9 patients (PEG-IFN add-on: 
5/22 [23%]; ETV monotherapy: 4/19 [21%]).
Conclusions. Beyond week 96 of follow-up, rates of serological response 
became comparable between PEG-IFN add-on and ETV monotherapy. Although 
in this LTFU study initial non-responders were overrepresented in the add-on 
arm, PEG-IFN add-on possibly leads rather to accelerated HBeAg loss than to 
increased long-term HBeAg loss rates. 
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INTRODUCTION
Chronic hepatitis B (CHB) infection is difﬁcult to cure due to intrahepatic per-
sistence of the main viral replication template cccDNA and due to complex 
host-virus interactions. At present it is not only debated how to achieve cure, but 
also which event is the best surrogate endpoint indicating cure of disease 49. 
Functional cure, often reﬂected by HBsAg seroconversion, is the most favorable 
outcome that currenty available treatment options can establish, but it is achieved 
in only a minority of patients with HBeAg-positive CHB 30, 50-52. Therefore sustain-
able disease remission remains one of the major aims in current clinical practice. 
HBeAg loss induced by (peg)interferon alpha (PEG-IFN) treatment, which mainly 
has immunomodulating effects, occurs in approximately 30% of patients and is 
associated with an increased probabilty of HBsAg loss and a reduced incidence 
of liver-related complications 22, 24, 30. In contrast, during one year of antiviral 
therapy with potent nucleo(s)tide analogues (NA) entecavir (ETV) or tenofovir 
(TDF) HBeAg loss is achieved in only 20% of patients and is less durable 27, 53, 54. 
Although treatment guidelines suggest that NA therapy may be discontinued 
in non-cirrhotic patients when HBeAg loss is achieved 13, 55, 56, clinical relapse 
occurs in around 50% of patients and virological relapse in over 90% 28, 57. 
Consequently, the majority of patients on NA treatment require long-term or even 
lifelong therapy. 
Long-term NA therapy may not be desired for several reasons such as high costs, 
potential non-adherence and side-effects. Another disadvantage is that decline 
in serum level of HBsAg, which is presumed to partly reﬂect intrahepatic function-
ally active cccDNA, is very slow, resulting in low rates of on-treatment HBsAg 
clearance 58, 59. On the other side, long-term HBV suppression can improve 
both innate and adaptive immunity probably creating a window of opportunity 
for immunomodulatory treatment such as PEG-IFN to improve response 33, 60. 
Indeed, the ﬁrst studies in small patient groups reported that addition of PEG-IFN 
(PEG-IFN add-on strategy) in patients with completely suppressed HBV DNA by 
NA therapy increased responses rates and even leads to HBsAg loss 61, 62.
Our group recently reported the results of a randomized controlled trial compar-
ing ETV monotherapy to ETV + 24 weeks of PEG-IFN add-on. We observed 
higher rates of HBeAg loss and sustained off-treatment disease remission in the 
PEG-IFN add-on arm, and PEG-IFN add-on led to a signiﬁcantly stronger decline 
in serum HBsAg level 36, 63. However, at present it is not known whether these 
beneﬁts last over time. We therefore aimed to investigate the long-term effects of 
the PEG-IFN add-on strategy in comparison to ETV monotherapy.
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PATIENTS AND METHODS
Patients
Patients were eligible for participation in this observational long-term follow-
up study if they completed follow-up of a global randomized controlled trial 
comparing ETV + PEG-IFN add-on therapy to ETV monotherapy (ARES study), 
had at least one simultaneously obtained serum HBeAg and HBV DNA result 
after study completion at week 96, and were not (re)treated with PEG-IFN before 
start of the LTFU study. The inclusion and exclusion criteria of the initial study 
are described elsewhere 36. In short, patients with HBeAg positive, anti-HBe 
negative chronic hepatitis B infection (HBsAg positive >6 months) and serum ALT 
level >1.3 times the upper limit of normal (ULN) were included, who had not re-
ceived antiviral therapy against HBV in the 6 months prior to screening and who 
had no contraindication for PEG-IFN therapy. In the initial study, 175 patients 
started ETV treatment, and were randomized after 24 weeks of ETV treatment 
to either receive PEG-IFN add-on therapy from week 24 to 48, or to continue 
ETV monotherapy (Figure 1). At week 48, the primary endpoint of HBeAg loss 
in combination with HBV DNA level <200 IU/mL (initial response was assessed. 
Patients who had achieved combined response at week 48 stopped ETV at 
week 72 (PEG-IFN add-on: n=14, ETV mono: n=8), after at least 24 weeks of 
consolidation therapy. Patients without an initial response continued ETV through 
the end of the study (week 96). In the long-term follow-up study, all patients were 
followed and treated according to the protocols of the local study sites. The study 
was performed in accordance with the declaration of Helsinki and the Good 
Clinical Practice guidelines and were approved by the ethics committee of each 
participating centre. All subjects gave written informed consent.
Endpoints & definitions
The primary endpoint of this LTFU study was loss of HBeAg in combination with 
HBV DNA level <200 IU/mL (combined response). Secondary endpoints were 
HBeAg loss, HBeAg seroconversion (HBeAg loss + detectable anti-HBe), rever-
sion to HBeAg positivity after initial HBeAg loss (sustainability of response), HBV 
DNA negativity (below lower limit of detection), HBsAg loss +/- seroconversion, 
HBsAg level <1,000 IU/mL and <100 IU/mL, HBsAg decline of 1 log10 or more. 
End of long-term follow-up was deﬁned as the last moment at which both serum 
HBeAg and HBV DNA results were available. Retreatment was regarded as 
relapse for the assesment of off-treatment response.
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Laboratory test procedures
For the LTFU study, all biochemical, hematological and virological tests were 
performed at laboratories of the local centers. For HBV DNA quantiﬁcation, 
Abbott Realtime HBV or Taqman-based polymerase chain reaction assays were 
used with lower limits of quantiﬁcation varying from 15-500 IU/mL. Serum 
HBeAg and HBsAg levels were measured using the Cobas Elecsys 411 (Roche 
Diagnostics, Basel, Switzerland, lower limit of detection 0.30 IU/mL and 0.05 
IU/mL, respectively). For the initial study, all test procedures were described 
earlier 36.
Statistical analysis
Skewed laboratory values were log-transformed prior to analyses. Continuous 
variables were expressed as mean (standard deviation [SD]), categorical vari-
ables as n (%). Associations between variables were tested using Student’s t-test, 
Fisher’s exact test, or their non-parametric equivalents when appropriate. For the 
assessment of treatment response, follow-up time was censored when treatment 
with PEG-IFN based treatment was started during LTFU. In addition, a subgroup 
analysis was performed for patients who continued ETV at week 72 and at the 
end of the initial study. For the endpoint of HBeAg seroconversion, patients 
Figure 1. Trial design of the initial study.
Trial design of the ARES study.
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without an anti-HBe measurement were considered non-responders. For HBsAg 
related endpoints, only patients with at least one available HBsAg level were 
analysed. All statistical tests were two-sided and were evaluated at the 0.05 
level of signiﬁcance. Analyses were performed using SPSS version 24.0 (SPSS 
Inc., Chicago, IL, USA).
RESULTS
Patients
Of 175 patients who started treatment in the initial study, 169 (97%) patients 
completed the 96-week follow-up. Of these patients, 96 (57%) were enrolled in 
the LTFU study (Figure 2). The most common reason for non-participation was 
that patients could not be reached and were lost to follow-up (n=34 ). Out of 
48 PEG-IFN add-on treated patients included in the LTFU study, 45 (94%) were 
week 48 non-responders in the initial study and out of 48 ETV monotherapy 
treated patients, 41 (85%) were week 48 non-responders. Out of the 11 initial 
responders who stopped ETV treatment according to protocol at week 72 of the 
original study and had sustained off-treatment response through week 96 (end 
of the initial study), 3 patients were included (all add-on treated). Among the 
other 8, 4 could not be reached by the local physician, and 4 were reached 
but had no available HBeAg or HBV DNA measurement. Most of these patients 
were from rural areas of China and therefore difﬁcult to reach. Table 1 shows 
patient characteristics at baseline (start of ETV treatment) and at week 24 (ran-
domization) of patients who participated in the initial study and of patients who 
participated in the LTFU study. The median follow-up duration was 226 (IQR 51) 
weeks from baseline. The median follow-up time did not differ for add-on versus 
ETV treated patients [p=0.26]. 
HBeAg response and combined response
Overall, 43/48 (90%) patients treated with PEG-IFN add-on vs. 45/48 (94%) 
patients treated with ETV monotherapy in the initial study received any type of 
antiviral treatment during LTFU (p=0.71, Figure 2). At the end of follow-up, HBeAg 
was negative in 18/48 (38%) patients treated with PEG-IFN add-on and 19/48 
(40%) treated with ETV monotherapy (p=1.00, Figure 3). HBeAg seroconversion 
had occurred in 14/48 (29%) vs. 10/48 (21%) patients, respectively (p=0.48). 
Combined response was present in 13/48 patients (27%) allocated to PEG-IFN 
add-on vs. in 11/48 (23%) patients allocated to ETV monotherapy (p=0.81). 
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Among the 3 included patients whose initial response at week 48 had persisted 
through week 96, documented relapse was observed in 2 patients (week 111 
and week 151). In the last patient, HBeAg was negative and HBV DNA level 
was <500 IU/mL. Among the remaining 93 included patients with non-response 
at week 96, 41 patients continued ETV at both week 72 and at the end of the 
initial study. In these 41 patients, HBeAg loss at end of LTFU was observed in 
7/22 (32%) patients previously treated with add-on and 7/19 (37%) patients 
treated with ETV monotherapy (p=0.75), and late HBeAg seroconversion in 
6/22 (27%) vs. 3/19 (16%), respectively (p=0.47). Combined response at the 
last moment of follow-up was present in 9 patients (add-on: 5/22 [23%]; ETV 
monotherapy: 4/19 [21%]). In 3/9 patients, ETV had been successfully discon-
tinued 5-11 months prior to the end-of-follow-up visit (all add-on treated). In one 
patient treated with ETV monotherapy who did not fulﬁll criteria of combined 
response but had achieved HBeAg loss with an HBV DNA level below 500 IU/
mL, ETV was succesfully discontinued (week 120).
Figure 2. Flowchart of inclusion.
Overview of patients included and not included for this long-term follow-up study.
ETV, entecavir; LTFU, long-term follow-up; NA, nucleos(t)ide analogue; PEG-IFN add-on, peginterferon addition; TDF, 
tenofovir.
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Table 1. Patient characteristics
Initial study 
(n=175)
LTFU study
(n=96)
Characteristics
ETV 
monotherapy 
(n=90)
PEG-IFN
add-on 
(n=85)
ETV 
monotherapy 
(n=48)
PEG-IFN
add-on 
(n=48)
Demography
Age, years 31 (9) 32 (10) 32 (9) 33 (11)
Male, n (%) 62 (69) 63 (74) 34 (71) 35 (73)
Race, n (%)
Caucasian 35 (39) 30 (35) 23 (48) 20 (42)
Asian 54 (60) 53 (63) 24 (50) 26 (54)
Other 1 (1) 2 (2) 1 (2) 2 (4)
HBV Genotype: A/B/C/D (%) 10/14/46/30 5/23/39/33 10/8/42/40 8/23/31/38
INNO-LiPA result, n (%)
Wildtype virus 7 (8) 9 (12) 4 (9) 5 (11)
PC mutation 13 (16) 21 (27) 5 (11) 13 (29)
BCP mutation 16 (19) 7 (9) 7 (16) 7 (16)
PC & BCP mutation 48 (57) 40 (52) 28 (64) 20 (44)
Histology
Cirrhosis, n (%) 5 (6) 3 (4) 1 (2) 3 (7)
Week 0 laboratory results *
ALT (x ULN) † 2.7 (2.1) 3.1 (3.3) 2.7 (2.1) 3.4 (3.1)
HBV DNA ‡ 7.8 (1.1) 7.8 (1.3) 7.8 (1.1) 7.7 (1.4)
qHBsAg ‡ 4.1 (0.8) 4.2 (0.8) 4.1 (0.9) 4.2 (0.9)
qHBeAg ‡ 2.3 (1.0) 2.3 (1.0) 2.4 (1.0) 2.3 (1.1)
Week 24 laboratory results
ALT (x ULN) † 0.8 (0.6) 0.8 (0.4) 0.8 (0.7) 0.8 (0.5)
HBV DNA ‡ ˞ 2.3 (1.4) 2.8 (1.5) 2.4 (1.3) 3.1 (1.3)
qHBsAg ‡ 3.7 (0.8) 3.7 (0.7) 3.8 (0.8) 3.7 (0.7)
qHBeAg ‡ 0.9 (1.2) 1.1 (1.1) 0.9 (1.2) 1.2 (1.0)
ALT, alanine aminotransferase; BCP, basal core promoter; ETV, entecavir; HBV, hepatitis B virus; qHBeAg, quantitative 
hepatitis B e antigen; qHBsAg, quantitative hepatitis B surface antigen; PEG-IFN, peginterferon; PC, Precore; SD, 
standard deviation; ULN, upper limit of normal.
Continuous variables are expressed as mean (SD), categorical variables as n (%).
* Patients were randomised at week 24 and thus not yet allocated at week 0.
† Multiples of upper limit of the normal range
‡ Logarithmic scale, IU/mL
 HBV DNA levels differed at week 24 (p=0.021 for n=175, p=0.01 for n=96)
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Virological response
At the end of follow-up, HBV DNA level was undetectable (<20 IU/mL in most 
participating centers) in 33/48 (69%) add-on treated patients vs. in 32/48 
(67%) ETV monotherapy treated patients (p=1.00). At this visit, 38/48 (79%) 
add-on treated patients and 39/48 (81%) were receiving NA treatment. In the 
subgroup of patients (n=37) who continued ETV throughout the entire initial 
study and LTFU period, the proportions of patients with undetectable HBV DNA 
level were 18/19 (95%) and 16/18 (89%), for add-on vs. ETV monotherapy, 
respectively.
HBsAg response
Serum qHBsAg level was available for 32 add-on treated patients and 29 ETV 
monotherapy treated patients. The mean qHBsAg level at the end of follow-up 
was 3.0 (SD 0.5) log IU/mL for PEG-IFN add-on and 3.1 (1.0) log IU/mL for 
ETV monotherapy (p=0.65), and the mean declines from baseline were -1.3 (SD 
Figure 3. HBeAg response and virological response.
Rates of combined response (HBeAg loss and HBV DNA <200 IU/mL), HBeAg loss, and HBV DNA undetectability at 
week 96 and the end of LTFU. Bars in watermark represent the original response rates of the total ARES study popula-
tion (n=175), bars not in watermark represent the patients included in this LTFU study (n=96). In each set of bars, 
bars in dark grey represent patients treated with ETV monotherapy, bars in lighter grey represent patients treated with 
PEG-IFN add-on. P-values with lines represent differences between ETV monotherapy and PEG-IFN add-on, p-values 
with brackets represent differences between week 96 and LTFU within each treatment arm. For the endpoint of HBeAg 
seroconversion, patients without an anti-HBe measurement (n=10) were considered non-responders.
ETV, entecavir; LTFU, long-term follow-up; PEG-IFN add-on, peginterferon addition.
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1.0) vs. -0.7 (SD 1.3) IU/mL, respectively (p=0.06). When compared to ETV 
monotherapy, PEG-IFN add-on treatment resulted in a twofold higher propor-
tion of patients with a qHBsAg decline of ≥1 log (add-on: 19/32 (59%), ETV 
monotherapy: 8/29 (28%); p=0.02; Figure 4). An HBsAg level below 1000 IU/
mL was achieved in 14/32 (44%) add-on treated patients and in 6/29 (21%) 
patients treated with ETV monotherapy (p=0.06); an HBsAg level below 100 
IU/mL in 2/32 (6%) vs. 3/29 (10%) patients (p=0.66). One patient treated 
with add-on lost HBsAg at week 96 (45-year-old male, genotype A). During 
LTFU, HBsAg reappeared at week 110, but became negative again at week 
151 and remained negative through the end of follow-up (week 239). Anti-HBs 
was positive and HBV DNA remained undetectable. HBsAg loss did not occur 
in other patients.
DISCUSSION
This study is the ﬁrst to describe the long-term effects of a PEG-IFN add-on 
strategy for the treatment of HBeAg positive CHB in comparison to ETV mono-
therapy. Although we showed earlier that response rates 24 weeks after PEG-
Figure 4. HBsAg response.
Rates of HBsAg decline 1 log10 or more and HBsAg level <100 IU/mL at week 96 and the end of LTFU. Bars in wa-
termark represent the original response rates of the total ARES study population (n=175), bars not in watermark rep-
resent the patients included in this LTFU study who had at least 1 quantitative HBsAg (qHBsAg) measurement (n=61). 
In each set of bars, bars in dark grey represent patients treated with ETV monotherapy, bars in lighter grey represent 
patients treated with PEG-IFN add-on. P-values with lines represent differences between ETV monotherapy and PEG-
IFN add-on, p-values with brackets represent differences between week 96 and LTFU within each treatment arm.
ETV, entecavir; LTFU, long-term follow-up; PEG-IFN add-on, peginterferon addition
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IFN discontinuation were higher in PEG-IFN add-on treated patients than in ETV 
treated patients, we were not able to demonstrate that PEG-IFN add-on treatment 
has late beneﬁcial effects over ETV monotherapy with respect to HBeAg loss or 
serum HBV DNA level undetectabilty. However, the strong add-on induced serum 
HBsAg decline was sustained through LTFU. 
These ﬁndings provide valuable information in the search for the optimal use 
of both currently approved treatment options which is essential as long as 
treatment leading to higher rates of functional cure or to complete cure is not 
available. Strategies that combine PEG-IFN and NA therapy simultaneously for 
the treatment of HBeAg-positive CHB have been studied for over a decade but 
no or limited clinical beneﬁt could be demonstrated 25, 30, 64. The observations of 
partially restored immune reactivation in patients on long-term NA therapy have 
led to the investigation of strategies in which PEG-IFN is added to NA therapy 
or in which NA therapy is switched to PEG-IFN. 
In the OSST study, switching from long-term ETV to 48 weeks of PEG-IFN resulted 
in a similar rate of on-treatment HBeAg loss as in our study, which was also 
higher when compared to ETV continuation 65. However in the OSST study, in 
which only patients with low HBeAg level were included, follow-up data has only 
been reported for the switch arm so the long-term added value in comparison 
to NA continuation could not be determined. Also, end-of-follow-up HBsAg level 
was not reported 66. More recently, our group reported the results of the PEGON 
study that compared 48 weeks of PEG-IFN add-on to continuation of longterm 
NA therapy, which demonstrated an increased response but only in patients na-
ïve to PEG-IFN 37. Nonetheless, no follow-up data beyond week 96 is available 
yet. The current study is the ﬁrst to report that PEG-IFN add-on does not appear 
to have late beneﬁcial effects over continued ETV monotherapy with regard to 
HBeAg loss and HBV DNA undetectability in initial non-responders, in a setting 
were PEG-IFN add-on is added for 24 weeks after 24 weeks of ETV lead-in. 
A possible explanation for the lack of long-term beneﬁt could be that IFN therapy 
only accelerates HBeAg loss but eventually does not lead to higher rates of 
HBeAg loss later during follow-up when compared to natural history or NA 
therapy 67. Another option is, because duration of NA therapy appears to be 
associated with functional T cell restoration, and it still has not been established 
what the optimal durations for NA pretreatment and PEG-IFN add-on are, that 
ETV pretreatment duration or the add-on duration in the initial study were too 
short to establish a durable clinical beneﬁt of PEG-IFN add-on over ETV mono-
therapy in terms of an increased rate of HBeAg loss or HBV DNA undetectability 
over time 5.
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Alternatively, the lack of signiﬁcant beneﬁt as observed in this LTFU study may 
represent the late effects of PEG-IFN add-on only, and not the durability of the 
early effects due to the fact that more initial non-responders were included in this 
retrospective LTFU study, primarily in the add-on arm. Particularly in our Chinese 
sites it was common that patients who achieved treatment response did not 
remain in follow-up at the same site which logically leads to an overrepresenta-
tion of patients without an early treatment success. Therefore unfortunately, we 
were not able draw a conclusion on the off-treatment sustainability of response. 
Results of an additional post-hoc analysis, extrapolating the current percentage 
of response sustainability to the ARES participants who were not included in this 
LTFU study, indeed suggest that when all original ARES participants would have 
been included in the LTFU study, the response rates achieved by PEG-IFN add-on 
remained higher than those of ETV monotherapy even at LTFU (data not shown). 
Further, the number of patients included in this LTFU study may be too low to 
demonstrate a clinical signiﬁcant beneﬁt.
We observed that PEG-IFN add-on led to an HBsAg decline of at least 1 log10 in 
58% of patients, which was double the rate of ETV monotherapy treated patients. 
This was stable over time, which is probably due to the fact that most patients 
remained on NA therapy, and it may indicate improved immune control 63, 68. 
This same phenomenon has been shown earlier by our group comparing trials 
with combination of PEG-IFN and ETV or Lamivudine [23]. Lower end-of-treatment 
HBsAg level is associated with sustained off-treatment response after both NA 
and PEG-IFN discontinuation 69-71, but because almost all patients included in this 
LTFU study received treatment after the initial study, we have not been able to 
assess this. Future follow-up of these patients could reveal if indeed off-treatment 
sustainability is better in those who have achieved a low HBsAg level.
In conclusion, although early response was stronger in PEG-IFN add-on treated 
patients, rates of HBeAg loss and combined response became comparable 
between the treatment arms beyond week 96 of follow-up. We hypothesize 
that PEG-IFN add-on accelerates serological response without eventually lead-
ing to higher absolute response rates than ETV on the long-term. The data we 
presented here provide unique insights in the long-term outcome of a PEG-IFN 
add-on strategy as compared to ETV monotherapy. Although no recommenda-
tion towards the exact clinical application of PEG-IFN add-on as a strategy to 
increase HBeAg response or virological response can be made yet, this study 
may serve as a lead for exploring other pretreatment and add-on durations. We 
additionally suggest that the PEG-IFN add-on strategy may be used in future 
treatment settings when low HBsAg levels or HBeAg loss would be indicated to 
start a novel treatment therapeutic agent.
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ABSTRACT
Background & aims. Hepatitis B core-related antigen (HBcrAg) is a new 
serum marker for the combined measure of HBeAg, HBcAg and p22cr. HBcrAg 
correlates with intrahepatic cccDNA, which is the main template for viral protein 
synthesis. HBcrAg levels may therefore be associated with viral replication activ-
ity, response to antiviral therapy, and immune control in chronic hepatitis B 
infection (CHB). 
Methods. Serum HBcrAg levels were measured in 175 HBeAg-positive patients 
treated with entecavir (ETV) ± peginterferon (PEG-IFN) add-on therapy within a 
randomised trial. To study HBcrAg dynamics, and associations between HBcrAg 
and treatment response, we evaluated combined response (CR; HBeAg loss and 
HBV DNA<200 IU/mL) and HBsAg response (qHBsAg <1000 IU/mL and/or 
qHBsAg decline ≥1 log IU/mL). 
Results. At baseline, the mean HBcrAg was 8.1 (SD 0.8) log U/mL. HBcrAg 
declined during therapy (ETV vs. PEG-IFN add-on: -2.10 vs. -1.96 log U/mL, 
p=0.12), with stronger declines in patients who achieved CR than in patients 
without CR (ETV: -3.22 vs. -1.71 log U/mL, p<0.001; PEG-IFN add-on: -3.16 
vs. -1.83 IU/mL, p<0.001). Similarly, HBcrAg decline was more prominent 
in patients with HBsAg response compared with those without (ETV: -2.60 vs. 
-1.74 log U/mL, p<0.001; PEG-IFN add-on: -2.38 vs. -2.15 log U/mL, p=0.31). 
HBcrAg levels at randomisation were associated with CR (adjusted OR 0.3, 
CI-95% 0.2-0.5, p<0.001), but were not better than serum quantitative HBsAg 
levels (qHBsAg) in response prediction. 
Conclusions. HBcrAg levels were associated with response to ETV mono-
therapy and ETV with PEG-IFN add-on therapy for HBeAg-positive CHB, but 
were not superior to qHBsAg in response prediction.
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INTRODUCTION
In the management of chronic hepatitis B (CHB) infection, adequate assessment 
of viral replication activity is warranted in order to predict disease outcome 
and risk of reactivation. In addition, it is important for predicting response to 
nucleos(t)ide analogue (NA) and peginterferon (PEG-IFN) therapy, the two avail-
able treatment modalities for CHB. 
Measurement of intrahepatic covalently closed circular DNA (cccDNA) is thought 
to provide information on the replication activity of the virus, because it is the 
main template for synthesis of viral proteins 42, 52. PEG-IFN treatment induces a 
reduction of intrahepatic cccDNA 72, and Sung et al. reported the potential value 
of cccDNA measurement in post-treatment liver biopsies for the prediction of sus-
tained response to PEG-IFN treatment 73. To assess functional cure of CHB with 
current or future therapies, it is probably essential to assess the cccDNA levels in 
a reliable way. A major limitation for the clinical use of cccDNA measurements 
is the need for a liver biopsy. Availability of a serum surrogate marker could be 
a solution to this problem. 
A possible marker associated with cccDNA is the Hepatitis B core-related anti-
gen (HBcrAg), a combined measure of three proteins coded by the precore/core 
region of the cccDNA: Hepatitis B core antigen (HBcAg), Hepatitis B e antigen 
(HBeAg) and a 22-kDa precore protein (p22cr). It was recently demonstrated 
that HBcrAg correlates with intrahepatic cccDNA in CHB patients 74, 75. More-
over, HBcrAg could be detected in patients with loss of serum Hepatitis B surface 
antigen (HBsAg), which is nowadays regarded to as the most favorable clinical 
outcome, or in patients with undetectable serum HBV DNA levels 74-76. HBcrAg 
dynamics have been described in natural history and during NA therapy 77-79, 
but it is unknown how HBcrAg levels are inﬂuenced by PEG-IFN therapy. 
The purpose of this study was to describe serum HBcrAg dynamics in HBeAg-
positive CHB patients treated within an international multicenter randomised 
controlled trial comparing ETV monotherapy with ETV + PEG-IFN add-on therapy, 
and to assess the role of HBcrAg in (sustainable) treatment response in addition 
to HBV DNA and quantitative HBeAg (qHBeAg) and HBsAg (qHBsAg) levels. 
PATIENTS AND METHODS
Study population. 
HBcrAg levels were studied in 175 HBeAg-positive CHB patients treated within 
an international randomised trial in which patients were treated with ETV from 
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week 0 – 24 and were allocated at week 24 to either receive ETV with PEG-IFN 
add-on therapy (n=85) up to week 48, or to continue ETV monotherapy (n=90) 
80. Patients who achieved a combination of HBeAg loss and HBV DNA levels 
<200 IU/mL (combined response, CR) at week 48 discontinued ETV at week 
72, while non-responders continued ETV for the complete study period up to 
week 96. All patients were followed through week 96 (Supplementary ﬁgure 
1). During PEG-IFN treatment, study visits were performed every 4 weeks for 
routine examination and laboratory tests, while patients on ETV monotherapy 
visited the clinic every 12 weeks. The inclusion and exclusion criteria for this 
trial are described elsewhere 80. The study was conducted in agreement with 
the guidelines of the Declaration of Helsinki and the principles of Good Clinical 
Practice. All patients gave written informed consent according to standards of 
the local ethics committees.
Endpoints
HBcrAg level dynamics are described both during and after treatment. Also, the 
association between serum HBcrAg levels and combined response (CR; HBeAg 
loss and HBV DNA <200 IU/mL) or HBsAg response (qHBsAg decline of ≥1 
log10 IU/mL and/or a level of <1000 IU/mL) were assessed at week 72 (24 
weeks after PEG-IFN cessation), as these endpoints are associated with long-
term disease remission 81. We speciﬁcally chose week 72 as the time-point for 
assessment of on-treatment response, because 22 patients stopped ETV after 
week 72 80. Finally, we assessed the association between HBcrAg levels and 
week 96 off-treatment response. Relapse was deﬁned as HBeAg seroreversion 
and/or an HBV DNA >200 IU/mL after stopping ETV. 
Laboratory measurements
Serum samples were taken at baseline and during treatment. HBcrAg was mea-
sured using the Lumipulse® G HBcrAg assay (Fujirebio Europe, Belgium) in serum 
samples stored at -200 Celsius. In the present study units were expressed as U/mL. 
A detailed description of the test procedure is provided as a supplementary ﬁle. 
Serum ALT levels were standardized by calculating the value times the ULN per 
centre and gender. HBV DNA was measured using the Cobas TaqMan 48 poly-
merase chain reaction assay (Roche Diagnostics, Basel, Switzerland, lower limit 
of quantiﬁcation 20 IU/mL). Serum qHBeAg and qHBsAg levels were measured 
using the Cobas Elecsys 411 (Roche Diagnostics, Basel, Switzerland, lower limit 
of detection 0.30 IU/mL and 0.05 IU/mL, respectively). HBV genotype analysis 
was performed using the INNO-LiPA HBV genotype assay (Innogenetics, Ghent, 
Belgium). The presence of precore (PC, nucleotide position G1896) and/or 
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basal core promoter (BCP, nucleotide positions A1762 and G1764) was as-
sessed using the INNO-LiPA HBV PreCore assay (Innogenetics, Ghent, Belgium).
Statistical analysis 
SPSS version 21.0 (SPSS Inc., Chicago, IL, USA) and the SAS 9.3 program (SAS 
Institute Inc., Cary, NC, USA) were used to perform statistical analyses. Skewed 
laboratory values were log-transformed prior to analyses and were expressed as 
mean (standard deviation [SD]). Associations between variables were tested using 
Student’s t-test, Chi-square, Pearson correlation or their non-parametric equivalents 
when appropriate. Subgroup analysis for mean HBcrAg levels at baseline was 
performed using ANOVA with Bonferroni correction for intergroup comparison. 
HBcrAg, qHBsAg, qHBeAg and HBV DNA declines were analyzed with repeated 
measurement models adjusting for baseline values. We performed logistic regres-
sion analysis to determine factors associated with CR. The performance of the 
retrieved models was tested with Receiver Operating Characteristic (ROC) Curve 
Analysis. All analyses were performed two-sided at the 0.05 level of signiﬁcance. 
RESULTS
Study cohort 
Of the 175 patients included, 85 were treated with PEG-IFN add-on and 90 patients 
with ETV monotherapy. The patient characteristics are shown in Table 1. In total 
107 (61%) Asian and 65 (37%) Caucasian patients were included, which was 
reﬂected by the distribution of HBV genotype A/B/C/D, found in 5/23/39/33% 
and 10/14/46/30% for add-on vs. ETV monotherapy, respectively. 
Serum HBcrAg levels at baseline
For the total cohort, the mean of baseline serum HBcrAg levels was 8.1 (0.8) log 
U/mL. Mean HBcrAg levels did not signiﬁcantly differ across HBV genotypes at 
baseline (p=0.12, Supplementary ﬁgure 2). Among the 16 patients infected with 
wildtype HBV only, HBcrAg levels ranged from 6.4 to 9.0 log U/mL. Mean se-
rum HBcrAg levels were lower in the presence of BCP mutation than PC mutation 
(8.0 (0.8) log U/mL vs. 7.7 (0.9) log U/mL, p=0.034, Supplementary ﬁgure 2). 
Baseline HBcrAg levels correlated with baseline qHBeAg (r=0.9, p<0.001), qH-
BsAg (r=0.4 p<0.001) and HBV DNA (r=0.7, p<0.001) (Supplementary ﬁgure 
3). By Bland-Altman analysis, standardized HBcrAg and qHBeAg measurements 
showed close agreement at baseline (Supplementary ﬁgure 4).
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Table 1. Patient characteristics
Characteristics
ETV monotherapy 
(n=90)
PEG-IFN
add-on (n=85)
Demography
Age, years 31 (9) 32 (10)
Male, n (%) 62 (69) 63 (74)
Race, n (%)
Caucasian 35 (39) 30 (35)
Asian 54 (60) 53 (63)
Other 1 (1) 2 (2)
HBV Genotype: A/B/C/D (%) 10/14/46/30 5/23/39/33
INNO-LiPA result, n (%)
Wildtype virus 7 (8) 9 (12)
Precore mutations 13 (16) 21 (27)
Basal core promoter mutations 16 (19) 7 (9)
Precore & Basal core promoter mutations 48 (57) 40 (52)
Histology
Ishak ﬁbrosis
0-2 47 (54) 53 (65)
3-4 35 (40) 25 (31)
5-6 5 (6) 3 (4)
Cirrhosis, n (%) 5 (6) 3 (4)
Week 0 laboratory results *
ALT (x ULN) † 2.7 (2.1) 3.1 (3.3)
HBV DNA ‡ 7.8 (1.1) 7.8 (1.3)
HBcrAg § 8.0 (0.9) 8.1 (0.8)
qHBsAg ‡ 4.1 (0.8) 4.2 (0.8)
qHBeAg ‡ 2.3 (1.0) 2.3 (1.0)
Week 24 laboratory results
ALT (x ULN) † 0.8 (0.6) 0.8 (0.4)
HBV DNA ‡ ˞ 2.3 (1.4) 2.8 (1.5)
HBcrAg § 6.8 (1.1) 7.0 (1.0)
qHBsAg ‡ 3.7 (0.8) 3.7 (0.7)
qHBeAg ‡ 0.9 (1.2) 1.1 (1.1)
Continuous variables are expressed as mean (SD), categorical variables as n (%).
* Patients were randomised at week 24 and thus not yet allocated at week 0.
† Multiples of upper limit of the normal range
‡ Logarithmic scale, IU/mL
§ Logarithmic scale, U/mL
˞ HBV DNA levels differed at week 24 (p=0.021)
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On-treatment serum HBcrAg dynamics
At week 72, CR had been achieved in 27/85 (32%) of patients assigned PEG-
IFN add-on and 16/90 (18%) of patients assigned ETV monotherapy (p=0.032). 
Furthermore, HBsAg response was achieved in 39/85 (46%) vs. 25/90 (28%) 
for PEG-IFN add-on vs. monotherapy (p=0.013). HBcrAg decline at week 72 
did not differ between patients treated with PEG-IFN add-on and patients treated 
with ETV monotherapy (-2.10 vs. -1.96 log U/mL, p=0.12).
ETV monotherapy
For patients allocated to the ETV monotherapy arm, signiﬁcantly more decline 
was observed at week 72 for patients with CR than for those without CR (-3.22 
vs. -1.71 log U/mL, p<0.001, Figure 1). During the ﬁrst 24 weeks of treatment, 
this distinction between responders and non-responders was already apparent 
with a mean HBcrAg decline at week 24 of -2.19 vs. -1.04 log U/mL, p<0.001, 
respectively. This was also observed from week 48 to week 72: HBcrAg decline 
in responders was stronger than in non-responders (-0.59 vs. -0.28 log U/mL, 
p=0.05). Likewise, in those patients who achieved HBsAg response, mean 
declines were stronger than in non-responders (week 24: -1.64 vs. -1.10 log U/
mL, p=0.03; week 72: -2.60 vs. -1.74 log U/mL, p<0.001). HBcrAg decline dif-
fered across HBV genotype, with strongest decline in genotype A and weakest 
decline in genotype D (A: -2.62 log U/mL; B: -2.16 log U/mL; C: -1.90 log U/
mL; D: -1.74 log U/mL; A vs. D: p=0.02; other comparisons p>0.10).
Peginterferon add-on therapy
Within the group of PEG-IFN add-on treated patients, there was also a difference 
in HBcrAg decline between patients who achieved CR and those who did not 
(-3.16 vs. -1.83 log U/mL, p<0.001). Between week 48 (the moment of PEG-IFN 
cessation) and week 72, HBcrAg decline in responders was -0.49 log U/mL, 
whereas it was -0.15 log U/mL in non-responders (p=0.04). Patients in the 
add-on arm with HBsAg response at week 72 showed more HBcrAg decline 
than HBsAg non-responders (-2.51 vs. -2.04 log U/mL, p=0.05). Like in ETV 
monotherapy, HBcrAg decline differed across genotype with strongest decline 
in genotype A and weakest decline in genotype D (A: -3.16 log U/mL; B: -2.61 
log U/mL; C: -2.37 log U/mL; D: -1.76 log U/mL; A vs. D: p=0.01; B vs. D: 
p=0.002; C vs. D: p=0.013). 
One patient lost HBsAg at week 48, and still had detectable HBcrAg (5.33 log 
U/mL). In this patient, HBsAg had reappeared at week 72. At week 72, no 
patient was HBsAg negative. At week 96, another patient had conﬁrmed HBsAg 
loss, who also had detectable HBcrAg (3.30 log U/mL). 
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On-treatment serum HBcrAg in relation to serum HBV DNA, qHBsAg and 
qHBeAg
Serum qHBsAg, qHBeAg, and HBV DNA, also declined signiﬁcantly stronger in 
patients who achieved combined response than in patients who did not (qHBsAg 
decline -0.80 vs. -0.50 IU/mL, p=0.03, ﬁgure 1b; qHBeAg decline -3.46 vs. 
-1.63 log IU/mL, p<0.001; and HBV DNA decline -7.13 vs. -5.98 log IU/mL, 
p<0.001). In patients treated with PEG-IFN add-on, both HBcrAg and qHBsAg 
decline continued after HBeAg loss. In patients treated with ETV monotherapy, 
HBcrAg decline also continued after HBeAg loss, whereas qHBsAg levels did 
not. From week 48 to 72, HBcrAg and qHBeAg declined further (HBcrAg: -0.29 
log U/mL, p<0.001; qHBeAg: -0.34 log IU/mL, p<0.001). In contrast, qHBsAg 
levels remained stable within this time interval (-0.02 IU/mL, p=0.244). No dif-
ference in decline between treatment arms was observed within this time interval 
(HBcrAg: p=0.55; qHBeAg: p=0.36, qHBsAg: p=0.50).
Figure 2 shows dynamics of all markers in 6 example patients, illustrating differ-
ences between these markers for different treatment and response combinations. 
Figure 1a. HBcrAg decline according to week 72 response
a. HBcrAg decline in the ETV monotherapy arm between week 0 and 72 according to combined response at week 
72.
b. HBcrAg decline in the PEG-IFN add-on arm between week 0 and 72 according to combined response at week 72.
c. HBcrAg decline in the ETV monotherapy arm between week 0 and 72 according to HBsAg response at week 72.
d. HBcrAg decline in the PEG-IFN add-on arm between week 0 and 72 according to HBsAg response at week 72.
Declines are expressed as mean log U/mL with error bars representing standard errors of mean.
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Serum HBcrAg as a predictor of week 72 combined response 
Adjusted for therapy allocation, HBV genotype and week 24 serum ALT, lower 
HBcrAg at week 24 was independently associated with increased probability 
of achieving CR (OR 0.3, 95% conﬁdence interval [CI-95%] 0.2-0.5, p<0.001, 
Table 2). There were no signiﬁcant interactions with therapy allocation. There 
was a good predictive ability for this model (AUC 0.86, CI-95% 0.80-0.91, 
p<0.001). In a sensitivity analysis, in which 13 patients who were already 
HBeAg-negative at week 24 had been excluded, performance of the HBcrAg 
model was comparable (AUC 0.86, CI-95% 0.80-0.92, p<0.001). To demon-
strate the performance of week 24 qHBsAg, qHBeAg, or HBV DNA levels in 
a similar prediction model, we substituted HBcrAg by each of these markers 
separately: qHBeAg AUC 0.89 (CI-95% 0.84-0.94); qHBsAg AUC 0.81 (CI-
95% 0.75-0.88); HBV DNA AUC 0.86 (CI-95% 0.80-0.91) (all p<0.001). 
Lower HBcrAg at week 36 (12 weeks after randomization) was also associ-
ated with increased probability of achieving CR (OR 0.1, CI-95% 0.04-0.2, 
Figure 1b. qHBsAg decline according to week 72 response
a. qHBsAg decline in the ETV monotherapy arm between week 0 and 72 according to combined response at week 
72.
b. qHBsAg decline in the PEG-IFN add-on arm between week 0 and 72 according to combined response at week 72.
c. qHBsAg decline in the ETV monotherapy arm between week 0 and 72 according to HBsAg response at week 72.
d. qHBsAg decline in the PEG-IFN add-on arm between week 0 and 72 according to HBsAg response at week 72.
Declines are expressed as mean log IU/mL with error bars representing standard errors of mean.
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Figure 2. Dynamics of HBcrAg, qHBeAg, qHBsAg and HBV DNA in 6 example patients. 
a. Patient with 96 weeks of ETV therapy, no CR.
b. Patient with 96 weeks of ETV therapy, CR.
c. Patient with 72 weeks of ETV therapy + PEG-IFN add-on from week 24-48. CR at week 48, sustained off-treatment 
CR.
d. Patient with 96 weeks of ETV therapy + PEG-IFN add-on from week 24-48. CR and HBsAg loss. 
e. Patient with 72 weeks of ETV therapy + PEG-IFN add-on from week 24-48. CR at week 48, but off-treatment HBeAg 
seroreversion and HBV DNA >200 IU/mL.
f. Patient with 72 weeks of ETV therapy + PEG-IFN add-on from week 24-48. CR at week 48, off-treatment sustained 
HBeAg negativity, but HBV DNA >200 IU/mL at week 96.
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p<0.001, adjusted for therapy allocation, HBV genotype and week 36 serum 
ALT), and was good at predicting CR (AUC 0.88, CI-95% 0.83-93, p<0.001). 
Substitution of HBcrAg by week 36 qHBeAg, qHBsAg, or HBV DNA levels led 
to AUCs of 0.91 (CI-95% 0.86-0.96), 0.76 (CI-95% 0.68-0.83) and HBV DNA 
AUC 0.83 (CI-95% 0.76-0.89), respectively (all p<0.001). 
Serum HBcrAg in relation to relapse
At week 72, 14/85 (17%) assigned to PEG-IFN add-on and 8/90 (9%) assigned 
to ETV monotherapy stopped treatment because of CR achievement at week 48. 
CR was maintained through week 96 in 9/14 (64%) and 2/8 (25%) patients, 
respectively. Regardless of therapy allocation, HBcrAg declined off-treatment in 
9 out of these 11 patients, and in 1 patient HBcrAg remained stable. HBcrAg 
was missing at week 96 in 1 patient. In contrast, in 11 patients who did not 
maintain CR after ETV cessation, HBcrAg decline was seen in 2 patients only 
(both allocated to PEG-IFN add-on). The individual patterns of HBcrAg after 
cessation of ETV are shown in Figure 3. 
DISCUSSION
In this study of HBeAg-positive patients treated with ETV monotherapy or ETV 
+ PEG-IFN add-on therapy, we have shown that HBcrAg levels decline during 
treatment. HBcrAg dynamics strongly resembled those of qHBeAg, but HBcrAg 
Figure 3. Individual HBcrAg dynamics in patients who stopped ETV at week 72.
Twenty-two patients stopped ETV at week 72 based on achievement of CR at week 48.
Week 72 and 96 HBcrAg levels available at both time points in 20/22 patients. Red lines represent patients who 
did not maintain CR through week 96 (HBeAg seroreversion and/or HBV DNA >200 IU/mL after stopping ETV).
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levels declined even after HBeAg loss. Although HBcrAg levels were not superior 
to qHBsAg, qHBeAg, or HBV DNA levels in response prediction, we demon-
strated that HBcrAg levels at randomization were independently associated with 
response to both ETV monotherapy and PEG-IFN add-on therapy. Interestingly, 
HBcrAg patterns were predictive for sustained off-treatment response. HBcrAg 
strongly declined prior to HBsAg loss, but could still be detected at time of 
conﬁrmed HBsAg negativity. HBcrAg may thus be useful as a new serum marker 
for CHB treatment, particularly now that our next challenge in therapy is to 
achieve functional cure with HBsAg seroconversion.
The ﬁndings of our study are important, because few serum markers are consid-
ered to be accurate to assess immune control and to predict the sustainability of 
treatment response in CHB. Measurement of intrahepatic cccDNA is superior to 
serum qHBsAg or HBV DNA in the prediction of sustained response to antiviral 
treatment 73. In addition, cccDNA can still be detected after loss of HBsAg, acting 
as a substrate for viral reactivation during immunosuppressive states 82. There 
is a need for serum makers that correlate with cccDNA and HBcrAg has been 
shown to do that in both HBeAg-positive and HBeAg-negative patients 74, 75. To 
our knowledge, we are the ﬁrst to describe on-treatment HBcrAg measurements 
for NA and PEG-IFN combination therapy, a treatment strategy that has been 
shown to induce increased immune control over NA alone 61, 80. Our data on the 
comparison with other serum markers provides important information for future 
studies on HBcrAg, and gives a better understanding of the clinical applicability 
of HBcrAg in HBeAg-positive CHB.
Mean HBcrAg levels at baseline in our study population were in the same range 
as the mean levels reported for HBeAg-positive patients in other studies 74, 77, 78. 
Previously, it has been described that the correlation of HBcrAg to serum HBV 
DNA and HBsAg is strongest for HBeAg-positive CHB 74, 83, 84. Our results were 
similar, and showed comparable correlation coefﬁcients. In natural history stud-
ies, the correlation of HBcrAg with HBV DNA and HBsAg in the HBeAg-negative 
low replicative phase was either week or absent 83, 84. This may explain why the 
differences in decline between HBsAg responders and HBsAg non-responders 
were less apparent than those between combined responders and non-respond-
ers. HBcrAg was still detected in patients with undetectable HBsAg, which is also 
in line with observations by others 74, 76. In addition to possibilities for monitoring 
treatment response and relapse in CHB, it would therefore be interesting to 
validate this ﬁnding, and to explore HBcrAg as a marker for reinfection after 
liver transplantation, or for reactivation during immunosuppression 76. 
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The close agreement of the results of HBcrAg and qHBeAg measurements in 
HBeAg-positive CHB illustrates that HBeAg comprises a considerable fraction of 
HBcrAg 85. For HBeAg-positive disease, we did not ﬁnd HBcrAg measurements 
to be superior to qHBsAg, qHBeAg, or HBV DNA levels in response prediction. 
Therefore, HBcrAg levels may not provide additional beneﬁt in clinical practice 
for this patient group. However, as serum markers for immune control in HBeAg-
negative CHB are lacking, new markers for response prediction in this group 
are in demand. The observation of continuous decline of HBcrAg after HBeAg 
loss suggests that the levels of at least one out of three HBcrAg components 
further decreases. This ﬁnding therefore highlights the importance of investigat-
ing HBcrAg measurements in HBeAg-negative disease, preferably in PEG-IFN 
monotherapy as we may not be able to directly extrapolate our ﬁndings towards 
this treatment strategy. The predictive ability of HBcrAg levels for relapse after 
NA cessation has previously been described by a Japanese group 86. Due to 
the limited number of patients that stopped treatment in our study, we could 
not conﬁrm this speciﬁc role of HBcrAg. By multivariable analysis, genotype 
and presence of PC and/or BCP mutations were not associated with response, 
but his may be explained by the small subgroups. No interaction was found 
between HBV genotype and HBcrAg levels. 
In conclusion, we have shown that serum HBcrAg levels were associated with on-
treatment and off-treatment response in HBeAg-positive CHB. For better assess-
ment of the role of this marker in off-treatment response, longer follow-up after 
treatment cessation is needed. Although HBcrAg was not superior to qHBsAg 
and HBV DNA, which are the commonly used markers for response prediction 
in HBeAg-positive patients,HBcrAg performed well in the prediction of response. 
This ﬁnding, and our ﬁndings of continuing HBcrAg decline after HBeAg loss 
and the detectibility of HBcrAg after HBsAg loss are an important step towards 
future studies of this marker in HBeAg-negative patients and HBsAg-negative 
patients. 
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SUPPLEMENTARY FIGURES
Supplementary ﬁgure 1. Original study design.
* Response was deﬁned as HBeAg loss with HBV DNA <200 IU/mL
**Responders were to stop ETV therapy at week 72 and thus received at least 24 weeks of consolidation therapy. 
Two responders assigned to add-on and 1 responder assigned monotherapy continued ETV monotherapy (protocol 
violation).
Supplementary ﬁgure 2. Baseline HBcrAg according to precore/core mutations and genotype. 
HBcrAg expressed as mean (SD) log U/mL. Mean HBcrAg levels did not signiﬁcantly differ across HBV genotypes 
at baseline (p=0.12).  Mean serum HBcrAg levels were lower in the presence of BCP mutation than PC mutation.
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Supplementary ﬁgure 3. Correlation of HBcrAg to HBV DNA, qHBsAg and qHBeAg at baseline. 
At baseline, HBcrAg was correlated to HBV DNA, qHBeAg and qHBsAg (r=0.7, r=0.9, r=0.4, all p<0.001). 
Supplementary ﬁgure 4. Standardized comparison of HBcrAg and qHBeAg.
Graph markers represent standardized comparison of HBcrAg and qHBeAg per patient. Tests are considered compa-
rable if the slope of the regression line that can be ﬁt is signiﬁcantly different from 0. HBcrAg and qHBeAg measure-
ments showed close agreement at baseline.


4
Hepatitis B core-related antigen 
monitoring during 
peginterferon alfa treatment for 
HBeAg-negative chronic hepatitis B
Margo J.H. van Campenhout1, Vincent Rijckborst1, Willem Pieter Brouwer1, Gertine W. van 
Oord1, Peter Ferenci2, Fehmi Tabak3, Meral Akdogan4, Binnur Pinarbasi5, Krzysztof Simon6, 
Robert J. de Knegt1, André Boonstra1, Harry L.A. Janssen7, and Bettina E. Hansen1,7,8
1Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The 
Netherlands; 2Department of Internal Medicine, Gastroenterology and Hepatology, Medical University of Vienna, 
Vienna, Austria; 3Cerrahpasa Medical Faculty, Istanbul, Turkey; 4Department of Gastroenterology, Yuksek Ihtisas 
Hospital, Ankara, Turkey; 5Division of Gastroenterohepatology, Department of Internal Medicine, Istanbul Faculty 
of Medicine, Istanbul University, Turkey; 6Division of Infectious Diseases and Hepatology, Wroclaw Medical 
University, Wroclaw, Poland; 7Toronto Center for Liver Disease, Toronto Western and General Hospital, University 
Health Network, Toronto, Canada; 8 Institute of Health Policy, Management and Evaluation, University of Toronto, 
Toronto, Canada.
Journal of Viral Hepatitis
72 Chapter 4
ABSTRACT
Background & aims. Serum Hepatitis B core-related antigen (HBcrAg) level 
moderately correlates with cccDNA. We examined whether HBcrAg can add 
value in monitoring the effect of peginterferon (PEG-IFN) therapy for HBeAg-
negative chronic hepatitis B (CHB) infection. 
Methods. Serum HBcrAg level was measured in 133 HBeAg-negative, mainly 
Caucasian CHB patients, treated with 48 weeks of PEG-IFN alfa-2a. We as-
sessed its association with response (ALT normalization & HBV DNA <2,000 
IU/mL) at week 72. 
Results. HBcrAg level strongly correlated with HBV DNA level (r=0.8, 
p<0.001) and weakly with qHBsAg and ALT (both r=0.2, p=0.01). At week 48, 
mean HBcrAg decline was -3.3 log U/mL. Baseline levels were comparable for 
patients with and without response at week 72 (5.0 vs. 4.9 log U/mL, p=0.59). 
HBcrAg decline at week 72 differed between patients with and without response 
(-2.4 vs. -1.0 log U/mL, p=0.001), but no cut-off could be determined. The pat-
tern of decline in responders resembled that of HBV DNA, but HBcrAg decline 
was weaker (HBcrAg -2.5 log U/mL; HBV DNA: -4.0 log IU/mL, p<0.001). 
For early identiﬁcation of nonresponse, diagnostic accuracy of HBV DNA and 
qHBsAg decline at week 12 (AUC 0.742, CI-95% [0.0.629-0.855], p<0.001) 
did not improve by adding HBcrAg decline (AUC 0.747, CI-95% [0.629-0.855] 
p<0.001), nor by replacing HBV DNA decline by HBcrAg decline (AUC 0.754, 
CI-95% [0.641-0.867], p<0.001). 
Conclusions. In Caucasian patients with HBeAg-negative CHB, decline of 
HBcrAg during PEG-IFN treatment was stronger in patients with treatment re-
sponse. However, HBcrAg was not superior to HBV DNA and qHBsAg to predict 
response in PEG-IFN treatment. 
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BACKGROUND
While awaiting new therapeutic agents for chronic hepatitis B (CHB) that induce 
a high rate of functional cure, peginterferon (PEG-IFN) treatment remains an 
important therapeutic strategy. In order to avoid unnecessary exposure to the 
common side-effects, early identiﬁcation of non-responders is warranted. In 
patients with HBeAg-negative CHB, on-treatment monitoring of serum hepatitis 
B virus (HBV) DNA levels and serum quantitative hepatitis B surface antigen 
(qHBsAg) levels allows premature treatment cessation in those who have a low 
probability of achieving response. Unfortunately, identiﬁcation of these patients 
before treatment is limited by the lack of patient and viral characteristics that 
accurately predict therapy response, particularly in HBeAg negative disease. 87 
In addition, it is difﬁcult to predict relapse after stopping PEG-IFN which neces-
sitates long-term monitoring of patients after the treatment course. 
The preferential method to predict and assess the effect of therapy in CHB 
would be to directly assess the levels of intrahepatic covalently closed circular 
DNA (cccDNA), as this is the main template for viral protein synthesis and viral 
replication. 42, 52 However, cccDNA is difﬁcult to quantify and its measurement 
requires a liver biopsy, which is not a desired procedure to routinely perform due 
to its invasiveness. Monitoring levels of a surrogate serum marker correlating 
with cccDNA may be an alternative option.
A possible surrogate marker is hepatitis B core-related antigen (HBcrAg), which 
is a serum marker for the combined measure of 3 proteins coded by the pre-
core/core region of the cccDNA: hepatitis B core antigen (HBcAg), hepatitis 
B e antigen (HBeAg) and a 22-kD precore protein (p22cr). 85 HBcrAg levels 
moderately correlate with cccDNA 74, 76, 88, are associated with relapse after ces-
sation of nucleos(t)ide analogue (NA) therapy 86, 89-91, and can still be detected 
after HBsAg loss. 74, 92 In addition, HBcrAg levels at baseline predict response 
to PEG-IFN treatment in HBeAg-positive CHB. 93 It is yet unknown if HBcrAg can 
be used to monitor PEG-IFN treatment and to predict response and relapse in 
HBeAg-negative disease. Our aims were therefore to describe the dynamics of 
serum HBcrAg before, during and after PEG-IFN treatment in HBeAg-negative 
CHB patients, and to investigate the association between HBcrAg levels and 
sustained treatment response.
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PATIENTS AND METHODS
Study population
Serum HBcrAg levels were measured in available serum samples of 133 HBeAg-
negative CHB patients who were treated with PEG-IFN alpha-2a ± ribavirin 
within an international, double-blind randomised controlled trial. The inclusion 
criteria and exclusion criteria of the initial study have been described elsewhere. 
94 Patients were treated for 48 weeks and were followed for an additional 24 
weeks. The treatment arms were pooled for all analyses, as the response rates 
between the treatment groups did not differ. Serum samples were taken at 
baseline, during treatment at week 4, 8, 12, 24, 36, and week 48, and during 
post-treatment follow-up at week 60 and 72. Of 79 patients long-term follow-
up (LTFU) data regarding treatment response was available. The mean interval 
between week 48 and this LTFU visit was 2.1 (SD 0.2) years. 95
Endpoints
Serum HBcrAg dynamics were evaluated during treatment and during post-
treatment follow-up of the initial study. We primarily assessed the correlation of 
HBcrAg levels with combined response (response; ALT normalization and HBV 
DNA <2,000 IU/mL) at week 72. Secondary endpoints were response at LTFU, 
and relapse (deﬁned as not fulﬁlling criteria of response) at week 72 and at LTFU 
for patients with week 48 response.
Serum HBcrAg measurements
HBcrAg was measured using the Lumipulse® G HBcrAg assay (Fujirebio Europe, 
Belgium) in serum samples stored at -800 Celsius. A pre-heat treatment in pres-
ence of a provided detergent solution was applied for extracting denatured 
precore/core proteins and for the inactivation of circulating antibodies to HBcAg 
and HBeAg. The monoclonal antibodies used in the subsequent two-step immu-
noassay simultaneously detect all 3 HBV core-related proteins (HBeAg, HBcAg, 
p22cr), also when HBeAg is bound in HBeAg/anti-HBe immunecomplexes. This 
fully-automated assay uses ferrite particle suspension as solid phase in an immu-
noreaction cartridge and the relative luminescence intensity reﬂects the amount 
of HBV core-related proteins. HBcrAg concentration is calculated by a standard 
curve generated using recombinant pro-HBeAg (aa -10 to 183) and is expressed 
in unit of kU/mL by the Lumipulse® G system. The analytical sensitivity is 1 kU/
mL and the measurement range is from 1 to 10,000 kU/mL. 85 In the present 
study units were expressed as U/mL. For statistical analysis, the value of 100 
U/mL (2 log U/mL) was used for results below the lower limit of quantiﬁcation. 
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Other laboratory measurements
Routine biochemical and hematological tests were performed locally. Serum ALT 
levels were standardized by calculating the value times for the upper limit of nor-
mal (ULN) per centre and gender. For all visits, virological tests were performed 
at one central laboratory (Erasmus Medical Center, Rotterdam, The Netherlands). 
HBV DNA was measured using the Taqman HBV assay (Roche Diagnostics, 
lower limit of quantiﬁcation 35 copies/mL [6 IU/mL]). Serum qHBsAg levels 
were measured using the Architect HBsAg assay (Abbott Laboratories; range 
0.05-250 IU/mL) or the Elecsys Assay (Roche Diagnostics, Basel, Switzerland, 
lower limit of detection 0.05 IU/mL). HBV genotype analysis was performed 
using the INNO-LiPA HBV genotype assay (Fujirebio Europe, Ghent, Belgium). 
The presence of PC and BCP mutants was assessed using the INNO-LiPA HBV 
PreCore assay (Fujirebio Belgium, Ghent, Belgium), which detects precore (PC) 
mutations at nucleotide position 1896 and basal core promoter (BCP) mutations 
at nucleotide positions 1762 and 1764. 
Statistical analysis
SPSS version 21.0 (SPSS Inc., Chicago, IL, USA) and the SAS 9.3 program (SAS 
Institute Inc., Cary, NC, USA) were used to perform statistical analyses. Skewed 
laboratory values were log-transformed prior to analyses and were expressed 
as mean (standard deviation [SD]). Associations between variables were tested 
using Student’s t-test, Chi-square, Pearson correlation or their non-parametric 
equivalents when appropriate. Subgroup analysis for mean HBcrAg levels at 
baseline was performed using ANOVA with Bonferroni correction for intergroup 
comparison. We performed logistic regression analysis to determine factors 
associated with response. The performances of the retrieved prediction models 
were tested with Receiver Operating Characteristic (ROC) Curve Analysis. All 
analyses were performed two-sided at the 0.05 level of signiﬁcance. 
RESULTS
Study cohort
Patient characteristics are shown in Table 1. The majority of patients were of 
Caucasian ethnicity, which is reﬂected by the high proportion of patients with 
HBV genotype D and A. At baseline, mean HBV DNA level was log 6.1 (1.2) 
log IU/mL and mean qHBsAg level was 3.8 (0.6) log IU/mL. In 6 patients 
(5%) no mutations in the basal core promoter (BCP) regions 1762 and 1764 
or the precore (PC) region could be detected. In the other 127 (95%) patients, 
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mutations were detected in one or both of the BCP regions (n=14, 10%), the 
PC region (n=24, 18%), or in BCP and PC regions (n=89, 67%). In 93 patients 
(70%) a mutation in the HBV precore region was detected without the simultane-
ous presence of HBV PC wildtype virus, leading to disabled HBeAg and p22cr 
production (non-sense G-A change in nucleotide 1896). In 20 patients (15%), 
both PC mutant and wildtype were detected. 
HBcrAg levels at baseline 
At baseline, mean serum HBcrAg level was 5.0 (1.2) log U/mL. Correlation of 
HBcrAg levels with levels of HBV DNA was strong (r=0.8, p<0.001) and cor-
relations with qHBsAg and ALT were weak (both r=0.2, p=0.01). Mean HBcrAg 
Table 1. Patient characteristics
Characteristics
All patients 
(n=133)
Demography
Age, years 42 (11)
Male, n(%) 98 (74)
Caucasian race, n (%) 127 (95)
HBV genotype
A/B/C/D/other (%) 13/1/2/81/3
HBV basal core promoter and precore mutations
Wildtype / any BCP / any PC / any BCP or PC (%) 5/10/18/67
 A1762: mutant / mixed / wildtype only (%) 43/10/47
 G1764: mutant / mixed / wildtype only (%) 65/12/23
 A1896: mutant / mixed / wildtype only (%) 70/15/15
History
Previous interferon therapy (≥4 weeks) 24 (18)
Cirrhosis, n (%) 4(3)
Laboratory results*
ALT (x ULN) † 3.2 (2.6)
HBV DNA ‡ 6.1 (1.2)
HBcrAg § 5.0 (1.2)
qHBsAg ‡ 3.8 (0.6)
ALT, alanine aminotransferase; HBcrAg, hepatitis B core-related antigen; HBV, hepatitis B virus; qHBsAg, quantitative 
hepatitis B surface antigen
* Continuous variables are expressed as mean (SD), categorical variables as n (%).
† Multiples of upper limit of the normal range
‡ Logarithmic scale, IU/mL
§ Logarithmic scale, U/mL
Legends to ﬁgures
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was lowest in patients with mutations in both BCP and PC regions (4.8 log U/
mL), which was signiﬁcantly lower than in patients with PC mutation only (5.6 
log U/mL, p=0.03), but did not signiﬁcantly differ to HBcrAg level in patients 
with BCP mutations only (5.3 log U/mL) or in patients infected with wildtype 
HBV (4.7 log U/mL). In the 6 patients infected with wildtype virus only, HBcrAg 
levels ranged from undetectable to 6.11 log U/mL. To assess the correlation of 
HBcrAg with HBV DNA, qHBsAg and ALT when HBeAg and p22cr production 
are disabled by PC mutation, subgroup analysis was performed in 93 patients 
with a mutation in the HBV precore region without the simultaneous presence of 
HBV precore wildtype. For these 93 patients, the correlations of HBcrAg with 
HBV DNA and ALT were similar as the correlations for the entire cohort (HBV 
DNA: r=0.8, p<0.001; qHBsAg: r=0.2, p=0.11; ALT: r=0.3, p=0.11). 
HBcrAg levels at baseline in relation to combined response
Combined response (response) was achieved in 25/133 (19%) patients at week 
72, and in 16/79 (20%) patients at long-term follow-up (LTFU). HBcrAg levels 
at baseline were comparable for patients with vs. without response at week 72 
(5.0 vs. 4.9 log U/mL, p=0.59, Figure 1a) and with vs. without response at 
LTFU (5.1 vs. 4.6 log U/mL, p=0.18, Figure 1b). The mean levels of HBV DNA 
and qHBsAg were also not discriminative for response at week 72 (HBV DNA: 
p=1.00, qHBsAg: 0.99). In 5 patients HBcrAg was undetectable already at 
baseline. Among these 5 patients, 2 patients achieved response at both week 
72 and LTFU. 
Figure 1a. Absolute serum HBcrAg levels in according to response at week 72.
Black dots represent single HBcrAg measurements, with black dots representing patients who achieved response 
(HBV DNA <2,000 IU/mL and normal ALT) at week 72, and grey circles representing patients who did not achieve 
response at week 72. HBcrAg is expressed as log U/mL. For results below the lower limit of quantiﬁcation (1000 U/
mL, 3 log U/mL), the value of 100 U/mL (2 log U/mL) was used. 
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HBcrAg levels during and after treatment in relation to combined 
response at week 72 and LTFU
On-treatment HBcrAg dynamics. 
During one year of PEG-IFN therapy a mean decline in HBcrAg of 3.3 log U/mL 
was reached, which did not differ between patients treated with ribavirin and 
patients treated with placebo (p=0.62). During treatment, absolute values of 
HBcrAg did not differ signiﬁcantly between patients with and without response 
at week 72. (Figure 1a; week 12: 3.7 vs. 3.3 log U/mL, p=0.18; week 24: 3.6 
vs. 3.0 log U/mL, p=0.09, week 36: 3.5 vs. 3.0 log U/mL, p=0.20). In contrast, 
absolute HBV DNA levels and qHBsAg levels already differed from week 24 
onward (week 24: HBV DNA: 2.0 vs. 3.2 log IU/mL, p=0.02; qHBsAg: 2.9 vs. 
3.7 log IU/mL, p<0.001). For response at LTFU, absolute HBcrAg levels differed 
signiﬁcantly from week 24 onward (Figure 1b). When considering decline in 
HBcrAg from baseline (Figure 2), no signiﬁcant difference between patients with 
and without response at week 72 was observed early on-treatment (week 4: 
1.00 vs. 0.94 log U/mL, p=0.65; week 8: 1.66 vs. 1.15 log U/mL, p=0.05), 
At week 12, 24, 60 and 72 however, HBcrAg decline was stronger in patients 
with response than in patients without response at week 72. In comparison, 
decline of HBV DNA differed signiﬁcantly between patients with and without 
week 72 response already from week 4 onward (week 4: -1.9 vs. -1.4 IU/mL, 
p=0.03), and qHBsAg decline differed from week 12 onward (week 12: -0.33 
Figure 1b. Absolute serum HBcrAg levels in according to response at long-term follow-up.
In a subset of 79/133 patients, long-term follow-up (LTFU) data regarding treatment response was available. Black 
dots represent single HBcrAg measurements, with black dots representing patients who achieved response (HBV DNA 
<2,000 IU/mL and normal ALT) at long-term follow-up, and grey circles representing patients who did not achieve 
response at long-term follow-up. HBcrAg is expressed as log U/mL. For results below the lower limit of quantiﬁcation 
(1000 U/mL, 3 log U/mL), the value of 100 U/mL (2 log U/mL) was used.
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vs. -0.05 IU/mL, p=0.02). In all patients with response at week 72, HBcrAg had 
declined from baseline (Figure 3). For early identiﬁcation of non-responders at 
week 72, the diagnostic accuracy based on HBV DNA and qHBsAg decline at 
week 12 (Supplementary table 1; area under the curve [AUC] 0.742, CI-95% 
[0.629-0.855], p<0.001) remained comparable when adding week 12 or week 
24 HBcrAg decline (AUC 0.747, CI-95% [0.629-0.855]; AUC 0.747, CI-95% 
[0.634-0.859]; both p<0.001), or replacing week 12 HBV DNA decline by 
week 12 HBcrAg decline (AUC 0.754, CI-95% [0.641-0.867], p<0.001). 
End-of-treatment HBcrAg levels and relapse prediction
At week 48, the proportion of patients with undetectable HBcrAg was 60% 
vs. 44% (p=0.18) for patients with vs. without response at week 72, and 80% 
vs. 39% for patients with vs. without response at LTFU (p=0.008). Within the 
subgroup of patients who had response at week 48 (n=51), no signiﬁcant as-
sociation of week 48 levels with relapse at week 72 could be demonstrated for 
HBcrAg (OR 2.5, CI-95% [0.7-6.8], p=0.16). In comparison, qHBsAg levels at 
week 48 were associated with relapse at week 72 (OR 1.8, CI-95% [1.1-3.0], 
p=0.02). This was similar for relapse at LTFU (week 48 HBcrAg: OR 2.0, CI-95% 
[0.6-7.0], p=0.27; week 48 qHBsAg: OR 3.1, CI-95% [1.2-8.1], p=0.02).
Off-treatment HBcrAg levels
Between week 48 and week 72, the overall mean of HBcrAg additionally 
declined -0.33 log U/mL (p=0.02), whereas qHBsAg remained stable (-0.05 
IU/mL, p=0.34). HBcrAg and qHBsAg dynamics from week 48-72 were not 
signiﬁcantly associated with relapse (OR 0.3, CI-95% [0.07-1.1], p=0.07). At 
Figure 3. Individual serum HBcrAg dynamics in patients with response at week 72 (n=25).
Lines represent individual HBcrAg dynamics in the 25 patients who achieved response (HBV DNA <2,000 IU/mL 
and normal ALT) at week 72. HBcrAg is expressed as log U/mL. For results below the lower limit of quantiﬁcation, 
the value of 100 U/mL (2 log U/mL) was used. The bold line represents the patient with negative HBsAg from week 
60 onward, which was a 24-year-old female infected with genotype D.
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week 72, HBcrAg was undetectable in 70% of patients with response vs. in 30% 
of patients without response (p=0.001), and mean HBcrAg levels were lower in 
patients with response compared to patients without response (2.5 vs. 4.0 log 
U/mL, p<0.001). In 36/51 patients who had a response at week 48 LTFU data 
regarding response was available. Ten of these 36 patients sustained response 
through LTFU. Neither the degree of HBcrAg decline from week 48 to 60, nor 
from week 48 to week 72 could identify patients with relapse at LTFU (p=0.18 
and p=0.14).
HBcrAg levels during and after treatment in patients with HBsAg loss
HBsAg became negative in 1 patient at week 60, and in 4 patients during LTFU. 
HBcrAg at baseline in these 5 patients ranged from undetectable to 6.32 log 
U/mL. Figure 4 shows individual dynamics of HBcrAg, HBV DNA and qHBsAg 
Figure 4. Individual marker dynamics in patients with HBsAg loss at long-term follow-up
Each panel represents an individual patient with HBsAg loss at LTFU. Dynamics of HBcrAg, HBV DNA and qHBsAg 
are shown. In all 5 patients, HBcrAg was the ﬁrst virological marker to become undetectable. For HBcrAg results 
below the lower limit of quantiﬁcation (1000 U/mL, 3 log U/mL), the value of 100 U/mL (2 log U/mL) was used.
Supplementary tables
82 Chapter 4
during treatment and 24 weeks after treatment. In all 5 patients, HBcrAg became 
undetectable prior to HBV DNA and qHBsAg negativity. 
DISCUSSION
HBcrAg is a serum marker that measures 3 precore/core HBV proteins. Whether 
it can be used in clinical practice of HBV treatment is largely unknown. We mea-
sured serum HBcrAg levels during and after PEG-IFN treatment in 133 patients 
with HBeAg-negative chronic hepatitis B who were previously treated within a 
multicentre randomised controlled trial. 94 HBcrAg levels strongly correlated with 
HBV DNA levels during and after treatment. Although the degree of HBcrAg 
decline was larger in patients who achieved a sustained off-treatment response 
than in patients who did not, the difference in HBV DNA decline appeared 
earlier during the treatment course than the difference in HBcrAg. For the predic-
tion of combined response, relapse and nonresponse, we could not demonstrate 
superiority of either absolute levels or decline of HBcrAg over serum HBV DNA 
or qHBsAg. 
The ﬁndings regarding clinical applicability of HBcrAg for PEG-IFN treatment 
are comparable to the ﬁndings we published for HBeAg-positive CHB. In HBeAg-
positive CHB, HBcrAg was also associated with response but was not superior 
to qHBsAg and HBV DNA in response prediction. 93 In the current study, a previ-
ously described and validated stopping rule based on HBV DNA and qHBsAg 
decline at week 12 could not be improved by adding HBcrAg or by replacing 
qHBsAg or HBV DNA by HBcrAg. 39 This will also be related to the fact that HBV 
DNA is part of the endpoint deﬁnition of combined response, which logically 
makes HBV DNA one of the strongest predictors for therapy response. Our 
results are in line with a recent single-centre study of 62 HBeAg-negative patients 
focussing on baseline laboratory parameters, in which HBcrAg could also not 
improve prediction of response using qHBsAg. 96 
In 70% of patients with treatment response HBcrAg levels became undetectable, 
but this was also the case in 30% of patients without a response. In addition, we 
were not able to demonstrate that end-of-treatment and post-treatment HBcrAg 
levels predict relapse, which is in contrast to other studies in which HBcrAg 
levels predicted relapse after nucleos(t)ide analogue cessation. 86, 89-91 This may 
not only be explained by the difference in treatment modality and deﬁnitions 
of relapse but also by the limited number of patients that we could assess for 
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this endpoint as well as by differences in HBeAg and HBV genotype status. In 
addition, it was previously reported that the correlation of HBcrAg with cccDNA 
is weaker in HBeAg negative CHB than in HBeAg positive CHB. 74
We found a strong correlation of HBcrAg levels with HBV DNA, a weak cor-
relation with qHBsAg, and a less apparent on-treatment decline of HBcrAg 
levels compared to HBV DNA levels, which all corresponds to results that have 
been described earlier for natural history cohorts and during NA treatment. 
75, 85, 86, 88-91, 97-101 The weak correlation between HBcrAg and qHBsAg may be 
explained by the recent observation in chimpanzees that qHBsAg in HBeAg 
negative CHB is predominantly produced by HBV DNA integrated in the host 
genome, in contrast to HBcrAg which is a likely product of the cccDNA. 102 One 
could therefore hypothesize that HBcrAg would be a better marker of treatment 
response in HBeAg-negative patients, but we were not able to demonstrate 
this for PEG-IFN treatment in this Caucasian population. Further, as HBV DNA 
replication and HBV precore/core protein synthesis are separate processes in 
the hepatocyte nucleus, the different kinetics of serum HBV DNA and HBcrAg de-
cline might be explained by a difference in the degree of IFN-induced inhibition 
of these distinct pathways. 103 However, to our knowledge speciﬁc effects of IFN 
on certain transcriptional or translational pathways have not been described. It 
was hypothesized earlier that HBcrAg would not reﬂect HBV DNA levels if only 
precore mutant virus is present, but in our study and in a previous Japanese 
study, the correlation between HBV DNA and HBcrAg remained strong. 99 Thus, 
HBcAg may well be the major component of HBcrAg, since it correlates with 
HBV DNA, while HBeAg and p22cr cannot be synthesized in presence of pre-
core mutations. This is in line with the important role that HBcAg plays in HBV 
replication. 104 
Our study is unique because it describes HBcrAg levels during PEG-IFN treat-
ment for HBeAg-negative chronic hepatitis B infection in a large and well-deﬁned 
group of mainly Caucasian patients of whom 19 percent had developed disease 
remission or functional cure after 24-weeks of off-treatment follow-up. Although 
recently a Thai study reported that HBcrAg levels in patients infected with HBV 
genotypes B and C were able to predict virological response when combined 
with HBsAg levels, the predictive value of HBcrAg was not compared to the pre-
dictive value of HBV DNA 105. Future studies will therefore still have to elucidate 
whether our results can be extrapolated to Asian patients with HBV genotype 
B and C, and whether the limited clinical value also applies when response is 
assessed at a later stage during off-treatment follow-up.
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In conclusion, during one year of PEG-IFN therapy a mean decline in HBcrAg 
of 3.3 log U/mL was reached in this population of Caucasian HBeAg-negative 
CHB patients. Although decline of HBcrAg during PEG-IFN treatment in HBeAg-
negative CHB was stronger in patients with treatment response than in patients 
without, HBcrAg did not add clinical value to the current response prediction 
strategies that are based on monitoring HBV DNA and qHBsAg early on-
treatment. Additional studies should be performed in genotype B and C infected 
patients. 
SUPPLEMENTARY TABLES
Supplementary table 1. HBcrAg in comparison to other serum markers in the early on-treatment 
prediction of response
Model AUC CI-95% p-value
p-value for comparison 
to reference model
HBsAg decline week 12
HBV DNA decline week 12
(PARC stopping rule)
0.742 0.629-0.855 p<0.001 reference 
HBsAg decline week 12
HBV DNA decline week 12
HBcrAg decline week 12
0.747 0.629-0.855 p<0.001 0.460
HBsAg decline week 12
HBV DNA decline week 12
HBcrAg decline week 24
0.747 0.634-0.859 p<0.001 0.919
HBsAg decline week 12
HBcrAg decline week 12
0.754 0.641-0.867 p<0.001 0.786
AUC, area under the curve; CI-95%, 95% conﬁdence interval alanine aminotransferase; HBcrAg, hepatitis B core-
related antigen; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen
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ABSTRACT
Background & aims. Hepatitis B virus (HBV) RNA in serum is a novel bio-
marker for intrahepatic HBV replication and treatment response. For its proper 
use it is essential to identify factors inﬂuencing serum HBV RNA level. 
Methods. Using a RACE PCR technique (lower limit of detection 800 copies/
mL [c/mL]), serum HBV RNA levels were measured in samples of 488 untreated 
individuals with chronic HBV infection who were eligible to treatment according 
to currently used recommendations. We explored the association of serum levels 
of HBV RNA with patient and virus associated factors.
Results. HBV genotype distribution was 21/10/20/46/3% for A/B/C/D/
other. Mean HBV RNA serum level was 5.9 (1.6) log10 c/mL (HBeAg-positive 
CHB: 6.5 [1.2] log c/mL, HBeAg-negative CHB: 4.1 [1.2] log c/mL; p<0.001). 
By multivariable linear regression, factors associated with lower HBV RNA 
level were HBeAg-negativity (E=-0.69, p<0.001), HBV genotypes A (E=-0.13, 
p=0.002), B (E=-0.07, p=0.049) and C (E=-0.61, p<0.001) in comparison to 
D, and presence of HBV basal core promoter mutation either alone (E=-0.14, 
p=0.001) or in combination with precore mutation (E=-0.22, p<0.001). Higher 
serum ALT was associated with higher HBV RNA (E=0.23, p<0.001). HBV RNA 
correlated strongly with HBV DNA (HBeAg-pos: r=0.72, p<0.001; HBeAg-
neg: r=0.78, p<0.001), and moderately with qHBsAg (HBeAg-pos: r=0.54, 
p<0.001; HBeAg-neg: r=0.19, p=0.04) and qHBeAg (r=0.41, p<0.001). 
Conclusion. In this multi-ethnic cohort of 488 untreated individuals with chronic 
hepatitis B, factors associated with serum HBV RNA level were HBeAg status, 
serum ALT, HBV genotype, and presence of basal core promotor mutations. For 
the future use of serum HBV RNA as a clinical marker it seems mandatory to take 
these factors in consideration. 
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INTRODUCTION
Currently available treatment strategies for chronic hepatitis B virus (HBV) infec-
tion can inhibit viral replication to a great extent as reﬂected by suppression of 
HBV DNA in serum. However loss of HBsAg, which is regarded as functional 
cure, is achieved in only a minority of patients, and treatment does not eliminate 
the intrahepatic covalently closed circular DNA (cccDNA), which is the main 
transcriptional template of the HBV. Also, HBV genome that is integrated in 
the host genome remains largely unaffected. Currently investigated therapeutic 
agents may have stronger effect on cccDNA and are potentially more effective, 
and therefore, serum markers which reﬂect the cccDNA activity are needed. 
These markers may allow a reliable prediction of response, ideally before treat-
ment initiation or early during treatment, and can also help to individualize the 
use of already available treatments42. 
HBV RNA in serum could fulﬁll criteria of such a biomarker, as the 4 major types 
of HBV RNAs are direct transcriptional products of the cccDNA. HBV RNA can 
be detected in serum and can be quantiﬁed by using PCR techniques 106. The 
nature of HBV RNA in serum has not fully been researched, but it most likely 
includes the 3.5 kb pregenomic RNA (pgRNA), which is the template for reverse 
transcription to HBV DNA and for translation of core protein and polymerase. It 
is probably released from infected hepatocytes in virion-like capsids 46, 107, 108.
The potential of serum HBV RNA as a baseline marker for treatment response was 
recently demonstrated by studies revealing its strong correlation with cccDNA 
activity on the one hand and its response to currently available treatments on 
the other hand. Thus, before and during treatment with nucleos(t)ide analogue 
(NA) or pegylated interferon alfa (PEG-IFN), a correlation between serum HBV 
RNA and the transcriptional activity of cccDNA was demonstrated47. In addi-
tion, serum HBV RNA levels were found to be associated with the probability of 
response to treatment with the either NAs or PEG-IFN 45, 46, 106, 109, 110. However, 
prior to the further development of serum HBV RNA as a response-predicting 
marker it is mandatory to evaluate which factors which may inﬂuence HBV RNA 
levels in individuals who are eligible for treatment. To study this, we measured 
serum HBV RNA level in a large multi-ethnic population of well-characterized 
individuals with chronic HBV infection, who are in need for treatment according 
to recent guidelines 56. We assessed the association with between HBV RNA 
level and host and viral factors, including levels of other biomarkers.
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PATIENTS AND METHODS
Study population.
Full-length poly-adenylated HBV RNA levels were measured in available baseline 
serum samples of 441 HBeAg-positive and 133 HBeAg-negative CHB patients 
who participated in 3 previously conducted global randomized controlled trials 
(99-01 study, ARES study, PARC study) and had not received antiviral treatment 
in the preceding 6 months 30, 36, 94. Speciﬁc inclusion and exclusion criteria have 
been described earlier. Serum samples were stored in -20 or -80 degrees Celsius 
since the original studies. Serum samples were available for 366 HBeAg-positive 
patients and 122 HBeAg-negative patients. We speciﬁcally chose to combine 
these three cohorts in order to create a large population and to ensure a better 
generalizability of HBV RNA level in serum as a biomarker for patients with 
different characteristics. 
Endpoints
We explored factors associated with serum level of HBV RNA, and the correla-
tion of HBV RNA to other serum markers.
Serum HBV RNA quantification
HBV RNA was quantiﬁed from serum samples using a rapid ampliﬁcation of 
complimentary DNA (cDNA)-ends (RACE)-based real-time polymerase chain 
reaction (PCR) technique that has been previously described. Quantiﬁcation 
of polyadenylated HBV RNA was performed using speciﬁc primers (including 
HBV RNA RT primer 5’-acc acg cta tcg cta ctc ac (dT17)gwa gct c) designed 
according to van Bömmel et al 45. For the current study the assay’s lower limit 
of detection (LOD) for HBV RNA was 800 (2.9 log10) copies/mL (c/mL), with 
a corresponding linear range of 800 to 106 c/mL. HBV RNA levels measured 
below the LOD were set to 450 c/mL prior to statistical analysis.
Other laboratory measurements
Routine biochemical and hematological tests were performed locally. Serum ALT 
levels were standardized by calculating the value times for the ULN per centre 
and gender. Virological tests were performed at one central laboratory (Erasmus 
Medical Center, Rotterdam, The Netherlands). HBV DNA was measured using 
TaqMan-based PCR assays (Roche Diagnostics, Basel, Switzerland; lower limit 
of detection of 400 copies/mL, 35 copies/mL, or 20 IU/mL depending on the 
study cohort). HBV DNA results in copies/mL were converted into IU/mL using a 
conversion factor of 5.8 copies per IU. The comparabiltiy of the assays was as-
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sessed previously (Bland-Altman test, r=0.12, p=0.49) 23. Serum qHBsAg levels 
were measured using the Architect HBsAg assay (Abbott Laboratories; range 
0.05-250 IU/mL) or the Elecsys Assay (Roche Diagnostics, Basel, Switzerland, 
lower limit of detection 0.05 IU/mL). Serum HBeAg levels were quantiﬁed us-
ing the Cobas Elecsys HBeAg assay (Roche Diagnostics, Basel, Switzerland, 
measurement range 0.2 – 100 IU/mL). HBV genotype analysis was performed 
using the INNO-LiPA HBV genotype assay (Fujirebio Europe, Ghent, Belgium). 
The presence of PC and BCP mutants was assessed using the INNO-LiPA HBV 
PreCore assay (Fujirebio Belgium, Ghent, Belgium), which detects precore (PC) 
mutations at nucleotide position 1896 and basal core promoter (BCP) mutations 
at nucleotide positions 1762 and 1764. Results were classiﬁed into 4 groups: 
wildtype (WT, only WT virus detectable), PC (only PC or both PC and WT detect-
able), BCP (either or both BCP mutations detected, with or without WT), or as PC 
+ BCP when both types of mutants were found. 
Statistical analysis
SPSS version 21.0 (SPSS Inc., Chicago, IL, USA) was used to perform statisti-
cal analyses. Skewed laboratory values were log-transformed prior to analyses 
and were expressed as mean (standard deviation [SD]). After log transforma-
tion, HBV RNA level showed a near to normal distribution in both the HBeAg 
positive population (skewness: -0.59 [SE 0.13]; kurtosis: 0.11 [SE 0.25]), and 
the HBeAg negative population (skewness: 0.29 [SE 0.24]; kurtosis: 0.03 
[SE 0.47]). Associations between variables were tested using Student’s t-test, 
Chi-square, Pearson correlation or their non-parametric equivalents when ap-
propriate. Subgroup analysis of mean HBV RNA levels was performed using 
ANOVA with Bonferroni correction for intergroup comparison. We performed 
linear regression analysis to determine factors associated with HBV RNA level. 
R2 was calculated as a measure of goodness-of-ﬁt for the linear model. For 
linear correlations Pearson correlation coefﬁcients (r) were provided, and for 
skewed distributions the Spearman rank coefﬁcients (U) were provided. Logistic 
regression analysis was performed to determine factors associated with HBV 
RNA level below LOD. Genotypes other than A, B, C and D were not analyzed 
in linear regression. All analyses were performed two-sided at the 0.05 level of 
signiﬁcance. 
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RESULTS
Study cohort
Study population characteristics are shown in Table 1.The mean age was 33 (SD 
11) years for HBeAg-positive patients and 42 (SD 11) for HBeAg-negative pa-
Table 1. Patient characteristics
Characteristics
All patients
n=488
HBeAg-pos
n=366
HBeAg-neg
n=122
p-value
Demography
Age, years 35 (12) 33 (11) 42 (11) <0.001
Male, n (%) 362 (74) 274 (74) 88 (72) 0.55
Race, n (%) <0.001
Caucasian 313 (64) 197 (54) 122 (95)
Asian 153 (31) 149 (41) 4 (3)
Other 22 (5) 20 (5) 2 (2)
HBV genotype, n (%) <0.001
 A 91 (19) 75 (21) 16 (13)
 B 50 (10) 49 (13) 1 (1)
 C 113 (23) 110 (30) 3 (2)
 D 222 (46) 125 (34) 97 (80)
 Other 12 (2) 11 (2) 5 (4)
INNO-LiPA result, n (%) <0.001
Wildtype virus 81 (17) 75 (21) 6 (5)
PC mutation 52 (11) 38 (11) 14 (11)
BCP mutation 102 (21) 78 (21) 24 (20)
PC & BCP mutation 203 (42) 125 (34) 78 (64)
Histology
Cirrhosis, n (%) 31 (6) 27 (7) 4 (3) 0.13
Treatment history
Previous NA 58 (12) 36 (10) 22 (18) 0.02
Previous (PEG-)IFN 86 (18) 64 (18) 22 (18) 0.89
Laboratory results
HBV RNA § 5.9 (1.6) 6.5 (1.2) 4.1 (1.2) <0.001
 HBV RNA undetectable, n(%) 30 (6) 2 (0.5) 28 (23) <0.001
HBV DNA ‡ 7.5 (1.4) 8.1 (1.1) 6.0 (1.2) <0.001
qHBsAg ‡ 4.2 (0.7) 4.3 (0.7) 3.8 (0.6) <0.001
qHBeAg ‡ n.a. 2.4 (0.9) n.a. n.a.
ALT (x ULN) † 3.7 (3.2) 3.8 (3.4) 3.2 (2.5) 0.07
ALT, alanine aminotransferase; BCP, basal core promoter; HBV, hepatitis B virus; NA, nucleos(t)ide analogue; (PEG-)
IFN, (peg)interferon; PC, precore; qHBeAg, quantitative hepatitis B e antigen; qHBsAg, quantitative hepatitis B sur-
face antigen; SD, standard deviation; ULN, upper limit of normal.
Continuous variables are expressed as mean (SD), categorical variables as n (%).
† Multiples of upper limit of the normal range
‡ Logarithmic scale, IU/mL
§ Logarithmic scale, c/mL
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tients (p<0.001), and the majority of patients were male (n=362, 74%). Patients 
were mostly of Caucasian (n=313, 64%) or Asian (n=153, 31%) origin. All 
main HBV genotypes were represented. Mean serum HBV DNA levels were 8.1 
(1.1) log IU/mL for HBeAg-positive patients and 6.0 (1.2) for HBeAg-negative 
patients (p<0.001), and mean serum quantitative HBsAg (qHBsAg) levels were 
4.3 (0.7) log IU/mL vs. 3.8 (0.6) IU/mL (p<0.001), respectively. 
Serum HBV RNA level in relation to viral and clinical characteristics.
The mean HBV RNA level was 5.9 (1.6) c/mL, and differed by HBeAg status 
(HBeAg-positive CHB: 6.5 [1.2] log c/mL, HBeAg-negative CHB: 4.1 [1.2] 
log c/mL; p<0.001; Figure 1a). HBV RNA levels were below LLD in 2 (0.5%) 
HBeAg-positive patients and in 28 (23%) HBeAg-negative patients (p<0.001). 
In these 30 patients, mean HBV DNA level was 4.7 (SD 0.7) log IU/mL. HBV 
RNA levels were associated with the degree of ALT elevation (r=0.29, p<0.001; 
Figure 1b), and HBV RNA level varied by HBV genotype (p<0.001), with mean 
unadjusted HBV RNA levels of 6.0 / 6.5 / 6.0 / 5.6 log c/mL for genotypes 
A/B/C/D (p=0.003, Figure 2a). In patients infected with wildtype HBV, highest 
mean unadjusted HBV RNA levels were found (6.7 log c/mL), and presence of 
BCP mutation either alone or in combination with PC mutation led to lower HBV 
RNA levels (Figure 2b, 5.5 log and 5.3 log c/mL, both p<0.001 in comparison 
to wildtype HBV). HBV RNA level did not differ by sex (p=0.26), presence of 
cirrhosis (p=0.55), or treatment history (previous IFN: p=0.96, previous NA: 
0.38), but did negatively correlate with age (r=-0.23, p<0.001). 
Figure 1. HBV RNA level according to HBeAg status and ALT level
Dots represent individual HBV RNA measurements, with lines representing the unadjusted mean level of HBV RNA 
(log c/mL) according to HBeAg status (a) and serum ALT level (b)  expressed in times the upper limit of normal (xULN). 
The lower limit of detection (LLD) for the HBV RNA PCR is 800 c/mL (2.90 log c/mL).
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Regression analysis of factors associated with HBV RNA level
By univariable linear regression, factors associated with HBV RNA level were 
age, HBeAg status, HBV genotype and presence of any PC or BCP mutation 
(Table 2). By multivariable linear regression, factors associated with lower HBV 
RNA level were HBeAg-negative CHB (E=--0.69, p<0.001), HBV genotypes A, B 
and C in comparison to genotype D (genotype A: E=-0.13, p=0.002; genotype 
B: E=-0.07, p=0.049 ; genotype C: E=-0.61, p<0.001), presence of any BCP 
mutation either alone (E=-0.14, p=0.001) or in combination with PC mutation 
(E=-0.22, p<0.001). Higher serum ALT was associated with higher HBV RNA 
level (E=0.23, p<0.001). This particular linear model explains 56.2% of the vari-
ance of the HBV RNA level (r2 = 0.562), which diminishes to 25.3% if HBeAg is 
excluded from the model. When studying the factors associated with HBV RNA 
level below LLD using logistic regression analysis, the only factors independently 
associated with HBV RNA level below LLD were HBeAg-negative CHB (OR 86 
CI-95% [9.1-811], p<0.001) and ALT (OR 0.07 CI-95% [0.01-0.40], p<0.001). 
As HBeAg was negative in 28/30 patients with HBV RNA below LLD, analysis 
was repeated in HBeAg-negative patients, which did not result in any additional 
factors independently associated with HBV RNA below LLD.
Figure 2. HBV RNA level according to HBV genotype and presence of precore and basal core 
promoter mutations
Dots represent individual HBV RNA measurements, with lines representing the unadjusted mean level of HBV RNA 
(log c/mL) according to HBV genotype (a) and presence of precore (PC) and basal core promoter (BCP) mutations 
(b). The lower limit of detection (LLD) for the HBV RNA PCR is 800 c/mL (2.90 log c/mL).
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Serum HBV RNA level in relation to serum HBV DNA, qHBsAg and 
qHBeAg
Overall, HBV RNA correlated highly with HBV DNA (r=0.85 / U=0.84, 
p<0.001), moderately with qHBsAg (r=0.52 / U=0.60, p<0.001), and with 
qHBeAg (r=0.41 / U=0.34, p<0.001). Because HBeAg status is the strongest 
factor independently associated with HBV RNA level in linear regression, we 
also studied correlations of HBV RNA to other markers in HBeAg-positive and 
HBeAg-negative patients separately. 
In HBeAg-positive patients, levels of HBV RNA correlated strongly correlated 
with HBV DNA (r=0.72, p<0.001), and moderately correlated with qHBsAg 
Table 2. Univariable and multivariable linear regression analysis of factors associated with se-
rum HBV RNA level
Univariable Multivariable
(Full model)
B CI-95% p-value B  CI-95% β p-value
Age, years -0.03 -0.04 ; -0.02 <0.001 0.003 -0.007 ; 0.01 0.02 0.59
Sex 0.26
 Male reference
 Female -0.19 -0.51 ; 0.14 0.26
HBeAg <0.001 <0.001
 Pos reference reference
 Neg -2.37 -2.62 ; -2.13 <0.001 -2.46 -2.74 ; -2.18 -0.69 <0.001
HBV Genotype 0.003 <0.001
 A 0.39 0.01 ; 0.76 0.04 -0.53 -0.86 ; -0.19 -0.13 0.002
 B 0.84 0.36 ; 1.31 0.001 -0.36 -0.72 ; -0.001 -0.07 0.049
 C 0.32 -0.03 ‘; 0.67 0.07 -0.61 -0.91 ; -0.32 -0.16 <0.001
 D reference reference
PC/BCP variants <0.001 <0.001
 Wildtype HBV reference reference
 PC mutation -0.38 -1.68 ; -0.90 <0.001 -0.19 -0.56 ; 0.18 -0.05 0.44
 BCP mutation -1.12 -1.66 ; -0.59 <0.001 -0.70 -1.09 ; -0.30 -0.14 0.001
 PC & BCP mutation -1.29 -0.82 ; 0.07 0.10 -0.68 -1.02 ; 0.35 -0.22 <0.001
ALT (log xULN) 1.46 1.02 ; 1.90 <0.001 1.18 0.85 ; 1.51 0.23 <0.001
BCP, basal core promoter; HBV, hepatitis B virus; CI-95%, 95% conﬁdence interval; PC, precore; qHBeAg, quantita-
tive hepatitis B e antigen. B, unstandardized regression coefﬁcient; ˟, standardized regression coefﬁcient.
Patients with genotype other than one of the main genotypes genotypes A, B, C, D were excluded for this analysis. 
When a signiﬁcance level of p<0.20 was reached In univariable analysis, the factor was assessed in multivariable 
analysis. No interactions were found between HBeAg status and genotype (p=0.14), HBeAg status and INNO-LiPA 
result (p=0.81), genotype and INNO-LiPA result (p=0.12), HBeAg status and ALT (p=0.19), genotype and ALT 
(p=0.64), or INNO-LiPA result and ALT (p=0.42).
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(r=0.54, p<0.001) and qHBeAg (r=0.41, p<0.001). Correlations of HBV RNA 
to other HBV markers, however, were HBV genotype dependent, with strongest 
correlation with HBV DNA observed for genotype A, strongest correlation with 
qHBsAg for genotype B and C, and a weakest correlation with qHBsAg for 
genotype D (Figure 3). 
In HBeAg-negative patients, overall correlation of HBV RNA to HBV DNA was 
comparable to HBeAg-positive CHB (r=0.78 / U=0.80, p<0.001). Unlike in 
HBeAg-positive CHB, the overall correlation of HBV RNA to qHBsAg was weak 
(r=0.19, p=0.04; U=0.17, p=0.07). Genotype-speciﬁc correlations of HBV RNA 
levels could only be determined for HBV genotypes A and D. The correlation 
of HBV RNA with HBV DNA was comparable for these genotypes (genotype 
A: r=0.69 / U=0.82, p=0.003; genotype D: r=0.81 / U=0.84, p<0.001), but 
the correlation of HBV DNA with qHBsAg was genotype-dependent, indicated 
by a weak correlation within genotype D infected patients (r=0.23 / U=0.22, 
p=0.03), but no signiﬁcant correlation within genotype A infected patients (r=-
0.16 / U=-0.14, p=0.60; Figure 3).
DISCUSSION
HBV RNA in serum is a novel and promising marker for cccDNA transcriptional 
activity and could thus be used to monitor response for currently available treat-
ment, but in particular for future HBV treatments targeting the HBV life cycle. 
However, its interactions with host factors and viral factors, such as markers 
of HBV transcription have not yet been systematically studied. In this study we 
investigate the association of HBV RNA serum levels with currently used HBV 
markers and patient characteristics in a large multi-ethnic cohort including 441 
HBeAg-positive and 133 HBeAg-negative individuals who were candidates for 
antiviral treatment according to current guidelines 56. We found that HBV RNA 
levels are independently associated with HBeAg status, ALT levels, BCP variants 
and the HBV genotype. Our results indicate that these factors have to be taken 
in consideration for a correct interpretation of HBV RNA serum levels. 
From recent studies there is evidence that the level of HBV RNA in serum reﬂects 
cccDNA transcriptional activity 47, 48. We identiﬁed the HBeAg status as the 
strongest factor associated with serum HBV RNA levels, which is likely an expres-
sion of the higher transcriptionally activity of cccDNA in HBeAg-positive patients 
as compared to HBeAg-negative patients. The mean HBV RNA level was 2.4 
log10 lower in HBeAg-negative as compared to HBeAg-positive patients, and the 
98 Chapter 5
proportion of patients with undetectable HBV RNA serum level 23% in HBeAg-
negative as compared to only 0.5% in HBeAg-positive patients (p<0.001). 
This is in line with previous ﬁndings in smaller patient cohorts 45, 46, 111. The 
correlation of HBV RNA with HBV DNA levels was similar in HBeAg-positive 
and HBeAg-negative individuals. Interestingly, however, the correlation between 
HBV RNA and HBsAg was moderate in HBeAg-positive (r=0.54) but only weak 
in HBeAg-negative patients (r=0.19) (Figure 3). A possible explanation for this 
difference is that in HBeAg-negative patients HBsAg may be derived not only 
from cccDNA but in a profound number from integrated HBV genome. This 
hypothesis is supported by data of a recent study assessing the effect of small 
interfering RNA based inhibition of messenger HBV RNAs, where a signiﬁcant 
decrease in HBsAg levels was found in HBeAg-positive but not in HBeAg-
negative patients102. Applying this hypothesis to our observation could imply 
that in HBeAg-negative patients HBV RNA and HBsAg are partially derived from 
different matrices and that HBV RNA (and possibly also HBV DNA) might be a 
better marker of for remaining cccDNA in HBeAg-negative disease. 
Another factor we found to be associated with lower HBV RNA serum levels was 
the presence of BCP variants. In presence of these variants, either alone or in 
combination with PC variants, HBV RNA levels were signiﬁcantly lower than in 
wildtype virus (p<0.002). We also found lower HBV DNA and HBsAg levels in 
patients with BCP and/or PC variants (data not shown). Other studies, however, 
have reported inconclusive results regarding the effect of BCP mutations on 
HBV replication 112-115. These heterogenic results may be explained by testing 
patients with different disease phases, genotype distributions, and frequency of 
BCP mutants 116. It is yet unclear which mechanisms would explain lower HBV 
DNA and HBV RNA level in presence of BCP mutations, but the key may in HBV 
RNA packaging. Recently, virus-like particles have been proposed as medium 
for the transport of HBV RNA in serum 107, 117. Therefore lower HBV RNA levels 
in patients bearing these variants may be a result of decreased availability of 
those carriers of HBV RNA instead of a direct effect of BCP mutation on HBV 
replication 115, 118. Further studies are required to elucidate how BCP and PC 
variants truly affect serum HBV RNA levels. 
HBV genotype was associated with both absolute levels of HBV RNA and cor-
relations of HBV RNA with other serum markers. In multivariable regression 
analysis, genotype D was associated with the highest HBV RNA level, followed 
by genotypes B, A, and C. The HBV genotype mainly inﬂuenced the correlation 
between HBV RNA and qHBsAg in our cohort. This might be of relevance for 
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the use of serum HBV RNA as a clinical marker. HBV RNA levels were signiﬁ-
cantly higher in patients with ALT level >2x ULN compared to patients with ALT 
level <2X ULN, which was similar for HBV DNA and qHBsAg. Age and sex of 
individuals with chronic HBV infection did not inﬂuence HBV RNA serum levels.
In conclusion, our study is the ﬁrst to show that HBeAg status, serum ALT, HBV 
genotype, and presence of BCP variants are independently associated with 
serum HBV RNA level in a multi-ethnic cohort of patients currently considered 
eligible for treatment. These factors should be taken into consideration for the 
interpretation and comparison of HBV RNA serum levels across different infected 
individuals and in the development of HBV RNA as a potential serum marker for 
cccDNA transcriptional activity. This is in particular relevant for future studies 
with novel agents aiming targeting the HBV live cycle for functional cure of CHB. 
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SUPPLEMENTARY TABLE
Supplementary table 1. Univariable and multivariable logistic regression analysis of factors as-
sociated with undetectable level of serum HBV RNA (n=34)
Univariable Multivariable
(Full model)
OR CI-95% p-value OR CI-95% p-value
Age, years 1.04 1.01 ; 1.06 0.02 0.97 0.93 ; 1.01 0.16
Sex
 Male reference reference
 Female 1.65 0.79 ; 3.44 0.18 1.69 0.66 ; 4.30 0.59
HBeAg
 Pos reference reference
 Neg 67.2 15.8 ; 286 <0.001 91.1 13.7 ; 606 <0.001
HBV Genotype <0.001 0.59
 A 0.32 0.11 ; 0.94 0.04 0.55 0.12 ; 2.54 0.45
 B 0.14 0.02 ; 1.07 0.06 3.16 0.24 ; 42.1 0.38
 C 0.06 0.01 ; 0.46 0.007 0.48 0.04 ; 5.21 0.54
 D reference reference
PC/BCP variants 0.02
 Wildtype HBV reference reference
 PC mutation 4.05 0.46 ; 35.4 0.21 1.35 0.10 ; 18.9 0.82
 BCP mutation 6.70 0.73 ; 61.7 0.15 3.72 0.27 ; 51.2 0.33
 PC & BCP mutation 10.5 1.40 ; 79.0 0.02 3.42 0.30 ; 38.7 0.29
ALT (log xULN) 0.10 0.03 ; 0.35 <0.001 0.04 0.01 ; 0.27 <0.001
BCP, basal core promoter; HBV, hepatitis B virus; CI-95%, 95% conﬁdence interval; PC, precore; qHBeAg, quantita-
tive hepatitis B e antigen; OR; odds ratio.
Patients with genotype other than one of the main genotypes genotypes A, B, C, D were excluded for this analysis. 
When a signiﬁcance level of p<0.20 was reached In univariable analysis, the factor was assessed in multivariable 
analysis. 
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Treatment of chronic HBV infection leads to functional cure in only a minority 
of patients. Over the last decades, multiple strategies aiming to optimize the 
effect of the available therapeutic agents have been examined. To improve 
response to PEG-IFN monotherapy, response-guided treatment algorithms have 
developed for both HBeAg-positive and HBeAg-negative chronic hepatitis 38, 39. 
For nucleo(s)tide analogue (NA) monotherapy, one of the major hurdles has 
been to establish ﬁnite treatment either by selection of patients whose HBV char-
acteristics are associated with sustained off-treatment response, or by adding 
PEG-IFN. Many modiﬁed treatment strategies combining NA and PEG-IFN have 
been studied 30, 37, 64, 65, 131, 133, 138. For all of these studies, biomarkers have 
played an important role as they allow disease proﬁling and therefore treatment 
individualization. The aims of this thesis are to examine whether one of the latest 
researched combination strategies, the PEG-IFN add-on strategy, contributes to 
improved response rates, and whether novel serum biomarkers HBcrAg and 
HBV RNA can further individualize treatment for chronic HBV. 
RESPONSE TO PEGINTERFERON ADD-ON THERAPY
In Chapter 1, we studied virus and host characteristics associated with response 
to PEG-IFN add-on therapy. The reason to perform this study was an earlier 
observation of heterogeneity across different patient groups with regard to the 
effect of PEG-IFN add-on 37. We clustered two previously conducted randomized 
controlled trials studying the effect of PEG-IFN add-on therapy in HBeAg-positive 
patients. In the ARES trial patients were treated with 24 weeks of entecavir treat-
ment prior to 24 weeks of PEG-IFN initiation, whereas in the PEGON trial, initial 
NA treatment was given for at least 1 year and the duration of PEG-IFN add-on 
was 48 weeks 37, 138. This combination of study populations enabled us to also 
study the effect of different durations of initial NA treatment and different dura-
tions of PEG-IFN add-on on the probability of treatment response. However, the 
main ﬁnding of our study was that neither duration of NA therapy nor duration 
of PEG-IFN add-on were associated with the probability of response. The factors 
that were independently associated with treatment response (in this study deﬁned 
as HBeAg loss in combination with an HBV DNA level <200 IU/mL) were ab-
sence of prior PEG-IFN treatment, and lower HBV DNA and HBsAg levels upon 
PEG-IFN add-on initiation. These ﬁndings are in line with the hypothesis that HBV 
DNA suppression leads to immune restoration, and with earlier observations that 
lower serum HBsAg level may reﬂect better immune control and is associated 
with a higher chance of response to PEG-IFN monotherapy 139. The observation 
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that PEG-IFN treatment appears to be less successful after the ﬁrst course was 
already described in conventional IFN treatment for HBeAg-positive hepatitis 140 
. This may be related to IFN-induced mutations decreasing IFN susceptibility, 
such as precore or basal core promoter mutations, or polymorphisms of HLA-DP 
or IL28B 141-143. 
Because the study endpoint in Chapter 1 was chosen 24 weeks after discontinu-
ation of PEG-IFN add-on, conclusions on the long-term effect of PEG-IFN therapy 
could not be drawn. In Chapter 2 we studied the long-term effect of the PEG-
IFN add-on strategy, speciﬁcally for the ARES approach that includes 24 weeks 
of initial entecavir treatment followed by 24 weeks of PEG-IFN add-on. In this 
study we mainly focused on the additional occurrence of HBeAg loss after the 
follow-up of the initial ARES study ended and the durability of add-on induced 
HBsAg decline. Among initial non-responders, HBeAg loss beyond week 96 of 
follow-up did not differ between patients allocated to PEG-IFN add-on or enteca-
vir monotherapy continuation, suggesting that the gained increase in HBeAg loss 
by PEG-IFN add-on is mainly achieved in the ﬁrst 2 years of treatment initiation. 
Interestingly, the signiﬁcantly steeper decline in quantitative HBsAg level induced 
by PEG-IFN that was observed already in the ﬁrst year was sustained across 
long-term follow-up. We therefore hypothesize that there may be a role for PEG-
IFN add-on when HBeAg loss or a certain HBsAg level would be indicated to 
start a new therapeutic compound.
SERUM HBCRAG AND HBV RNA LEVELS IN RELATION TO 
TREATMENT RESPONSE
HBcrAg is a combined biomarker for the simultaneous detection of three proteins 
coded by the precore/core region of the cccDNA: HBcAg, HBeAg and a 22-
kDa precore protein (p22cr) 85. These proteins share a 149 amino acid se-
quence to which the labelled antibodies of the CLEIA-based assay are directed. 
Although it is well known that HBcAg can be found in infectious HBV particles 
and HBeAg is important for viral replication, the function of p22cr is unknown. 
HBcrAg was ﬁrst described in 2002. The correlation coefﬁcients described in 
literature for HBcrAg with intrahepatic cccDNA vary from 0.66 to 0.70 74, 88, 144. 
In Chapters 3 & 4, we studied on-treatment HBcrAg dynamics in patients with 
HBeAg-positive chronic hepatitis treated with entecavir with or without 24 weeks 
of PEG-IFN add-on, and in patients with HBeAg-negative patients treated with 
48 weeks of PEG-IFN with or without ribavirin. 
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In the HBeAg-positive add-on study (Chapter 3), we found baseline correlations 
of HBcrAg with other known biomarkers qHBsAg (r=0.4 p<0.001) and HBV 
DNA (r=0.7, p<0.001) that were comparable to correlations found by others, 
and Bland-Altman analysis showed close agreement for HBcrAg and qHBeAg 
measurements. Basal core promoter mutation was associated with lower baseline 
levels of HBcrAg. On-treatment, we observed only a trend for stronger HBcrAg 
decline in patients treated with PEG-IFN add-on when compared to entecavir 
monotherapy. However, HBcrAg decline was HBV genotype dependent. We 
found that lower HBcrAg was independently associated with response although 
unfortunately, we could not demonstrated superiority to qHBsAg level. Our ﬁnd-
ings were replicated in other PEG-IFN based treatment strategies for this is also 
what an Asian study found 145. We underline that in our study, we chose an com-
bined endpoint based on HBV DNA level because of the fact that an endpoint 
based on HBeAg loss only would logically correlate to HBcrAg level because 
HBeAg is part of the biomarker itself, and that we did not have enough patients 
with HBsAg loss in this study to examine the relation of HBcrAg with HBsAg loss. 
In the HBeAg-negative population (Chapter 4), correlations between HBcrAg 
and HBV DNA were comparable to those in the HBeAg-positive populations, but 
a signiﬁcant correlation of HBcrAg with qHBsAg was absent qHBsAg (r=0.2, 
p=0.11). This may be due to HBsAg production from integrated DNA 108. In line 
with our observations in HBeAg-positive patients, HBcrAg was associated with 
treatment response (in this study deﬁned as ALT normalizaton and an HBV DNA 
level <2000 IU/mL), but again superiority over previously validated decision 
rules could not be demonstrated. Almost simultaneously to our publication, a 
French group published comparable results 96. We therefore recommend for this 
speciﬁc patient category to choose HBV DNA and qHBsAg monitoring rather 
than HBcrAg monitoring in clinical settings, in particular because these biomark-
ers have been extensively validated and have been related to solid clinical 
outcomes, such as cirrhosis and liver cancer .
Based on these studies, we believe that HBcrAg may well be used together with 
other biomarkers to assess treatment effect, but in our opinion, some crucial 
aspects of this test have not been fully examined which leads us to be cau-
tious in recommending it as a single biomarker for treatment monitoring. Our 
most important point of discussion for research involving this new biomarker is 
that several studies give interpretation to results that are below the analytical 
sensitivity / lower limit of quantiﬁcation of 3.0 log U/mL (1000 kU/mL) that 
is reported by the manufacturer. This may result from the fact that the analyser 
that is used for testing displays values down to the lower limit of detection of 2 
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log U/mL (100 U/mL), so below the limit of 3.0 log U/mL. However in the ﬁrst 
studies reporting on this biomarker, HBcrAg levels between 2.0 and 3.0 log U/
mL were also found in healthy controls and patients with hepatitis C infection 85. 
Therefore it seems not appropriate to deviate from the manufacturer’s manual in 
order to retrieve a broader spectrum of HBcrAg results in those with estimated 
low levels of replication. As to our knowledge no other studies exist that examine 
the speciﬁcity of HBcrAg, it is important to cautiously interpret studies that claim 
that HBcrAg may be a more sensitive biomarker than HBsAg just because it is 
also detected in patients who cleared HBsAg. 
HBV RNA is a biomarker that can be detected by using RACE-PCR. The method 
we used for HBV RNA quantiﬁcation was designed a few years ago 45, but others 
have designed comparable probes and primers 46, 146. The nature of HBV RNA 
has not been fully examined, but several studies suggest that it predominantly 
concerns encapsidated pregenomic RNA but also comprises a minimum amount 
(<1%) of precore messenger RNA 46, 107, 146. Reports regarding correlation of 
HBV RNA in serum with cccDNA are interesting. It was reported to correlate with 
quantitative cccDNA level in untreated HBeAg-positive patients (r=0.39) but not 
in untreated HBeAg-negative patients 47. However HBV RNA detectability did 
seem to correlate with cccDNA transcriptional activity, and therefore undetect-
able HBV RNA may indicate silenced cccDNA. In Chapters 5, 6, 7 and 8, 
we studied HBV RNA levels in untreated patients and different treatment settings 
for both HBeAg-positive and HBeAg-negative patients. 
For every virologic biomarker, it is essential how it relates to different host and 
viral factors in order to avoid misinterpretation of results. In Chapter 5, we 
examined factors associated with HBV RNA level in a multi-ethnic group of 
untreated patients with chronic HBV hepatitis. The strongest factor associated 
with HBV RNA level was HBeAg status, which again emphasizes the inﬂuence 
of HBeAg on viral replication. basal core promoter mutation was independently 
associated with lower levels of HBV RNA, and HBV RNA level was clearly high-
est in patients infected with HBV genotype D. We additionally observed a clear 
positive correlation between HBV RNA level and and ALT level. We took these 
factors in consideration in our on-treatment studies. 
First, we examined HBV RNA dynamics in HBeAg-positive patients treated with 
PEG-IFN +/- lamivudine in Chapter 6. We observed that HBV RNA decline 
was stronger in combination therapy than in PEG-IFN monotherapy but rebounds 
to comparable levels after treatment discontinuation, which is a pattern already 
known for HBV DNA dynamics 30. Also we observed a trend towards lower 
HBV RNA levels in patients infected with wildtype virus when compared non-
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wildtype virus. Furthermore, we were able to validate the previously suggested 
HBV RNA level of ≥ 5.5 log c/mL for the prediction of non-response (deﬁned as 
no HBeAg loss) for HBV genotypes A and C 44. However we also observed that 
the speciﬁcity of HBV RNA as a marker for HBeAg loss was limited, as HBV RNA 
decline was also signiﬁcant in patients without HBeAg loss. This may mean that 
HBV RNA is a marker of current replication cccDNA activity but not so much for 
immune control. 
We secondly examined HBV RNA levels in patients with HBeAg-negative hepatitis 
treated with PEG-IFN +/- ribavirin in Chapter 7. Based on our prior ﬁndings in 
untreated patients, we expected to see lower HBV RNA levels. Indeed, HBV RNA 
levels were not only lower at baseline but also became undetectable already 
early during treatment in the vast majority of patients, regardless of allocation 
to monotherapy or combination therapy. Improving the sensitivity of the PCR 
method would therefore be very interesting in these patients. Nevertheless with 
the current lower limit of detection of 800 c/mL, we could ﬁnd that an HBV RNA 
value above 1,500 c/mL (3.2 log c/mL) at week 12 predicts non-response to 
PEG-IFN treatment. Moreover, adding an HBV RNA cut-off of 3.18 log c/mL to 
the validated PARC stopping rule (which is based on HBV DNA and qHBsAg 
monitoring) could lead to early PEG-IFN discontinuation for non-responders who 
would have continued therapy based on the prior stopping rule alone 39. 
Finally in Chapter 8, we report the interim results of our study on HBV RNA 
monitoring in PEG-IFN add-on therapy. Because we already found in Chapter 
1 that host and viral factors can help to select those patients with the highest 
probability of response to PEG-IFN add-on, we were interested to see if HBV 
RNA monitoring is useful for this purpose. Additionally the ARES study design 
allowed us to also study HBV RNA levels in the ﬁrst weeks of entecavir treatment. 
After 24 weeks of initial entecavir treatment, PEG-IFN add-on accelerated HBV 
RNA decline when compared to entecavir monotherapy, and HBV RNA level af-
ter 24 weeks of initial entecavir treatment allowed us to select patients in which 
adding PEG-IFN is expected to double the probability of achieving HBeAg loss. 
This may provide a valuable tool to individualize treatment.
CONCLUSION AND RECOMMENDATIONS
In order to establish higher response rates to PEG-IFN monotherapy, both se-
rum biomarkers HBV RNA and HBcrAg could be used for early on-treatment 
identiﬁcation of non-responders so that exposure to PEG-IFN side effects can be 
limited for these patients by premature discontinuation of the treatment course. 
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However, we could not demonstrate superiority of these markers over qHBsAg 
monitoring for HBeAg-positive patients, nor over previously validated stopping 
rules in our Caucasian HBeAg-negative population (former PARC study), espe-
cially for HBcrAg. Therefore we recommend to continue using already validated 
decision rules for PEG-IFN treatment unless more supportive data regarding the 
role of HBcrAg and HBV RNA becomes available. 
Future perspectives
We see a future opportunity for PEG-IFN add-on when acceleration of HBeAg loss 
of HBsAg decline would be required prior to treatment with a new compounds to 
establish functional cure (HBsAg loss). The effect of the PEG-IFN add-on strategy 
depends on patient and virus characteristics. When an attempt to discontinue 
NA treatment by adding PEG-IF add-on is desired, we advise to select patients 
with the highest probability of response, preferably by choosing patients with 
low levels of HBV DNA, HBV RNA and quantitative HBsAg who have not been 
treated with PEG-IFN before. For example, by adding PEG-IFN in patients with 
an HBV RNA level below <5.5 log c/mL HBeAg loss rates were doubled when 
compared to patients with similar levels who continued of entecavir monotherapy. 
Validation for different treatment populations of this cut-off and other biomarker 
cut-offs described in this thesis needs be performed before applying them in 
clinical practice or for research purposes. 
Lastly, one should always be aware of the possible effect of HBeAg status, HBV 
genotype, and baseline presence of precore and basal core promoter mutations 
on biomarkers levels, and perhaps also other factors that were not studied here. 
Newly developed HBV disease models may provide more information on how 
these factors exactly inﬂuence the HBV life cycle. Also on-treatment assessment of 
HBV mutation variants may provide additional insights. As the viral life cycle and 
immune response are very complex, future therapeutic strategies with improved 
response rates will probably require multiple virological and/or immunological 
approaches, and monitoring of multiple biomarkers in both treatment develop-
ment as treatment monitoring. Promising therapeutic agents that are now under 
development include HBV entry inhibitors preventing hepatocyte (re)infection, 
RNA interfering agents aiming to block protein synthesis and capsid inhibitors. 
We hypothesize that minimizing viral replication activity and risk for reinfection 
by using NA therapy and a combination of these modalities for a longer period 
of time, followed by a non-cytolytic elimination of cccDNA achieved by an IFN-
related or nonIFN-related immunological approach would provide the highest 
and safest chance of a durable cure of HBV. Assuming an 100% speciﬁcity of 
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HBV RNA and HBcrAg, undetectability of these biomarkers and other known 
virological biomarkers in serum could indicate silenced cccDNA, which could 
be sign to initiate immunomodulatory treatment. This would be in line with the 
observations made in this thesis that patients low levels of virological markers 
have a higher probability to respond to PEG-IFN based treatment. It is also 
likely that different HBV genetic proﬁles and different immunologic proﬁles will 
require different therapeutic strategies. To create such proﬁles, a possible but 
yet not clinically feasible approach could be to combine of HBV whole genome 
sequencing and human immune proﬁling by using multiplex immunoassays. 
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cccDNA activity
Antiviral therapy
Biomarkers
Mutation analysis
Biomarkers undetectable?
Mutation analysis
Serum sample
Serum sample
Immunotherapy
CURE?
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To conclude, as much as this thesis was focused on treatment optimization, it 
should not be forgotten that the elimination of HBV not only depends on success-
ful treatment, but just as much on ﬁnding those who are infected and who are in 
need for treatment. The worldwide prevalence is probably an underestimation, 
and part of HBV infected people does not know to be infected 147. Retrieval of 
these patients and offer them appropriate treatment together with vaccination 
of risk groups would not only reduce HBV-related morbidity and mortality but 
also reduce transmission rates. Only when our current or future improved treat-
ment options will actually reach the ones who require treatment, a signiﬁcantly 
decrease the worldwide HBV-related disease burden can be achieved
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Met de huidige behandelmogelijkheden voor een chronische hepatitis B (HBV) 
infectie kan het virus helaas nooit volledig uit het lichaam verdwijnen, en leidt 
behandeling bij slechts een klein deel van de behandelde patiënten tot controle 
van het afweersysteem over het virus. Die controle wordt ook wel HBsAg verlies 
of functionele genezing genoemd 38, 39. Patiënten die behandeld worden met 
virusremmers, nucleo(s)tide analogen (NA), zijn vaak jarenlang en meestal 
zelfs levenslang gebonden aan deze behandeling vanwege een grote kans op 
opvlamming van de virusactiviteit bij het staken van de behandeling. Om de 
behandeling toch te kunnen staken is de afgelopen jaren gezocht naar virus en 
patiënt gerelateerde factoren die kunnen voorspellen of het behandeleffect blij-
vend is, maar ook naar manieren om de duurzaamheid van het behandeleffect 
te verbeteren. Daartoe heeft men onder meer nieuwe combinatiebehandelingen 
van NA met peginterferon (PEG-IFN) onderzocht. PEG-IFN is een middel is dat 
meer probeert de afweerreactie van de patiënt tegen het virus te versterken 
maar daarnaast ook deels het virus remt. Een van de meest recent onderzochte 
combinatiestrategieën is het toevoegen van PEG-IFN aan een reeds langere tijd 
lopende behandeling met een NA 30, 37, 64, 65, 131, 133, 138. Deze strategie wordt de 
PEG-IFN add-on strategie genoemd. In alle onderzoeken naar het verbeteren van 
de behandeling hebben biomarkers een grote rol gespeeld. Dit zijn moleculen 
geproduceerd door het virus of door de patiënt die vaak worden gemeten in een 
onderdeel van het bloed van de patiënt, het serum. Door de gemeten waarden 
van deze biomarkers te combineren kan een ziekte- en patiëntproﬁel gemaakt 
kan worden zodat de behandeling ‘op maat’ aangeboden kan worden. De 
doelen van dit proefschrift zijn gebaseerd op de onderzoeken van de afgelopen 
jaren, en zijn daarom enerzijds te bepalen of de PEG-IFN add-on strategie 
het effect van NA behandeling kan verbeteren, en anderzijds of de nieuwe 
biomarkers HBcrAg en HBV RNA bij kunnen dragen aan geïndividualiseerde 
behandeling voor chronische HBV-infecties.
EFFECT VAN PEGINTERFERON ADD-ON 
In Hoofdstuk 1 hebben we gekeken naar welke virus- en patiëntkenmerken 
gerelateerd zijn aan de kans op behandelsucces van de PEG-IFN add-on behan-
deling. De reden om dit onderzoek uit te voeren was dat in recent onderzoek 
aanwijzingen werden gevonden dat de kans op succes van de behandeling niet 
hetzelfde was voor alle patiënten 37. Daarom voegden wij twee eerder uitge-
voerde onderzoeken (de ARES en de PEGON studie) samen die allebei gekeken 
hebben naar het effect van PEG-IFN add-on bij HBeAg-positieve ziekte. In de 
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ARES studie werden patiënten eerst 24 weken behandeld met alleen entecavir 
(een van de meest voorgeschreven NA), waarna de ene helft van de patiënten 
daarna ook 24 weken PEG-IFN kreeg en de andere helft doorging met alleen 
entecavir. In de PEGON studie waren patiënten niet 24 weken behandeld met 
een NA maar gebruikten ze dit al voor minimaal een jaar, en kreeg de helft van 
de patiënten niet 24 weken maar 48 weken PEG-IFN erbij 37, 138. Door deze 
verschillen in studieopzet konden we ook kijken naar of de duur van de aanvan-
kelijke NA behandeling en de duur van de PEG-IFN toevoeging uitmaken voor 
de kans op succes van de behandeling. We konden echter geen relatie ontdek-
ken tussen deze factoren en de kans op succes van de behandeling. De factoren 
die in onze studie wel gerelateerd waren met het succes van de behandeling 
waren het nooit eerder behandeld zijn met PEG-IFN, en lagere hoeveelheden 
van de biomarkers HBV DNA en HBsAg in het serum op het moment van het 
toevoegen van PEG-IFN. Deze bevindingen klopten met de hypothese die we 
voorafgaand aan deze studie hadden, namelijk dat het onderdrukken van 
het virus leidt tot herstel van de afweersysteem. Ook kwamen de bevindingen 
overeen met resultaten van eerdere onderzoeken die aantoonden dat een lage 
HBsAg hoeveelheid in het serum waarschijnlijk geassocieerd is met een sterkere 
mate van controle van het afweersysteem over het virus, en ook met een hogere 
kans op succes van behandeling met PEG-IFN alleen 139. Onze bevinding dat 
de kans op succes van een PEG-IFN behandeling kleiner is als het niet de eerste 
kuur is, is ook eerder beschreven bij behandeling met conventionele interferon 
(IFN), wat gebruikt werd voordat PEG-IFN werd ontwikkeld 140. Dat het effect 
minder is kan te maken hebben met mutaties in het virus die ontstaan door de 
behandeling zelf waardoor het virus minder gevoelig wordt voor PEG-IFN, zoals 
mutaties in de zogeheten precore en basal core promoter regio van het virus, of 
door mutaties bij de patiënt zelf in de HLA-DP of de IL28B regio 141-143. 
Omdat Hoofdstuk 1 speciﬁek keek naar het behandeleffect 24 weken na het 
staken van PEG-IFN add-on, kon geen uitspraak worden gedaan over het effect 
van de PEG-IFN add-on behandeling op langere termijn. Daarom keken we in 
Hoofdstuk 2 naar het lange termijneffect van de PEG-IFN behandeling bij 
patiënten die in de ARES studie waren behandeld, dus bij patiënten die waren 
behandeld met entecavir gedurende 24 weken voordat ze 24 weken PEG-IFN 
erbij kregen. We hebben ons met name gericht op het optreden van HBeAg 
verlies, wat een behandeluitkomst is die de kans vergroot op stabiele ziekte 
maar die ook later kan leiden tot functionele genezing. Ook keken we of de 
door PEG-IFN bereikte daling in de hoeveelheid HBsAg in het serum blijvend 
was, wat ook een uitkomst is die geassocieerd is met stabiele ziekte en een 
161Samenvatting en discussie
grotere kans op functionele genezing. Bij patiënten die geen succes van de 
behandeling hadden bereikt in de eerste 96 weken, werd na week 96 geen 
verschil in aantallen patiënten met extra HBeAg verlies gezien als we de twee 
behandelingen vergelijken. Dit suggereert dat de toename van HBeAg verlies 
met name bereikt wordt in de eerste twee jaar. We zagen daarnaast dat de 
duidelijk sterkere HBsAg daling die optrad na het toevoegen van PEG-IFN ook 
lang na het staken van PEG-IFN behouden bleef. Daarom denken wij dat de 
PEG-IFN add-on strategie later gebruikt zou kunnen worden om HBeAg verlies 
of HBsAg daling te induceren voorafgaand aan een behandeling met nieuwe, 
potentere middelen. 
SERUM HBCRAG EN HBV RNA IN RELATIE TOT BEHANDELEFFECT
HBcrAg is biomarker die drie virale eiwitten tegelijkertijd meet: HBcAg, HBeAg 
en een 22-kDa groot precore eiwit genaamd p22cr. Deze drie eiwitten worden 
allen afgeschreven van de precore/core regio van het cccDNA, een vorm van 
DNA die een sjabloon is voor bijna alle eiwitten die het virus produceert evenals 
voor het maken van volledige kopieën van het virus voor verdere verspreiding 
en infectie. De HBcrAg test is gebaseerd op de CLEIA-methode, wat inhoudt dat 
de lichtgevende antistoffen van de test zich binden zich aan de 149 aminozuren 
die de drie eiwitten gemeenschappelijk hebben, waarna het uitgestraalde licht 
kan worden gemeten 85. Hoewel van HBcAg bekend is dat het belangrijk onder-
deel is van de virusdeeltjes die voor infectie moeten zorgen en van HBeAg dat 
het een belangrijke rol speelt in het de virusreplicatie, is de rol van het derde 
eiwit p22cr niet bekend. HBcrAg werd voor het eerst beschreven in 2002. De in 
eerdere onderzoeken beschreven correlatiecoëfﬁciënten (getallen die uitdrukken 
hoe sterk twee factoren met elkaar samenhangen) tussen HBcrAg en cccDNA 
variëren van 0.66 tot 0.70, wat overeenkomt met een matige tot redelijke samen-
hang 74, 88, 144. In Hoofdstuk 3 & 4 hebben we tijdens behandeling gekeken 
naar de veranderingen in de hoeveelheid HBcrAg in het serum van patiënten. Bij 
patiënten met HBeAg-positieve ziekte was dit tijdens behandeling met entecavir 
met of zonder 24 weken PEG-IFN add-on, en bij patiënten met HBeAg-negatieve 
ziekte patiënten was dit tijdens behandeling met PEG-IFN gedurende 48 weken 
met of zonder ribavirine (een oude NA). 
In de studie in HBeAg-positieve patiënten (Hoofdstuk 3), vonden we voor de 
start van de behandeling correlaties van HBcrAg met andere biomarkers die ver-
gelijkbaar waren met correlaties die in voorgaande onderzoeken waren gevon-
den, namelijk r=0.4 voor qHBsAg en r=0.7 voor HBV DNA. In een analyse die 
162 Samenvatting en discussie
de vergelijkbaarheid van twee metingen test, de Bland-Altman analyse, zagen 
we zoals verwacht een sterke overeenkomst tussen HBcrAg en HBeAg metingen. 
Een mutatie in de basal core promoter regio van het cccDNA was geassocieerd 
met lagere hoeveelheden HBcrAg voorafgaand aan de behandeling. Tijdens 
de behandelingsperiode zelf leek HBcrAg iets sterker te dalen bij patiënten 
die PEG-IFN kregen dan bij patiënten die doorgingen met alleen entecavir, 
maar het verschil was niet statistisch signiﬁcant. De daling in HBcrAg verschilde 
wel tussen de verschillende HBV genotypes. Ook zagen we dat er een relatie 
bestond tussen HBcrAg en succesvolle behandeling, maar als we dit vergeleken 
de een reeds veelgebruikte biomarker HBsAg konden we niet aantonen dat 
HBcrAg het beter deed in onze groep met patiënten. Een Aziatische studie vond 
vergelijkbare resultaten voor andere PEG-IFN en NA combinatiestrategieën 145. 
Wat belangrijk te weten is bij het interpreteren van onze studieresultaten is dat 
we expliciet hebben gekozen voor een uitkomstmaat van behandeling waar 
niet alleen verlies van HBeAg is opgenomen maar ook een bepaalde hoogte 
van HBV DNA in het serum. Dit is gedaan omdat we vooraf reeds wisten dat 
HBcrAg logischerwijs sterk gecorreleerd is met HBeAg omdat HBeAg een van 
de drie componenten is van HBcrAg, en daarmee hoe dan ook een relatie tussen 
HBcrAg en therapiesucces zouden vinden als we de deﬁnite van succes alleen 
zouden baseren op HBeAg. In de HBeAg-negatieve patiënten (Hoofdstuk 4) 
vonden we ongeveer dezelfde correlatie tussen HBcrAg en HBV DNA als in de 
HBeAg-positieve patiënten, maar we vonden geen correlatie met de hoeveel-
heid HBsAg (r=0.2, p=0.11). Dit zou kunnen komen doordat HBsAg in HBeAg-
negatieve patiënten met name afkomstig is van HBV DNA geïntegreerd in het 
DNA van de levercel dan van het cccDNA 108. Zoals we eerder ook zagen in 
HBeAg-positieve patiënten was ook in HBeAg-negatieve patiënten HBcrAg geas-
socieerd met de kans op succesvolle behandeling, maar opnieuw konden we 
geen toegevoegde waarde aantonen van HBcrAg boven eerder gevalideerde 
klinische beslisregels. Een Franse studie die ongeveer tegelijkertijd verscheen 
met de onze liet vergelijkbare resultaten zien 96. Voor PEG-IFN behandeling van 
Westerse HBeAg-negatieve patiënten adviseren we daarom om in ieder geval 
voorlopig de eerder gemaakte ‘PARC stopping rule’ te blijven gebruiken die 
gebaseerd is op het monitoren van veranderingen in hoeveelheden HBV DNA 
en HBsAg. Dit is met name omdat deze biomarkers uitgebreid gevalideerd zijn 
en herhaaldelijk in relatie zijn gebracht met de klinische uitkomstmaten waarin 
we het uiteindelijke effect van behandeling willen zien, zoals levercirrose en 
leverkanker.
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Gebaseerd op de onderzoeken die wij hebben gedaan naar HBcrAg, zijn wij 
van mening dat HBcrAg zeker gebruikt zou kunnen worden om het effect van 
een behandeling te vervolgen indien dit in combinatie is met andere biomarkers. 
Voor het gebruik van HBcrAg als enige biomarker om behandeling te vervolgen 
zijn ons inziens nog te veel vragen onbeantwoord. Een van de belangrijkste 
punten die we hierbij willen noemen dat een deel van de gepubliceerde studies 
over deze biomarker ook HBcrAg waarden meeneemt die onder de gevoelig-
heidsdrempel van de test liggen. Het gaat hierbij om waarden tussen de 100 
U/mL en 1000 U/mL (2-3 log10 U/mL). De onduidelijkheid over het wel of niet 
gebruiken van waarden tussen deze grenzen zou ontstaan kunnen zijn door 
het feit dat de handleiding van de test weliswaar weergeeft dat waarden onder 
3 log U/mL niet kunnen worden gebruikt, maar dat het apparaat wat voor de 
test gebruikt wordt toch ook waarden geeft onder deze grens. Wat echter in de 
eerste studie over HBcrAg beschreven worden, is dat de ondergrens van 3.0 log 
U/mL is gekozen omdat waarden tussen de 2.0 en 3.0 log U/mL ook werden 
gemeten bij enkele gezonde patiënten en patiënten met hepatitis C 85. Om die 
reden lijkt het ons belangrijk om de ondergrens van 3.0 log U/mL aan te houden 
om de speciﬁciteit van de test te waarborgen in plaats van een breder spectrum 
aan HBcrAg metingen te gebruiken in analyses. Omdat er zover wij weten geen 
andere studies zijn die de speciﬁciteit van HBcrAg beschrijven, raden we aan 
om dit gegeven mee te nemen in de interpretatie van studies die een potentiële 
rol beschrijven voor HBV-activiteit in patiënten die functionele genezing hebben 
bereikt. Enkel en alleen op basis van het detecteerbaar zijn van HBcrAg in 
HBsAg-negatieve patiënten kan ons inziens niet gezegd worden dat HBcrAg 
een sensitievere marker is dan HBsAg omdat we de speciﬁciteit onvoldoende in 
beeld hebben. 
HBV RNA is een biomarker die gemeten kan worden met de RACE-PCR techniek. 
De speciﬁeke methode die wij gebruikt hebben is een aantal jaar geleden ontwik-
keld 45, maar anderen hebben vergelijkbare primers en probes gemaakt 46, 146. 
Het is niet geheel duidelijk welke type RNA we precies detecteren in serum, 
maar er zijn meerdere aanwijzingen dat het grotendeels gaat om ingekapseld 
pregenomic RNA en een minimale hoeveelheid (<1%) precore messenger RNA 
46, 107, 146. De correlaties die beschreven worden tussen HBV RNA in het serum 
en het cccDNA in de lever zijn opvallend. In onbehandelde HBeAg-positieve 
patiënten werd een correlatie gevonden (r=0.39) met de absolute hoeveelheid 
cccDNA, maar dit werd niet gezien in HBeAg-negatieve patiënten 47. Daar-
entegen lijkt de aanwezigheid van HBV RNA wel te corresponderen met de 
aanwezigheid van transcriptieactiviteit van het cccDNA, wat zou kunnen bete-
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kenen dat de afwezigheid van HBV RNA in serum duidt op inactief cccDNA. In 
de Hoofdstukken 5, 6, 7 & 8, hebben we gekeken naar HBV RNA levels in 
patiënten die nog niet worden behandeld en in op verschillende manieren be-
handelde patiënten, zowel bij HBeAg-positieve als HBeAg-negatieve patiënten. 
Om verkeerde interpretatie van de gemeten waarden van een nieuwe biomarker 
te voorkomen is het erg belangrijk om te kijken naar welke factoren van invloed 
kunnen zijn op de hoeveelheid van de biomarker die gemeten wordt. Daarom 
hebben we in Hoofdstuk 5 gekeken naar factoren die invloed kunnen hebben 
op de hoeveelheid HBV RNA binnen een grote groep patiënten die wel actieve 
ziekte hebben maar hiervoor nog niet worden behandeld. De factor die het 
sterkst geassocieerd met de hoeveelheid HBV RNA was de HBeAg-status, wat 
opnieuw benadrukt hoe belangrijk HBeAg is voor de virale replicatie. Daarnaast 
was de aanwezigheid van een basal core promoter mutatie onafhankelijk geas-
socieerd met lagere HBV RNA hoeveelheden, en HBV RNA level was duidelijk 
het hoogst in patiënten met HBV-genotype D. Ook zagen we dat grotere hoe-
veelheden HBV RNA ook samengingen met hogere ALAT-waarden in het bloed, 
dus met meer ontstekingsactiviteit. Al deze factoren hebben we meegenomen in 
de onderzoeken die we daarna hebben gedaan in groepen patiënten die wel 
werden behandeld.
We hebben allereerst in Hoofdstuk 6 gekeken naar veranderingen in de HBV 
RNA hoeveelheid tijdens PEG-IFN behandeling met of zonder lamivudine bij 
patiënten met HBeAg-positieve hepatitis. We zagen bij deze patiënten dat de 
daling in het HBV RNA duidelijker sterker was bij patiënten die met PEG-IFN 
en lamivudine werden behandeld dan bij patiënten die alleen met PEG-IFN 
werden behandeld. Na het staken van de behandeling zagen we echter dat de 
waarden niet meer verschilden, wat hetzelfde patroon is wat HBV DNA laat zien 
30. Ook leek het HBV RNA iets lager te zijn bij patiënten met wildtype virus dan 
bij patiënten waarbij het virus voor start van de behandeling een mutatie had 
in de precore en/of de basal core promoter regio, maar dit was niet statistisch 
signiﬁcant. In onze studie vonden we verder dat de door anderen voorgestelde 
HBV RNA afkapwaarde van ≥ 5.5 log kopieën per mL op week 12 goed kon 
voorspellen dat een patiënt geen HBeAg verlies zou behalen door de behande-
ling. Deze afkapwaarde was in onze studie echter alleen goed genoeg voor 
HBV genotypes A en C, omdat bij de genotypes B en D de negatief voorspel-
lende waarde niet boven de 90% uit kwam 44. Ondanks onze bevindingen dat 
HBV RNA een sensitieve marker is voor HBeAg verlies, zagen we een beperkte 
speciﬁciteit, aangezien HBV RNA ook signiﬁcant daalde bij patiënten waar 
geen HBeAg-verlies optrad. Dit zou kunnen betekenen dat de hoeveelheid HBV 
165Samenvatting en discussie
RNA in het serum meer de actuele replicatieactiviteit weerspiegelt dan de mate 
van controle van het afweersysteem over het virus. 
In Hoofdstuk 7 voerden we een soortgelijke studie uit, maar bekeken we nu 
HBV RNA tijdens PEG-IFN behandeling met of zonder ribavirine voor HBeAg-
negatieve hepatitis. Op basis van onze eerste studie verwachtten we in deze 
groep lagere HBV RNA hoeveelheden, wat inderdaad niet alleen terugzagen 
voor de start van behandeling maar ook tijdens de behandeling. Al na de eerste 
12 weken van behandeling was het HBV RNA ondetecteerbaar in het grootste 
deel van de patiënten, onafhankelijk van het type behandeling (combinatie-
therapie of alleen PEG-IFN). Omdat de laagste waarde die gedetecteerd kan 
worden 800 kopieën per mL is zou het verbeteren van de gevoeligheid van de 
test zeer interessant zijn voor deze groep patiënten. Met de huidige test vonden 
we dat het hebben van een HBV RNA waarde >1,500 kopieën/mL (3.2 log c/
mL) op week 12 van de behandeling voorspelt dat de behandeling niet gaat 
slagen. Bij het toevoegen van een HBV RNA afkapwaarde van 3.18 log c/mL 
aan de eerder gevalideerde PARC stopping rule (die gebaseerd is op HBV DNA 
en qHBsAg monitoring) konden extra patiënten die geen respons zouden gaan 
behalen geïdentiﬁceerd worden, en daarmee zouden deze patiënten niet de 
gehele kuur af moeten maken 39.
Tot slot keken we in Hoofdstuk 8 weer naar HBV RNA levels bij HBeAg-
positieve hepatitis, maar nu tijdens de PEG-IFN add-on strategie. Dit hoofdstuk 
beschrijft interim-resultaten omdat de HBV RNA waarden na week 36 op dit 
moment nog niet zijn gemeten. Omdat we in Hoofdstuk 1 al zagen dat 
patiënt- en viruskenmerken kunnen helpen bij het selecteren van patiënten met 
de hoogste kans op behandelsucces door PEG-IFN add-on wilden we graag 
onderzoeken of HBV RNA hieraan zou kunnen bijdragen. De studieopzet van 
de ARES studie maakte het ons ook mogelijk om naar HBV RNA veranderingen 
tijdens de eerste 24 weken entecavir behandeling. Na 24 weken entecavir was 
een duidelijke knik in de daling van HBV RNA in het serum gezien en versnelde 
de HBV RNA daling ten opzichte van HBV RNA van patiënten die doorgingen 
met alleen entecavir. De hoeveelheid HBV RNA die gemeten werd na 24 weken 
entecavir behandeling was een goede voorspeller voor het wel of niet behalen 
van HBeAg verlies op week 72. Indien alleen patiënten PEG-IFN add-on zouden 
krijgen waarbij de HBV RNA hoeveelheid onder een bepaalde afkapwaarde 
komt na 24 weken entecavir, dan kan voor deze groep patiënten PEG-IFN 
add-on de kans op het verliezen van HBeAg verdubbeld worden. Hiermee zou 
behandeling verder kunnen worden geïndividualiseerd. 
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CONCLUSIE EN AANBEVELINGEN
De nieuwe biomarkers HBV RNA en HBcrAg kunnen beiden gebruikt worden om 
patiënten met een lage kans op therapiesucces al vroeg tijdens PEG-IFN behande-
ling te kunnen identiﬁceren. Op deze manier kan de behandeling eventueel voor-
tijdig worden gestaakt zodat deze patiënten niet onnodig worden blootgesteld 
aan de bijwerkingen van PEG-IFN. We konden voor beide biomarkers, maar met 
name voor HBcrAg, echter niet aantonen dat ze deze inschatting beter kunnen 
maken dan HBsAg bij HBeAg-positieve patiënten of de PARC stopping rule bij 
onze westerse patiëntenpopulatie met HBeAg-negatieve hepatitis. We adviseren 
daarom op basis van deze data op dit moment alleen de reeds gevalideerde 
klinische beslisregels te gebruiken, in ieder geval zo lang geen data over HBcrAg 
en HBV RNA verschijnt die aantoont dat deze markers superieur zijn.
Toekomst
We zien een mogelijke rol voor de PEG-IFN add-on strategie indien een 
bepaalde hoeveelheid HBsAg in serum of HBeAg-negativiteit een vereiste is 
voor de behandeling met een nieuw middel dat wel tot functionele genezing 
(verlies van HBsAg) kan leiden. Er moet wel rekening gehouden worden met 
onze bevinding dat het effect van PEG-IFN add-on afhankelijk is van meerdere 
patiënt- en viruskenmerken. Om die reden adviseren we om, als deze behande-
ling overwogen wordt in een poging een patiënt met NA behandeling te laten 
stoppen, vooraf patiënten te selecteren met de grootste kans van slagen op basis 
van de hoeveelheden HBV DNA, HBV RNA en HBsAg in het serum, die liefst 
ook niet eerder behandeld zijn met PEG-IFN. Bijvoorbeeld, als PEG-IFN alleen 
toegevoegd wordt bij patiënten waarbij HBV RNA level lager is dan 5.5 log 
c/mL, dan verdubbelt het toevoegen van PEG-IFN de kans op HBeAg verlies. 
Deze afkapwaarde en de andere afkapwaardes die voorgesteld worden in dit 
proefschrift moeten nog wel in andere patiëntpopulaties worden gevalideerd 
voordat deze daadwerkelijk gebruikt kunnen worden in de kliniek of voor onder-
zoek. Tot slot moet men altijd bedacht zijn op de mogelijke effecten van HBeAg 
status, HBV-genotype, de aanwezigheid van mutaties in de precore en basal 
core promoter regio van het cccDNA voordat de behandeling, of misschien van 
nog andere factoren die niet in dit proefschrift zijn onderzocht. Recent ontwik-
kelde nieuwe ziektemodellen kunnen mogelijk meer inzicht geven in hoe deze 
factoren precies de levenscyclus van het virus beïnvloeden. Ook zou het bepalen 
van verschillende mutaties tijdens behandeling hierbij kunnen helpen. Omdat 
zowel de levenscyclus van het virus als de menselijke afweerreactie tegen het 
virus extreem complex zijn, is het erg waarschijnlijk dat nieuwe behandelingen 
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met betere effecten op meerdere punten zullen moeten aangrijpen, en dat bij 
het ontwikkelen en monitoren van behandeling ook meerdere biomarkers nodig 
zullen zijn. Veelbelovende middelen die nu ontwikkeld worden zijn bijvoorbeeld 
HBV entry inhibitors die zorgen dat HBV een hepatocyt niet kan infecteren, RNA 
interference leidend tot blokkade van eiwitproductie en capsid inhibitors die de 
het inkapselen van HBV DNA en RNA tegengaat. Wij denken dat de veiligste en 
meest succesvolle manier om duurzame genezing te bereiken zou zijn om eerst 
de transcriptieactiviteit van het cccDNA volledig te blokkeren voor langere tijd 
evenals de mogelijkheid tot re-infectie, om daarna een immunologisch middel 
in te zetten om cccDNA te elimineren zonder de hepatocyt zelf ten gronde te 
laten gaan. Dit zou in het verlengde liggen van wat wij in dit proefschrift hebben 
gevonden, namelijk dat bij lage hoeveelheden van virologische biomarkers in 
het serum de kans op succes met PEG-IFN groter is.
Wij verwachten verder dat voor verschillende genetische en immunologische 
proﬁelen ook verschillende behandelstrategieën nodig zullen zijn. Dergelijke 
proﬁelen zouden gemaakt kunnen worden door technieken die wel al in onder-
zoek worden gebruikt maar nog niet geschikt zijn voor klinische toepassing, 
zoals een combinatie van HBV whole-genome sequencing en het bepalen van 
de immuunstatus van de patiënt met multiplex immuno-assays.
Patiënt profiel?
HBV profiel?
cccDNA activiteit
Antivirale behandeling
Biomarkers
Mutatie-analyse
Biomarkers ondetecteerbaar?
Mutatie-analyse
Bloedafname
bloedafname
Immuuntherapie
GENEZING?
OVERLEVING?
Bloedafname
++
--
Tot slot willen we benadrukken dat, hoe zeer dit proefschrift ook gericht is op 
het optimaliseren van de behandelmogelijkheden voor HBV, het wereldwijd 
elimineren van HBV-infectie minstens zo sterk afhangt van het opsporen van pa-
tiënten en diegenen die behandeling nodig hebben. De wereldwijde prevalentie 
is waarschijnlijk een onderschatting, en een deel van de geïnfecteerde mensen 
weet niet dat zij geïnfecteerd is 147. Vaccinatie in bevolkingsgroepen met een 
hoog risico op HBV, in combinatie met het vinden van deze mensen én zorgen 
dat zij de juiste behandeling krijgen zal morbiditeit, mortaliteit en transmissie 
verminderen. Alleen als huidige of toekomstige behandelingen aankomen bij 
degenen die het nodig hebben is een signiﬁcante afname van de wereldwijde 
ziektelast veroorzaakt door HBV mogelijk. 
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ALT alanine aminotransferase
AUC area under the curve
BCP basal core promoter
cccDNA covalently closed circular DNA
CHB chronic hepatitis B infection
c/mL copies per milliliter
CR combined response
CI-95% 95% conﬁdence interval
ETV entecavir
HAI hepatic activity index
HBV hepatitis B virus
HBcAg hepatitis B core antigen
HBcrAg hepatitis B core-related antigen
HBeAg hepatitis B e antigen
HBsAg hepatitis B surface antigen
IU/mL international units per milliliter
IQR interquartile range
LAM lamuvidine
LLD lower limit of detection
LLQ lower limit of quantiﬁcation
LTFU long-term follow-up
MDQ minimal detectable quantity
MITT modiﬁed intention-to-treat
NA nucleos(t)ide analogue
p22cr 22-kD precore protein
PEG-IFN peginterferon
PC precore
PCR polymerase chain reaction
RACE rapid ampliﬁcation of cDNA ends
RBV ribavirin
qHBsAg quantitative hepatitis B surface antigen
qHBeAg quantitative hepatitis B e antigen
ROC receiver operating characteristic
SD standard deviation
TDF tenofovir disoproxil fumarate
ULN upper limit of normal
U/mL units per milliliter
WT wildtype
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het wordt een lang verhaal.
 
Allereerst wil ik mijn promotoren prof.dr. Harry Janssen en prof.dr. Her-
old Metselaar bedanken.
Herold, tijdens het laatste jaar van mijn studie kwam ik bij jou om afstudeeronder-
zoek te doen. Dit werd  uiteindelijk een onderzoek naar CMV infecties bij 
levertransplantatiepatiënten, en van daaruit kwam de combinatie hepatologie/
infectiologie voor het eerst op mijn pad. Bedankt voor het vertrouwen om mij ook 
als promovendus aan de slag te laten gaan, en bedankt voor de begeleiding en 
nuchtere kijk van de afgelopen jaren.
Harry, na enkele maanden maakte ik kennis met jou en aan jou was de soms 
logistiek ingewikkelde taak om mij op afstand te begeleiden. Onze Skype-
afspraken begonnen met de PAS studie, maar als snel kwamen daar meer en 
meer projecten bij die uiteindelijk samen tot dit proefschrift hebben geleid. Be-
dankt voor alle goede ideeën, tips en je alle mogelijkheden die ik heb gekregen 
tijdens mijn promotietraject.
Na mijn promotoren komt natuurlijk meteen mijn copromotor, dr. Bettina Han-
sen. Beste Bettina, ik heb er nog even over getwijfeld of ik jouw one-liner ‘a plot 
says more than a thousand words’ zou opnemen in mijn stellingen, maar helaas, 
je moet het toch doen met het dankwoord. Ik had nooit gedacht dat iemand het 
ooit voor elkaar zou krijgen om mijn statistische skills op dit niveau te krijgen. 
We hebben hard gewerkt en veel gelachen tijdens mijn promotie, maar ik heb je 
ook meer dan eens achter het behang willen plakken als je weer met een nieuwe 
analyse kwam wanneer ik dacht dat ik al klaar was haha! Dank je wel voor al 
je tijd en geduld, en ik kan met recht zeggen dat zonder jou dit proefschrift er 
niet was geweest. 
Verder wil ik graag dr. Rob de Knegt bedanken. Beste Rob, onze wekelijke 
overlegmomenten over de hepatitis B poli en onderzoek waren altijd enorm 
gezellig, en van begin af aan was je erg geïnteresseerd en betrokken. Als je mij 
ergens mee kon helpen deed je dat meteen, of zorgde je dat iemand anders dat 
kon doen. Dank je wel voor alle begeleiding. 
Dan kom ik hierna bij prof.dr. Janneke van der Woude, huidige opleider 
MDL, en prof.dr. Rob de Man, oud-opleider MDL. Ik ben heel erg blij dat 
ik de kans heb gekregen om de opleiding tot MDL-arts te starten, bedankt! Dr. 
Henk Boom, vooropleider interne geneeskunde, bedankt voor alle ruimte en 
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begeleiding die ik in Delft heb gekregen. Ik voel me nog steeds erg welkom. 
Lieve collega-arts assistenten uit Delft, bedankt voor alles wat ik van jullie 
leer en voor de gezellige werksfeer. Vanaf nu ben ik wat vaker bij de borrels!
 
Hepatitis B is niet te onderzoeken als je alleen maar op klinisch niveau kijkt.
Allereerst wil ik daarom dr. Annemiek van der Eik, viroloog, bedanken. 
Annemiek, ook jij bent ooit gepromoveerd op hepatitis B, en toen ik bij jou 
kwam voor mijn CMV-projecten en ik aankaartte dat ik promotieonderzoek 
wilde doen, zei jij: ‘Pauline gaat weg, jij moet NU naar Bettina Hansen om te 
zeggen dat je die plek wil’. Zo geschiedde, en hier ligt nu het resultaat. We 
bleven ook samenwerken tijdens mijn promotie, en ik wil je bedanken voor je 
enthousiasme en inspiratie in deze tijd. 
Ook wil ik natuurlijk dr. André Boonstra, immunoloog, bedanken. André, 
door onze regelmatige besprekingen heb ik nu toch het idee dat ik eindelijk 
wat van immunologie snap. Dank je wel voor alles wat je hebt gedaan voor 
de projecten en bedankt dat je vandaag plaats wilt nemen in de commissie. 
Dankzij jouw immunologische blik heeft menig discussie uit mijn proefschrift 
meer diepgang gekregen. 
Dr. Hanneke van Vuuren, hoofd MDL diagnostiek. Beste Han-
neke, waar in mijn proefschrift komt geen diagnostiek voor? Dank je 
wel voor alle uitleg over testen waarvan ik eerst geen idee had hoe ze 
werkten, en voor alle moeite die je hebt gedaan voor mijn projecten. 
Tegelijkertijd met André en Hanneke wil ik ook Gertine van Oord, Anthonie 
Groothuismink, Buddy Roovers, en Frances van Deurzen bedanken. 
Jullie hebben enorme bergen verzet om alle biomarker-resultaten te genereren. 
Ook zonder jullie was er geen proefschrift geweest. Heel erg bedankt!
En last maar zeker not least: dames van het CRB en de poli! Heleen, Melek, 
Esther, Irene, Elke en Judith, bedankt voor al jullie hulp, tips en gezel-
ligheid. Wilma, dank je wel voor je hulp aan mij als beginnende dokter op de 
poli. We hebben wat af gelachen!
 
Lieve daklabduifjes, wat bof ik om jullie als collega’s (gehad) te hebben. Niet 
alleen heb ik ontzettend veel van jullie geleerd, maar vooral waren de gezel-
ligheid van alle borrels, kofﬁemomentjes, uitjes etc. onmisbaar. Ook daarom 
weer een hoop mensen te bedanken. 
 
Allereerst mijn mede-HBV collega’s Heng, Willem-Pieter, Seng, Mina, 
Hannah en Lauke. Heng(ster), tijdens mijn afstudeeronderzoek was jij de 
eerste die op mijn toenmalige plekje in het Ha-gebouw kennis kwam maken. 
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Toen je hoorde dat ik jouw nieuwe collega zou worden was je meteen heel 
behulpzaam. Ik heb heel veel met je gelachen op het dak en bij de congressen, 
en ik kijk er nu al naar uit om later terug collega’s zijn in het EMC. WP, op 
mijn eerste dag stuurde je me vanuit Canada een hele lange welkomstmail met 
allemaal tips & tricks voor mij als beginnende collega. Ook in de jaren erna heb 
je me vaak geholpen, maar heb je ook daarbij nodige eigenwijsheid van mij 
mogen verduren. Bedankt! Seng, toen je net begon leek het alsof we beiden 
hele andere projecten zouden gaan doen, maar uiteindelijk hebben we heel 
wat samengewerkt. Jammer dat dit grotendeels op afstand was, maar ik hoop je 
snel weer terug in NL te zien. Mina and Hannah, the Toronto crew! It’s been 
a pleasure working with you both. Thank you for all your help. Hopefully we 
will continue working together in the future!  Lauke, als nieuwe translationele 
onderzoeker viel je meteen met je neus in de boter met de trialpoli die je van 
mij moest overnemen. Je enthousiasme om te beginnen met iets nieuws werkte 
erg aanstekelijk, en je vrolijke cynisme kan ik nog steeds erg waarderen. Be-
dankt, en veel succes met het afronden van je promotie. Pauline, Milan, en 
Vincent, aan mij was de taak om in jullie voetsporen te treden. Bedankt voor 
alle opstarthulp.
 
Ik heb de eer gehad om op twee kamers op het befaamde dak te mogen zitten. 
Toen ik net begon op het dak wisselde ik zo’n beetje wekelijks van werkplek, 
totdat de vraag kwam of ik interesse had in een plekje op de toffe-peren kamer. 
Raoel en Eline, ik vraag me weleens af of jullie daar qua rust weleens spijt van 
hebben gehad. Lieve Eline, ik heb het meer dan eens tegen je gezegd, maar 
het was ontzettend ﬁjn om jou als kamergenootje te hebben. Dankjewel voor je 
betrokkenheid, kletsuurtjes, werktips en ontbijtdates. Je wordt een supergoede 
huisarts! Lieve Raoel, je hebt je rol als buddy meer dan waar gemaakt. Naast 
dat ik oprecht SPSS en Graphpad tips heb gekregen vanuit je ‘ofﬁciële rol’ 
maakte jij het ook erg gezellig op kamer 419. Ik herken nog steeds in ‘Raoel-
nummers’ als er ze voorbijkomen over de speakers. Bedankt! 
Toen ik na 2,5 jaar alleen achterbleef op kamer 419 dacht ik dat ik het staartje 
van mijn promotie zonder kamergezelligheid zou gaan afronden. Ik had alleen 
niet bedacht dat ik ook zelf naar een andere kamer kon verhuizen, maar geluk-
kig hadden Floor en Priscilla wel door dat dit kon. Lieve Sil, al voordat ik je 
dakroomie werd hadden we al veel mooie momentjes achter de rug. Congres, 
risotto-dates, feestjes, borrels, we hebben wat meegemaakt! Ik heb je leren 
kennen als iemand die heel erg sociaal en zorgzaam is,  maar ook heel erg 
gedisciplineerd en georganiseerd. Ik ben hartstikke blij dat we tegelijkertijd in 
het EMC zijn begonnen, en dat we daardoor veel leuks hebben gedeeld en nog 
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zullen delen! Lieve Floor, wat ben jij een topper. Je staat altijd voor iedereen 
klaar, werkt superhard, en bent denk ik de meest optimistische persoon die ik 
ken. Gelukkig voor mij ben je in Delft komen werken en in Rotterdam komen 
wonen! Dankjewel voor al je steun en betrokkenheid.
 
Lieve Esmée, Els, Joany, Louisa, Shannon, Loes, Maren, Jorn, Wim, 
Sophia, Anniek, Fanny, Kasper, Mitchel, Marjolein, Ingrid, Vincent, 
Wesley, Michelle, Elmer, Rik, Yingying, Fanny, Evelien, Renske, 
Arjan, Rosalie, Alison, Carlijn, Julia en Michiel. Bedankt dat jullie mijn 
tijd op het dak zo leuk hebben gemaakt!
 
Lieve Kèren, Annabel, Jiska, Emily, Bas, Margreet en Tinus. Dank 
jullie wel dat jullie altijd begrip hebben gehad voor de vele uren die ik moest 
werken om dit voor elkaar te krijgen en me altijd hebben gesteund. Ik bof maar 
met jullie, en ik ben heel blij dat jullie er vandaag bij zijn (al dan niet in ge-
dachten vanwege verre reizen). Ik beloof dat ik hierna mijn leven beter en meer 
aanwezig ben bij alle leuke dingen die gepland worden!
 
Lieve, Roger, Eline, Cyril en Tea, ik had me geen lievere en leukere schoonfa-
milie kunnen wensen. Dank jullie wel voor jullie interesse en humor, en ik ben 
heel erg blij dat ik dit moment vandaag met jullie mag delen.
 
Allerbeste paranimfen van de hele wereld, Jihan en Lisanne. 
 
Lieve Lies, van begin af aan waren wij kamergenootjes bij congressen en al 
snel werden we ook vriendinnen. Onze gedeelde liefde voor muziek, eten en 
wijn heeft voor veel mooie herinneringen gezorgd waaronder onze vakantie. 
Meer dan eens hebben we zo hard gelachen dat we niet meer konden praten 
(en dat kunnen we normaal gesproken allebei toch wel goed). Ik baal er nog 
steeds van dat ik niet bij jouw promotie kon zijn, maar gelukkig jij wel bij de 
mijne, op een voor mij hele bijzondere plaats. Dankjewel voor alle mooie jaren, 
en we gaan er nog een hoop tegemoet!
 
Lieve Ji, ik heb het je al eens verteld, maar toen ik je net ontmoette dacht ik 
‘wie ís dit?’. Roze kerstboom, kauwgom, cola light, en een hele duidelijke eigen 
mening en wil. Toch hadden we al heel snel veel lol samen, met jouw eerste 
kampeerervaring op Rock Werchter toch wel als een van de hoogtepunten (ﬁrst 
of many). Je bent niet alleen regelmatig ontzettend grappig, maar je staat ook 
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altijd voor me klaar. Dankjewel dat ook jij vandaag naast me staat, ook zeker 
niet voor de laatste keer.
 
Lieve Jolien, ondanks het feit dat je zo’n zwaar jaar hebt gehad heb je altijd 
tijd voor mij gemaakt. Ook al wonen we niet bij elkaar om de hoek, je hebt me 
er met de vele telefoontjes toch veel geholpen. Dankjewel dat je hier vandaag 
bent. Ik ben trots op je!
 
Lieve papa en mama, hier is het langverwachte boekje dan. Ik heb van 
jullie altijd alle mogelijkheden en onvoorwaardelijke steun gekregen om te doen 
wat ik graag wilde, ook al betekende dat soms dat jullie mij langere tijd niet 
zagen of weinig spraken. Ik heb van jullie geleerd om positief in het leven te 
staan, anderen te helpen, en hard te werken voor wat je wilt bereiken. Al die 
dingen hebben ervoor gezorgd dat ik hier vandaag sta, ik kan jullie niet genoeg 
bedanken.
 
Lieve Mies, als geen ander weet jij hoeveel tijd en energie in dit boekje zit, 
maar ook als geen ander heb jij achter me gestaan. In alle hectiek van een 
nieuwe baan in de kliniek en het afronden van mijn promotie heb jij me met 
beide benen op de grond gehouden; zonder de vrijheid en steun die je me heb 
gegeven was het me niet gelukt. Dank je wel voor alles.
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Margo van Campenhout werd op 14 juni 1988 geboren te Hulst. In 2006 
behaalde zij haar gymnasiumdiploma aan het Reynaertcollege aldaar, waarna 
zij een jaar Biomedische Wetenschappen studeerde aan de Universiteit Gent. 
Vanaf 2007 studeerde zij geneeskunde aan de Erasmus Universiteit Rotterdam. 
Tijdens de studieperiode gaf zij als student-assistent les in lichamelijk onderzoek, 
werkte ze als teamleider van het studententeam Vaat- en Transplantatiechirurgie, 
en volgde zij keuzecoschappen in West-Pokot, Kenia. In 2013 werd het doc-
toraalexamen behaald met het afstudeeronderzoek ‘Cytomegalovirus infection 
in liver transplantation recipients’, begeleid door Prof. Dr. Herold Metselaar. 
Aansluitend werd na een oudste coschap Maag-Darm-Leverziekten in het Eras-
mus MC het artsexamen cum laude behaald. In november 2013 startte zij in het 
Erasmus MC onder begeleiding van Prof. Dr. Herold Metselaar en Prof. Dr. Harry 
Janssen promotieonderzoek naar het optimaliseren van hepatitis B behandeling. 
In deze periode heeft zij ook het deelcertiﬁcaat Basiskwaliﬁcatie Onderwijs 
‘Begeleiden van studenten’ behaald. Per 1 mei 2017 is zij in opleiding tot 
Maag-Darm-Leverarts (opleider Prof. Dr. Janneke van der Woude), waarbij zij 
tot 2021 zal werken in het Reinier de Graaf Gasthuis in Delft en de laatste twee 
jaar van de opleiding zal volgen in het Erasmus MC. Ze woont in Rotterdam, 
samen met Michel Ruijters.
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SUMMARY OF PHD TRAINING AND TEACHING
Name PhD student: Margo J.H. van Campenhout
Erasmus MC Department: Gastroenterology and Hepatology
PhD period: 2013-2018
Promotor(s): Prof. Dr. H.J. Metselaar, Prof. dr. H.L.A. Janssen
Supervisor: Dr. B.E. Hansen
1. PhD training
Year Workload
(Hours/ECTS)
General courses 
- Systematic Literature Searching in Pubmed
- Systematic Literature Searching in Embase, Medline, Cochrane
- Database and Web-of-Science
- Endnote
- BROK (‘Basiscursus Regelgeving Klinisch Onderzoek’, GCP course)
- Research Integrity
- Regression analysis
- Biomedical English Writing and Communication
2013
2013
2013
2014
2015
2014
2015
1 ECTS
12 hours
3 hours
4 hours
0.3 ECTS
1.4 ECTS
3 ECTS
Speciﬁc courses (e.g. Research school, Medical Training)
Research management for PhD students 2014 8 hours
Awards
Full bursary from the European Association for the Study of the Liver (EASL) 
awarded to the best scored abstracts at EASL Special Conference: Optimal 
Management of Hepatitis B Virus Infection.
Registration bursary from the European Association for the Study of the Liver 
(EASL) awarded to high-level abstracts at 50th EASL International Liver Congress.
Young Investigator Travel Award, American Association for the Study of Liver 
Diseases (AASLD) Foundation, awarded to promising early-career investigators
2014
2015
2017
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Poster presentations
Determinants of HBsAg response induced by addition of peginterferon to 
entecavir in HBeAg-positive chronic hepatitis B. EASL Special Conference: 
Optimal Management of Hepatitis B Virus Infection
Hepatitis B core-related antigen may be a marker for immune control in HBeAg-
negative chronic hepatitis B infection.
50th EASL International Liver Congress
Hepatitis B Core-Related Antigen Levels are Inversely Correlated With Fibrosis 
Stage in HBeAg-Positive Chronic Hepatitis B. 
The Liver Meeting 2015. 66th Annual Meeting of the American Association for 
the Study of Liver Diseases (AASLD). San Francisco, United States of America
Hepatitis B Core-Related Antigen Level Decline in the First 12 Weeks of 
Peginterferon Treatment is Associated with Response in HBeAg-Negative Chronic 
Hepatitis B.
The Liver Meeting 2015. 66th Annual Meeting of the American Association for 
the Study of Liver Diseases (AASLD). San Francisco, United States of America.
Clinical evaluation of hepatitis B core-related antigen monitoring during 
peginterferon alfa treatment for HBeAg-negative chronic hepatitis B
52th EASL International Liver Congress, Amsterdam, The Netherlands.
Serum HBV RNA level is associated with HBV genotype and BCP mutations in 
untreated patients with HBeAg positive chronic hepatitis B
52th EASL International Liver Congress, Amsterdam, The Netherlands.
Serum HBV RNA level monitoring for response prediction in HBeAg positive 
chronic hepatitis B infection
52th EASL International Liver Congress, Amsterdam, The Netherlands.
2014
2015
2015
2015
2017
2017
2017
32 hours
32 hours
32 hours
32 hours
32 hours
32 hours
32 hours
Oral presentations
Hepatitis B core related antigen levels are associated with response to ETV and 
PEG-IFN treatment in HbeAg-positive chronic hepatitis B patients. 
Twice annual meeting of the Netherlands Association of Hepatology, Veldhoven, 
the Netherlands
Hepatitis B Core-Related Antigen Level Decline in the First 12 Weeks of 
Peginterferon Treatment is Associated with Response in HBeAg-Negative Chronic 
Hepatitis B.
Twice annual meeting of the Netherlands Association of Hepatology, Veldhoven, 
the Netherlands
Addition of (pegylated) interferon to entecavir increases serological response in 
treatment naïve, Hepatitis B e Antigen positive patients with chronic hepatitis B
Twice annual meeting of the Netherlands Association of Hepatology, Veldhoven, 
the Netherlands
Serum HBV RNA level predicts response to peginterferon add-on therapy for 
HBeAg-positive chronic hepatitis B
The Liver Meeting 2017. 68th Annual Meeting of the American Association for 
the Study of Liver Diseases (AASLD). Washington D.C,, United States of America.
2014
2015
2016
2017
12 hours
12 hours
12 hours
12 hours
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(Inter)national conferences
7th Paris Hepatitis Conference
49th EASL International Liver Congress, London, UK
Twice annual meeting of the Netherlands Association of Hepatology, Veldhoven, 
the Netherlands
EASL Special Conference: Optimal Management of Hepatitis B Virus Infection
The Liver Meeting 2014. 65th Annual Meeting of the American Association for 
the Study of Liver Diseases (AASLD). Boston, MA, United States of America
50th EASL International Liver Congress, Vienna, Austria
The Liver Meeting 2015. 66th Annual Meeting of the American Association for 
the Study of Liver Diseases (AASLD). San Francisco, USA
Nationale Hepatitis Dag. Amsterdam, The Netherlands.
51th EASL International Liver Congress, Barcelona, Spain
52th EASL International Liver Congress, Amsterdam, The Netherlands.
2013
2014
2014
2014
2014
2015
2015
2015
2016
2017
12 hours
28 hours
12 hours
12 hours
28 hours
28 hours
28 hours
8 hours
28 hours
28 hours
Attended seminars and workshops
5e Lagerhuisdebat Hepatitis B en C. Utrecht, The Netherlands
1th Post-EASL symposium. Amsterdam, The Netherlands
12th Post-AASLD symposium. Rotterdam, The Netherlands
6e Lagerhuisdebat Hepatitis B en C. Utrecht, The Netherlands
2nd Post-EASL symposium. Amsterdam, The Netherlands
2013
2014
2014
2014
2015
2 hours
2 hours
2 hours
2 hours
2 hours
Other
- 
2. Teaching
Deelcertiﬁcaat Basiskwaliﬁcatie onderwijs (BKO)
- Training ‘Basisdidactiek’
- Training ‘Omgaan met groepen’
- Training ‘Individuele begeleiding’
- Training ‘Individuele voortgangsgesprekken’
2009
2014
2014
2016
4 hours
4 hours
1 ECTS
3 hours
Lecturing
A case with hepatitis B
Erasmus Liverday 2016
Hepatitis B
Minor ‘Infectieziekten in de grote stad’, Bachelor Geneeskunde (Faculty of 
Medicine, Erasmus University)
2016
2016
12 hours
12 hours
Supervising practicals and excursions, Tutoring
Tutoring ﬁrst-year bachelor students (Faculty of Medicine, Erasmus University)
Tutoring ‘Kennismaking met de Beroepspraktijk’ (Faculty of Medicine, Erasmus 
University)
Tutoring ﬁrst-year bachelor students (Faculty of Medicine, Erasmus University)
Tutoring ‘Kennismaking met de Beroepspraktijk’ (Faculty of Medicine, Erasmus 
University)
2014
2015
2015
2016
 
1.5 ECTS
5 hours
1.5 ECTS
5 hours
Supervising Master’s theses
- Long-term follow-up of patients treated with interferon alpha
- Cedric de Jong, Master Geneeskunde
Other educational activities
Assessing physical examination exams in third-year bachelor students (Faculty of 
Medicine, Erasmus University)
Shared coordination of the third-year minor program in Gastroenterology & 
Hepatology (Faculty of Medicine, Erasmus University)\
2014
2015
6 hours
12 hours

